<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/226041-lipase-inhibitor-compounds by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:31:28 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 226041:&quot;LIPASE INHIBITOR COMPOUNDS&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;LIPASE INHIBITOR COMPOUNDS&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A B S T R A C T Abstract: The subject invention features compounds having the structure:, wherein X is O, S, CH2 or NR5 Y is O or S; R1 is H, substituted or unsubstituted C1C15 alkyl, C1-C15 alkylafyl, -C(O)OR4, -C(O)NR1R5, (I) -CR6R6.OR4,-CR6R6&#x27;OC(0)R4, - CR6R6 OC(O)NHR7, -C(O)NR10R11, -C(O)NRSR9, NR8R9, -N(R5)C(O)NHRS, or CH2R4 R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3 C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl, R3 is H or substituted or unsubstituted C1-C6 alkyl or C3-C10 cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, (C6-C30 alkyl, aryl, CH2 aryl, aryl -C1-C15 alkyl, heteroaryl-C1-C15alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30alkyl, heteroarylalkyl or cycloalkyl; R6 and R6&#x27; are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered ring system; R7 is 11 or substituted or unsubstituted C1 C12 alkyl or C3-C10 cycloalkyl; Rs and R9are each independently H, substituted or unsubstiluted C1-C6 alkyl, C1--C6 alkoxy, C1-C6 alkylaryl, or NR8R? together form a substituted piperazine or piperidine ring or a ilihydro-lH-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof and a method for treating diabetes or obesity by administering a therapeutically effective amount of the compounds of the invention.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>PANCREATIC LIPASE INHIBITOR<br>
COMPOUNDS. THEIR SYNTHESIS AND USE<br>
This application claims priority of U.S. Provisional Application No. 60/342,617, filed<br>
December 20, 2001, and U.S. Provisional Application No. 60/357,015, filed February<br>
13, 2002, the entire contents of which are hereby incorporated by reference.<br>
Throughout this application, various publications are referenced by full citations. The<br>
disclosures of these publications in their entireties are hereby incorporated by<br>
reference into this application in order to more fully describe the state of the art as<br>
known to those skilled therein as of the date of the invention described and claimed<br>
herein.<br>
Background of the Invention<br>
During the last 20 years, obesity has become an increasingly common problem in<br>
the populations of developed countries. The increased incidence of obesity is partly<br>
due to the adoption of a westernised diet in many developed countries - which<br>
contains many foods with high fat and low fiber concentrations - and partly due to the<br>
lifestyle of westernized society. Obesity is known to increase the risk of contracting<br>
disorders such as diabetes, cardiovascular disease and hypertension.<br>
Pharmacological approaches to the treatment of obesity either try to increase the<br>
body's energy expenditure, thereby burning more fat, or reduce the body's energy<br>
intake. The latter approach has stimulated the development of a variety of drugs<br>
which attempt to reduce the body's ability to absorb fat. These drugs target the<br>
enzymes responsible for the digestion of fat in the human digestive cycle. The most<br>
important enzymes in the digestion of fat are hydrolytic enzymes. The most<br>
significant of these enzymes are lipases, pancreatic lipase in particular. Orlistat, a<br>
derivative of lipstatin, a lipase inhibitor, is disclosed as an anti-obesity drug in<br>
European Patent Application No. EP129748. Other lipase inhibitors are disclosed in<br>
PCT International Publication Nos. WO 00/40569 and WO 00/40247, respectively.<br>
Summary of the Invention<br>
The subject invention provides a compound having the structure:<br>
wherein,<br>
X is O, S, CH2 or NR5;<br>
Y is O or S;<br>
R! is H, substituted or unsubstituted d-Cis alkyl, CrC8 alkylaryl,<br>
-C(0)OR4, -C(0)NR4R5, -CReRe-ORA, -CReReOC(O)R4, -CR6R6-OC(O)NHR7l<br>
-C(O)NR10Rn, -C(O)NR8R9 NR8R9, -N(R5)C(O)NHR5, or CH2R4;<br>
R2 is a substituted or unsubstituted, straight chain CrCao alkyl or<br>
branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyl or cycloalkyl;<br>
and,<br>
R3 is H or substituted or unsubstituted CrCe alkyl or C3-Cio<br>
cycloalkyl,<br>
wherein<br>
R4 is H or a substituted or unsubstituted, straight chain or<br>
branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -CrC3o alkyl,<br>
heteroaryl-Ci-C30 alkyl or C3-Cio cycloalkyl;<br>
Rs is H or a substituted or unsubstituted, straight chain or<br>
branched, Ce-C3o alkyl, aryl Ci-C30alkyl, heteroarylalkyl or<br>
cycloalkyl;<br>
Re and R6- are each independently H, substituted or<br>
unsubstituted d-C6 alkyl, dialkyl or C3-Ci0 cycloalkyl or together<br>
form a 3-7 membered ring system;<br>
R7 is H or substituted or unsubstituted Ci-Ci2 alkyl or C3-<br>
C10 cycloalkyl; and<br>
R8 and Rg are each independently H, substituted or<br>
unsubstituted d-Ce alkyl, CrC6 alkoxy, CrC6 alkylaryl, or<br>
NR8Rg together form a substituted piperazine or piperidine ring<br>
or a dihydro-1H-isoquinoline ring system,<br>
or a specific enantiomer thereof, or a specific tautomer, or a<br>
pharmaceutically acceptable salt thereof.<br>
The subject invention also provides a compound having the structure:<br>
Q<br>
wherein,<br>
Rio is H or substituted or unsubstituted Ci-Ci5 alkyl, d-Ci5<br>
alkylaryl, or -C(O)R14,<br>
wherein R14 is hydroxyl, or a substituted or unsubstituted<br>
CrCso alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl,<br>
alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring;<br>
Rn is hydrogen or methyl;<br>
R12 is hydrogen or fert-butyl; and<br>
Ria is hydrogen or -C(O)ZRi5,<br>
wherein Z is CH2, O or N and R15 is substituted or<br>
unsubstituted CrCi5 alkyl or aryl.<br>
The subject invention also provides a method for treating obesity in a subject in<br>
need of such treatment, comprising administering to the subject a therapeutically<br>
effective amount of a compound of the invention so as to thereby treat obesity in<br>
the subject.<br>
The subject invention also provides a method for treating diabetes in a subject in<br>
need of such treatment, comprising administering to the subject a therapeutically<br>
effective amount of a compound of the invention so as to thereby treat diabetes in<br>
the subject.<br>
The subject invention also provides a method of inhibiting the hydrolytic activity of<br>
pancreatic lipase enzymes in a cell, comprising contacting the cell with an<br>
amount of a compound of the invention which is effective in inhibiting the<br>
hydrolytic activity of pancreatic lipase enzymes.<br>
Detailed Description<br>
The subject invention provides compounds having the structure:<br>
o<br>
wherein,<br>
X is O, S, CH2 or NR5;<br>
YisOorS;<br>
RI is H, substituted or unsubstituted CrCi5 alkyl, CrC8 alkylaryl,<br>
-C(O)OR4l -C(O)NR4R5, -CR6R6-OR4) -CR6R6'OC(O)R4, -CR6R6'OC(O)NHR7,<br>
-C(O)NRioRn, -C(O)NR8R9NR8R9, -N(R5)C(O)NHR5l or CH2R4;<br>
R2 is a substituted or unsubstituted, straight chain Ci-C30 alkyl or<br>
branched C3-C3o alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyl or cycloalkyi;<br>
and<br>
RS is H or substituted or unsubstituted d-Ce alkyl or Cs-Cio<br>
cycloalkyi,<br>
wherein<br>
R4 is H or a substituted or unsubstituted, straight chain or<br>
branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -CrC3oalkyl,<br>
heteroaryl-CrCao alkyl or C3-Cio cycloalkyi;<br>
R5 is H or a substituted or unsubstituted, straight chain or<br>
branched, C6-C3o alkyl, aryl CrC30alkyl, heteroarylalkyl or<br>
cycloalkyi;<br>
R6 and R6- are each independently H, substituted or<br>
unsubstituted CrC6 alkyl, dialkyl or C3-Ci0 cycloalkyi or together<br>
form a 3-7 membered ring system;<br>
R7 is H or substituted or unsubstituted CrCi?. alkyl or C3-<br>
Cio cycloalkyi; and<br>
R8 and R9 are each independently H, substituted or<br>
unsubstituted CrC6 alkyl, d-Ce alkoxy, CrC6 alkylaryl, or<br>
NRaRg together form a substituted piperazine or piperidine ring<br>
or a dihydro-1 H-isoquinoline ring system,<br>
or a specific enantiomer thereof, or a specific tautomer, or a<br>
pharmaceutically acceptable salt thereof.<br>
In one embodiment, the compound has the structure:<br>
O<br>
wherein,<br>
X is O, S or NR5;<br>
Y is O or S;<br>
R1 is H, -C(O)OR4, -C(O)NR4R5, -CR6R6'OR4, -CR6R6'OC(O)R4,<br>
-CR6R6OC(O)NHR7, or CHaR-iI<br>
Ra is a substituted or unsubstituted, straight chain or branched,<br>
C6-C3o alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; and<br>
R3 is H or substituted or unsubstituted Ci-C6 alkyl or cycloalkyi,<br>
wherein,<br>
R4 is H or a substituted or unsubstituted, straight chain or<br>
branched, Ce-Cao alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;<br>
RS is H or a substituted or unsubstituted, straight chain or<br>
branched, C$-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;<br>
Re and R6' are each independently H, substituted or<br>
unsubstituted Cr.CB alkyl, dialkyl or cycloalkyi or together form a<br>
3-7 membered ring system; and<br>
R7 is H or substituted or unsubstituted CrCi2 alkyl or<br>
cycloalkyi.<br>
In a further embodiment, the compound has the structure:<br>
o<br>
wherein,<br>
X is O, S or NR5;<br>
Ri is H, -C(O)OR4l -C(O)NR4R5, -CR6R6'OR4, -CR6R6OC(O)R4,<br>
-CR6R6'OC(O)NHR7, or CH2R4;<br>
R2 is a substituted or unsubstituted, straight chain or branched<br>
C6-C3o alkyl, arylalkyl, heteroarylalkyl or cycloalkyi; and<br>
R3 is H or substituted or unsubstituted CrCe alkyl or cycloalkyi,<br>
wherein,<br>
R4 is H or a substituted or unsubstituted, straight chain or<br>
branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;<br>
R5 is H or a substituted or unsubstituted, straight chain or<br>
branched, Ce-Cso alkyl, arylalkyl, heteroarylalkyl or cycloalkyi;<br>
R6 and R6' are each independently H, substituted or<br>
unsubstituted CrC6 alkyl, dialkyi or cycloalkyi or together form a<br>
3-7 membered ring system; and<br>
R7 is H or substituted or unsubstituted CrCi2 alkyl or<br>
cycloalkyi.<br>
In a further embodiment of the above compound,<br>
X is O or NR5;<br>
R! is -C(O)O-(C6-C30) alkyl, -C(O)NH-(C6-C30) alkyl or<br>
-C(0)OCH2(C6H5);<br>
R2 is C6-C30 alkyl; and<br>
R3 is CrC6 alkyl.<br>
In a further embodiment, R3 is H or CH3.<br>
In a further embodiment, X is O.<br>
In a further embodiment, R3 is methyl.<br>
In a further embodiment, X is N.<br>
In a further embodiment, R3 is methyl.<br>
In a further embodiment, the compound has the structure:<br>
o<br>
SN XR2<br>
wherein,<br>
Y is 0 or S;<br>
Ri is H, -(CH2)rCH3&gt; -CH(CH3)2, -CH(CH3)CH2C(CH3)3,<br>
-CH(CH3)(CH2)3C(=CH2)CH3,<br>
-CH(CH3)(CH2)3C(CH3)2OC(O)CH3,<br>
-CH(CH3)[CH2]3C(CH3)20CH3l -CHs(C6H5), -C(O)OH,<br>
-C(O)NH(CH2)tCH3l-C(O)O(CH2)uCH3,<br>
-C(O)OCH[(CH2)3CH3]2)-C(O)NH(CH2)VCH3,<br>
-C(0)N(CH3)2, -C(O)NHCH2(C6H5),<br>
-C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2)<br>
-C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2) -C(O)NH(C6Hn),<br>
-C(O)(NC4H8N)CH2(C6H5),-C(O)(NC5H9)CH2(C6H5),<br>
-C(0)NH(CH2)30(C6H5),-C(O)NHCH[(CH2)3CH3]2,<br>
-C(0)NH(CH2)3N(CH3)2,-C(O)NHCH2C(0)OCH2(C6H5),<br>
-C(0)N(CH3)CH2(C5H3N[CH3])1-C(0)NH(CH2)2(C5H4N))<br>
-C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30),<br>
-C(O)(NC4H8N)[CH2]2(NC5H10),-C(O)NHCH2CH(CH3)2)<br>
-C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3,<br>
-C(O)(NC4H8N)CH2C(O)NHCH(CH3)2,-C(O)(NC9H8)[OCH3]2,<br>
-C(0)NHCH2(C6H3[OCH3]2), -C(O)NHCH2(C7H5O2),<br>
-C(O)NH(CH2)2O(C6H5),-C(O)NH(CH2)2OCH3,<br>
-C(0)NH(CH2)3OCH3, -C(O)NH(CH2)4(C6H5), or<br>
-C(0)NH(CH2)3(C6H5);<br>
r is an integer from 1 to 15;<br>
s is an integer from 0 to 6;<br>
t is an integer from 0 to 6;<br>
u is an integer from 3 to 8;<br>
v is an integer from 5 to 15;<br>
XR2 is -(CH2)nCH3, -O(CH2)mCH3) -OCH(CH3)2,<br>
-OCH(CH3)(CH2)5CH3, -OCH2CH(CH3)2, -O(CH2)2OCH3)<br>
-0(CH2)2OCH2(C6H5), -0(CH2)P(C6H5), -OCH2(C6H4[(CH2)3CH3]),<br>
-0(C6H4[(CH2)3CH3]), -O(CH2)2(C6H4[CH3]), -O(CH2)3OCH2(C6H5),<br>
-O(CH2)4OCH2(C6H5), -N([CH2]7CH3)C(O)NH(CH2)7CH3,<br>
-N([CH2]6CH3)C(O)NH(CH2)6CH3l-NH(CH2)qCH3,<br>
-NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2,<br>
-NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2;<br>
n is an integer from 6 to 15;<br>
m is an integer from 1 to 15;<br>
p is an integer from 0 to 6;<br>
q is an integer from 6 to 15; and<br>
R3 is H, -CH3 or -CH2OCH3.<br>
In a further embodiment, the compound has the structure:<br>
o<br>
_ XR2<br>
wherein,<br>
Y is O or S;<br>
Ri is H, -(CH2)3CH3) -{CH2)5CH3, -(CH2)6CH3) -(CH2)7CH3,<br>
-(CH2)9CH3l -(CH2)nCH3&gt; -CH(CH3)2, -CH(CH3)CH2C(CH3)3,<br>
-CH(CH3}(CH2)3C(=CH2)CH3,<br>
-CH(CH3)(CH2)3C(CH3)2OC(O)CH3,<br>
-CH(CH3}[CH2]3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5),<br>
-(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(O)OH,<br>
-C(O)NHCH3, -C(O)NHCH2CH3, -C(0)NH(CH2)3CH3l<br>
-C(O)OCH2(C6H5), -C(O)O(CH2)SCH3, -C(O)O(CH2)6CH3,<br>
•€(0)O(CH2)7CH3l-C(O)OCH[(CH2)3CH3]2,<br>
-C(O)NH(CH2)5CH3&gt; -C(O)NH(CH2)7CH3l<br>
-C(0)NH(CH2)9CH3, -C(0)NH(CH2)nCH3)<br>
-C(0}NH(CH2)i5CH3, -C(0)N(CH3)2l -C(O)NHCH2(C6H5),<br>
-C(O)NHCH2(C5H4N),-C(O)N[(CH2)3CH3]2l<br>
-C{0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(O)NH(CeHn),<br>
-C(0)(NC4HBN)CH2{C6H5),-C(0)(NC5H9)CH2(C6H5),<br>
-C(O)NH(CH2)3O(C6H5)I-C(0)NHCH[(CH2)3CH3]2l<br>
-C(O)NH(CH2)3N(CH3)2)-C(O)NHCH2C(O)OCH2(C6H5),<br>
-C(0)N(CH3)CH2(C5H3N[CH3]))-C(0)NH(CH2)2(C5H4N)I<br>
-C(O)(NC4H8N)[CH2l2(NC5Hio),-C(0)NHCH2CH(CH3)2l<br>
-C(O)NHCH2(C5H4N)!-C(O)NHCH2C(CHS.)3)<br>
-C(O)(NC4H8N)CH2C(0)NHCH(CH3)2, -C(O)(NC9H8)[OCH332,<br>
-C(O)NHCH2(C6H3[OCH3]2), -C(O)NHCH2(C7H5O2),<br>
-C(O)NH(CH2)20(C6H5)1 -C(O)NH(CH2)2OCH3l<br>
-C(0)NH(CH2)3OCH3l -C(O)NH(CH2)4(C6H5), or<br>
-C(0)NH(CH2)3(C6H5);<br>
XR2 is -(CH2)6CH3, -(CH2)i0CH3l -(CH2)i4CH3,<br>
-0(CH2)3CH3l -0(CH2)5CH3) -O(CH2)6CH3, -0(CH2)7CH3,<br>
-0(CH2)9CH3, -CKCHsOnCHa, -O(CH2)15CH3, -OCH(CH3)2)<br>
-OCH(CH3)(CH2)5CH3l -OCH2CH(CH3)2) -O(CH2)2OCH3,<br>
-0(CH2)2OCH2(C6H5), -0(CH2)4(C6H5), -O(CH2)3(C6H5),<br>
-0(CH2)2(C6H5), -0(CeH5), -OCH2(C6H5),<br>
-OCH2(C6H4[(CH2)3CH3]),-0(C6H4[(CH2)3CH3]),<br>
-0(CH2)J(C6H4[CH3]),-0(CH2)30CH2(C6H5),<br>
-O(CH2)4OCH2(C6H5), -N([CH2]7CH3)C(O)NH(CH2)7CH3&gt;<br>
-N([CH2]6CH3)C(0)NH(CH2)6CH3,-NH(CH2)6CH3)<br>
-NH(CH2)7CH3l -NH(CH2)nCH3) -NH(CH2)i3CH3,<br>
-NH(CH2)i5CH3) -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3,<br>
-NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3) or<br>
-N([CH2]7CH3)2; and<br>
R3 is H, -CH3 or -CH2OCH3.<br>
In a further embodiment, the compound is selected from the group consisting of:<br>
6-Heptyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Hexyl-2-octyloxy-thieno[2,3-d][1)3]oxazin-4-one;<br>
2-Octyloxy-6-(1)3l3-trimethyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Butyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Heptyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Butyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Benzyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Heptyl-2-undecyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-(5-Methoxy-1,5-dimethyl-hexyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-<br>
one;<br>
6-( 1.5-Dimethyl-hex-4-enyl)-2-octyloxy-thieno[2:3-d][1,3]oxazin-4-one;<br>
6-(1,5-Dimethyl-hex-5-enyl)-2-octyloxy-thieno[2,3-d][1,31oxazin-4-one;<br>
Trifluoro-acetic acid 1,1-dimethyl-5-(2-octyloxy-4-oxo-4H-thieno[2,3-<br>
d][1,3]oxazin-6-yl)-hexyl ester;<br>
2-(2-Benzyloxy-ethoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Heptyl-5-methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-Octyloxy-6-phenethyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-Octyloxy-6-(5-phenyl-pentyl)-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-(3-Benzyloxy-propoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-(3-Benzyloxy-butyloxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-lsopropyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Octyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Dodecyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-Benzyloxy-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one;<br>
2-(4-Butylbenzyloxy)-6-Decyl-thieno[2,3-d][1j3]oxazin-4-one;<br>
6-Decyl-2-(2-p-tolyl-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one;<br>
6-Decyl-2-phenethyloxy-thieno[2,3-d][1,3]oxazin-4-one;<br>
3-Methyl-6-octyl-2-octyloxy-5H-thieno[2,3-b]pyridin-4-one;<br>
2-Butoxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;<br>
2-Hexyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;<br>
2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;<br>
6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridinr4-one;<br>
2-Decyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one;<br>
e-Benzyl^-octyloxythieno^.S-cdll.Sloxazin^-one;<br>
6-Decyl-2-octyloxythienot2,3-d][1,3]oxazin-4-one;<br>
6-Decyl-2-(1 -methylheptyloxy)thieno[2,3-cd[1,3joxazin-4-one;<br>
6-Heptyl-2-(1 -methylheptyloxy)thieno[2,3-c(l[1,3]oxazin-4-one;<br>
e-Decyl-2-(4-phenylpropoxy)thieno[2,3-c(|[1,3]oxazin-4-one; and<br>
6-Decyl-2-(4-phenylbutoxy)thieno[2,3-<j></j>
!3<br>
The subject invention also provides compounds having the structure:<br>
o<br>
wherein,<br>
RIO is H or substituted or unsubstituted CrC15 alkyl, CrC15<br>
alkylaryl, or -C(O)Ri4,<br>
wherein R^ is hydroxyl, or a substituted or unsubstituted<br>
CrC30 alkyl, alkylamino, dialkylamino, alkoxy, benzyloxy, cycloalkyl,<br>
alkylheteroaryl, alkylaryl, or a heterocyclic, heteroaryl or aryl ring;<br>
Rn is hydrogen or methyl;<br>
Ria is hydrogen or te/t-butyl; and<br>
Ria is hydrogen or -C(O)ZR15,<br>
wherein Z is CH2, O or N and RIB is substituted or<br>
unsubstituted Crds alkyl or aryl.<br>
The subject invention also provides a method for treating obesity in a subject in<br>
need of such treatment, comprising administering to the subject a therapeutically<br>
effective amount of a compound of the invention so as to thereby treat obesity in<br>
the subject.<br>
The subject invention also provides a method for treating diabetes in a subject in<br>
need of such treatment, comprising administering to the subject a therapeutically<br>
effective amount of a compound of the invention so as to thereby treat diabetes in<br>
the subject.<br>
The subject invention also provides a method of inhibiting the hydrolytic activity of<br>
pancreatic lipase enzymes in a cell, 'comprising contacting the cell with an<br>
amount of a compound of the invention which is effective in inhibiting thb<br>
hydrolytic activity of pancreatic lipase enzymes.<br>
The above method may contact the cell either in vitro or in vivo.<br>
The subject invention also provides a pharmaceutical composition comprising the<br>
a compound or the invention and a pharmaceutically acceptable carrier.<br>
In one embodiment, the pharmaceutical composition is formulated for oral,<br>
topical, parenteral, or nasal administration. ,<br>
The subject invention also provides a process for the manufacture of a<br>
pharmaceutical composition comprising admixing a compound of the invention<br>
with a pharmaceutically acceptable carrier.<br>
The subject invention also provides an article of manufacture comprising<br>
packaging material;<br>
the above pharmaceutical composition; and ,<br>
instructions for use of the pharmaceutical composition in the treatment<br>
of obesity.<br>
The subject invention also provides a process of manufacturing a compound<br>
having the structure:<br>
N XR2<br>
wherein,<br>
X is 0, S, CH2 or NR6;<br>
RI is H, substituted or unsubstituted CrCi5alkyl, CrC6 alkylaryl,<br>
-C(0)OR4, -C(O)NR4R5, -CR6R6.OR4, -CR6R6.OC(O)R4,<br>
-CReR6OC(O)NHR7, -C(O)NR8R9, -<br>
-N(R5)C(0)NHR5, or CH2R4;<br>
R2 is a substituted or unsubstituted, straight chain CrCso alkyl or<br>
branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, heteroarylalkyi or cycloalkyi;<br>
R3 is H or substituted or unsubstituted d-C6 alkyl or cycloalkyi;<br>
R4 is H or a substituted or unsubstituted, straight chain or<br>
branched, Ce-Cso alkyl, aryl, -CH2-aryl, arylalkyi, heteroarylalkyi<br>
or cycloalkyi;<br>
R5 is H or a substituted or unsubstituted, straight chain or<br>
branched, Ce-Cso alkyl, arylalkyi, heteroarylalkyi or cycloalkyi;<br>
R6 and R6* are each independently H, substituted or<br>
unsubstituted CrC6 alkyl, dialkyi or cycloalkyi or together form a<br>
3-7 membered ring system;<br>
R7 is H or substituted or unsubstituted CrC12 alkyl or<br>
cycloalkyi;<br>
R8 and R9 are each independently H, substituted or<br>
unsubstituted CrC6 alkyl, C-i-Ce alkoxy, d-C6 alkylaryl, or<br>
NR8R9 together form a substituted piperazine or piperidine ring<br>
or a dihydro-1 H-isoquinoline ring system,<br>
comprising<br>
(a) reacting<br>
o<br>
NC and<br>
Rin<br>
the presence of sulfur, a base and solvent to produce:<br>
o<br>
H<br>
(b) reacting the product of step (a) with<br>
0<br>
c<br>
in the presence of a base to produce:<br>
(c) reacting the product of step (b) with trifluoroacetic acid (TFA) in the presence<br>
of solvent to produce:<br>
Q<br>
(d) reacting the product of step (c) with SOCI2 in the presence of solvent to<br>
produce the compound.<br>
In one embodiment of the above process, the base in step (a) is triethyl amine<br>
and the solvent is dimethylformamide (DMF).<br>
In a further embodiment, the solvent in step (c) is dichloromethane,<br>
In a further embodiment, the solvent in step (d) is pyridine:CH2CI2.<br>
The subject invention also provides a compound produced by the above process.<br>
The subject invention also provides the use of the compounds of the invention for<br>
manufacturing a medicament useful for treating obesity in a subject.<br>
The subject invention also provides the use of the compounds of the invention<br>
for manufacturing a medicament useful for treating diabetes in a subject.<br>
The subject invention also provides the use of the compounds of the invention<br>
for manufacturing a medicament useful for inhibiting the hydrolytic activity of<br>
pancreatic lipase enzymes in a cell.<br>
The inhibition of the cell may be effected either in vitro or in vivo.<br>
The subject invention also provides the above compounds, wherein any<br>
heterocyclic or heteroaryl ring, if present, is a piperazine, piperidine,<br>
(1,4)diazepan, pyrazine, pyridine, pyrrolidine, pyrazole, pyrimidine, thiophene,<br>
imidazole, azetidine, pyrrole, benzothiazole, benzodioxolane, dithiolane,<br>
oxathiine, imidazolidine, quinoline, isoquinoline, dihydroisoquinoline, indole,<br>
isoindole, triazaspiro[4.5]decane, morpholine, furan or an isothiazole ring.<br>
The subject invention also provides any of the above compounds, wherein any<br>
substituent, if present, is halogen, hydroxyl, straight chain (CrC3o)alkyl,<br>
branched chain (C3-C30)alkyl, (C3-Ci0)cycloalkyl, straight chatn(Ci<br>
C30)alkylcarbonyloxy, branched chain (C3-C3o)alkylcarbonyloxy, arylcarbonyloxy,<br>
straight chain(Ci-C3o)alkoxycarbonyloxy, branched chain(C3-<br>
C3o)alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight chain(d-<br>
C3o)alkylcarbonyl, branched chain (C3-C3o)alkylcarbonyl, straight chain (d-<br>
C30)alkoxycarbonyl, branched chain (C3-C3o)alkoxycarbonyl, aminocarbonyl,<br>
straight chain . (d-CsoJalkylthiocarbonyl, branched chain (C3-<br>
C3o)alkylthiocarbonyl, straight chain (C-rC3o)alkoxyl, branched chain (Cr<br>
C3o)alkoxyl, phosphate, phosphonato, cyano, amino, straight chain (Cr<br>
C3o)alkylamino, branched chain (C3-C30)alkylamino, straight chain (d-<br>
C3o)dialkylamino, branched chain (C3-C3o)dialkylamino, arylamino, diarylamino,<br>
straight chain (Ci-C30)alkylarylamino, branched chain (Cs-C^alkylarylamino,<br>
acylamino, straight chain (CrC3o)alkylcarbonylamino, branched chain (C3-<br>
C3o)alkylcarbonylamino, arylcarbonylamino, carbamoyl, ureido, amidino, imino,<br>
sulfhydryl, straight chain (Ci-C30)alkylthio, branched chain (C3-C30)alkylthio,<br>
arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl, sulfonamido, nitro,<br>
trifluoromethyl, azido, 4-10 membered heterocyclyl, straight chain (d-<br>
C30)alkylaryl, branched chain (C3-Cx)alkylaryl, benzo(1,3)dioxole, or an aromatic<br>
or 5-6 membered heteroaromatic moiety,<br>
which substituent may be further substituted by any of the above.<br>
The number of carbons when represented as "(CrC30)" or "(C3-C3o)M is intended to<br>
mean any incremental whole number between 1 and 3 and 30, e.g. 1, 2, 3, 4, 5 ... or<br>
30.<br>
Additional embodiments of the compounds of this invention are described below.<br>
Entry structure MW k<br>
0-3.S-1<br>
Ymax % inhibit MP<br>
399.5<br>
CH,<br>
H.C<br>
455.6<br>
511.7<br>
-o V 393.6<br>
Crt,<br>
429.! 0.649<br>
485.7<br>
541.8 0.779<br>
H,C CH,<br>
415.E 1.052<br>
451J 0.924 0.286 58.5-60.2<br>
10 rY 423J 1.349<br>
11<br>
PH<br>
339.4 0.547<br>
12 381.5 0.438 47.5-48.0<br>
13 583.8 0.414<br>
14 555.7 0.459<br>
15 450.', 1.548<br>
16 OH,<br>
428.6 1.711 153.5-154.Q<br>
17 414.5 1,74<br>
18 449.7 1.036 18.03% 152.0-152.8<br>
19<br>
:«, p<br>
506.6 0.981<br>
20 450. 0.922<br>
21<br>
H.I<br>
427.6 1.079<br>
22<br>
CH,<br>
365.5 0.537<br>
23 295.4 0.893<br>
24 505.8 1.849 137.1-138.C<br>
25 533.8 1.629 145.0-145.8<br>
26 561.9 1.709 146.3-147.0<br>
•Vv<br>
27 421.6 2.577<br>
28 477; 0.998<br>
29 505.8 0.797<br>
•A*<br>
30 61.9 0.433<br>
31 351.5 0.777 152.5-158<br>
32 ,<br>
f<br>
393.6 2.447<br>
33<br>
rNH<br>
CH,<br>
365.5 0.547<br>
34 ^ H"<br>
428.6 0.864<br>
35 428.6 1.544 148-150<br>
36 449.7<br>
CH,<br>
0.146 0.616<br>
514.7 0.574 0.211<br>
193.5-195<br>
(decomp)<br>
p<br>
o<br>
CO<br>
T— CM<br>
CD<br>
O)<br>
CO co<br>
CM<br>
O&gt;<br>
CO<br>
CO<br>
in<br>
CO in CM<br>
I-;<br>
CD<br>
en co<br>
O<br>
i—<br>
T— d<br>
r-.<br>
cd 01<br>
oi<br>
n<br>
06<br>
oco<br>
oino<br>
CO in<br>
in •*<br>
CM<br>
CM<br>
d<br>
CO<br>
CM<br>
00<br>
in<br>
CM<br>
coo<br>
en8<br>
d<br>
in at •&gt;*•<br>
CO<br>
co<br>
CO<br>
or-. iv<br>
CD<br>
r-.<br>
CO<br>
CO<br>
CM coq<br>
d<br>
cq<br>
co<br>
47 CM, 449.7 0.191 0.943<br>
48 485.6 0.440 147-149<br>
49 456.6 0.022<br>
50 442.6 0.719<br>
51 CH,<br>
H3C 470.6 0.012<br>
52 417.5 1.257<br>
53 517. 0.166<br>
,CH,<br>
54 393.6 0.702<br>
55 428. 0.754<br>
56 444.6 0.114<br>
57<br>
K,C 0<br>
414.5 0.070 86-88<br>
58 407.6 0.723 173-174.5<br>
59 442.6 0.222 136-138<br>
60 540.8 0.013<br>
61 378.6 0.247 0.460 89-91<br>
62 370.5 0.103 1.901 123.0-124.0<br>
63 336.5 0.074 10.091 93.0-94.0<br>
64 505.7 0.176 3.917<br>
65<br>
,-CH,<br>
513.7 0.284 0.339 77-80<br>
66<br>
Hfl<br>
fiV^O<br>
K.C-O"<br>
487.6 1.027 0.118 159.0-163,<br>
67 405.7 0.064 10.973 oil<br>
68 ,CM, 379.6 5.825 0.020 78.94% oil<br>
69<br>
H,o<br>
471.6 1.137 0.112 149-152<br>
70 ,« -^ 457.6 1.999 0.140<br>
71 428.6 0.086<br>
H,C O<br>
14.657<br>
72 395.5 1.102 0.185<br>
H.O-0<br>
73 Y 409.i 0.794 1.594<br>
74 393.6 0.422 0.982<br>
75 n,c 337.5 2.219 0.054 oil<br>
76 H3C 323.5 1.288 0.161 oil<br>
77 371.5 0.392 0.482 oil<br>
78 379.6 1.315 0.126 17.86% oil<br>
79 469.7 69.49% 153-154<br>
80 455.6 66.27% 139-141<br>
81 391.6 66.46% oil<br>
82 491.6 84.90% oil<br>
83<br>
o<br>
H.C-0<br>
423.6 36.93% Oil<br>
84 365.5 3.033 0.029 71.26% Oil<br>
85 393.6 96.13% oil<br>
86 421.6 73.58% oil<br>
87 407.6 27.91% 36<br>
88 449.7 74.21%<br>
89 OY"-^—^C<br>
c«» 429.5 -14.14% oil<br>
90 421.7<br>
CM.<br>
15.03% oil<br>
91 379.6 12.44% Oil<br>
92 397.6<br>
O CH,<br>
oil<br>
93 411.6 oil<br>
94 H.C 365. 83.03% oil<br>
95 337.5 60.26% oil<br>
96 367.5 38-41<br>
97 443.6 oil<br>
98<br>
H,C<br>
441.6 oil<br>
99<br>
H.C<br>
427.6 oil<br>
100 449.7 Oil<br>
101<br>
yo<br>
o / 357.5 oil<br>
102 441.6 55-58<br>
10C 385.! oil<br>
HO'<br>
1.1.<br>
ou<br>
601-<br>
801<br>
901-<br>
9'668 JO I.<br>
9'66e<br>
'HO'<br>
113 429,5<br>
K,C O<br>
114<br>
•0 /<br>
Hi 395.5<br>
'-3<br>
"k" and "Ymax" in the above table correspond to values inn the equation appearing<br>
on page 159. All compounds listed as oils were oils at room temperature.<br>
The language "therapeutically effective amount" of the compounds of the invention,<br>
described infra, refers to that amount of a therapeutic compound necessary or<br>
sufficient to perform its intended function within a mammal. An effective amount of<br>
the therapeutic compound can vary according to factors such as the amount of the<br>
causative agent already present in the mammal, the age, sex, and weight of the<br>
mammal, and the ability of the therapeutic compounds of the present invention to<br>
affect the desired result in the mammal. One of ordinary skill in the art would be able<br>
to study the aforementioned factors and make a determination regarding the<br>
effective amount of the therapeutic compound without undue experimentation. An in<br>
vitro or in vivo assay also can be used to determine an "effective amount" of the,<br>
therapeutic compounds described infra. The ordinarily skilled artisan would select<br>
an appropriate amount of the therapeutic compound for use in the aforementioned<br>
assay or as a therapeutic treatment.<br>
A therapeutically effective amount preferably diminishes at least one symptom or<br>
effect associated with the disorder being treated by at least about 20%, (more<br>
preferably by at least about 40%, even more preferably by at least about 60%, and<br>
still more preferably by at least about 80%) relative to untreated subjects. Assays<br>
can be designed by one skilled in the art to measure the diminishment of such<br>
symptoms and/or effects. Any art recognized assay capable of measuring such<br>
parameters are intended to be included as part of this invention.<br>
The term "animal" includes any organism with adenosine receptors. Examples of<br>
animals include yeast, mammals, reptiles, and birds. It also includes transgenic<br>
animals.<br>
The term "mammal" is art recognized and is intended to include an animal, more<br>
preferably a warm-blooded animal, most preferably cattle, sheep, pigs, horses, dogs,<br>
cats, rats, mice, and humans. Mammals susceptible to obesity associated disorders<br>
are included as part of this invention.<br>
33<br>
The term "alky!" refers to the radical of saturated aliphatic groups, including straightchain<br>
alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl<br>
substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred<br>
embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms<br>
in its backbone (e.g., Ci-C30 for straight chain, C3-C3o for branched chain), and more<br>
preferably 20 or fewer. Likewise, preferred cycloalkyls have from 4-10 carbon atoms<br>
in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring<br>
structure.<br>
The term "substituted alkyl", refers to alkyl moieties having substituents replacing a<br>
hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents<br>
can include, for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy,<br>
alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl,<br>
aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato,<br>
cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and<br>
alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino,<br>
carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate,<br>
sulfates, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido,<br>
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. It will be understood<br>
by those skilled in the art that the moieties substituted on the hydrocarbon chain can<br>
themselves be substituted, if appropriate. Cycloalkyls can be further substituted,<br>
e.g., with the substituents described above. An "alkylaryl" moiety is an alkyl<br>
substituted with an aryl (e.g., phenylmethyl (benzyl)). The term "alkyl" also includes<br>
unsaturated aliphatic groups analogous in length and possible substitution to the<br>
alkyls described above, but that contain at least one double or triple bond<br>
respectively.<br>
The term "aryl" as used herein, refers to the radical of aryl groups, including 5- and<br>
6-membered single-ring aromatic groups that may include from zero to four<br>
heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole,<br>
benzoxazole, benzothiazole, triazole, tetrazole, pyrazole, pyridine, pyrazine,<br>
pyridazine and pyrimidine, and the like. Aryl groups also include polycyclic fused<br>
aromatic groups such as naphthy', quinolyi, indolyl, and the like. Those aryl groups<br>
having heteroatoms in the ring structure may also be referred to as "aryl<br>
heterocycles", "heteroaryls" or ' heteroaromatics". The aromatic ring can be<br>
substituted at one or more ring positions with such substituents as described above,<br>
as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy,<br>
alkoxycarbonyloxy, aryloxycarbonyioxy, carboxylate, alkylcarbonyl, alkoxycarbonyl,<br>
aminocarbonyl, alkylthiocarbonyi, phosphate, phosphonato, phosphinato, cyano,<br>
amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and<br>
alkylarylamino), acylamino (incUding alkylcarbonylamino, arylcarbonylamino,<br>
carbamoyi and ureido), amidino, irruno, sulfhydryl, alkylthio, arylthio, thiocarboxylate,<br>
suifates, sulfonato, sulfamoyl, suifonamido, nitro, trifluoromethyl, cyano, azido,<br>
heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Aryl groups can also<br>
be fused or bridged with alicyclic or heterocyclic rings which are not aromatic so as<br>
to form a polycycle (e.g., tetralin).<br>
The terms "alkenyl" and "alkynyl" refer to unsaturated aliphatic groups analogous in<br>
length and possible substitution to the alkyls described above, but that contain at<br>
least one double or triple bond respectively. For example, the invention<br>
contemplates cyano and propargyl groups.<br>
Unless the number of carbons is otherwise specified, "lower alky!" as used herein<br>
means an alkyl group, as defined above, but having from one to ten carbons, more<br>
preferably from one to six carbon atoms in its backbone structure, even more<br>
preferably one to three carbon atoms in its backbone structure. Likewise, "lower<br>
alkenyl" and "lower alkynyl" have similar chain lengths.<br>
The terms "alkoxyalkyl", "polyaminoalkyl" and "thioalkoxyalkyl" refer to alkyl groups,<br>
as described above, which further include oxygen, nitrogen or sulfur atoms replacing<br>
one or more carbons of the hydrocarbon backbone, e.g., oxygen, nitrogen or sulfur<br>
atoms.<br>
The terms "poiycyclyl" or "polycyclic radical" refer to the radical of two or more cyclic<br>
rings (e.g., cycloalkyls, cycloalkenyls, c.ycloalkynyls, aryls and/or heterocyclyls) in<br>
which two or more atoms are common to two adjoining rings, e.g., the rings are<br>
"fused rings". Rings that are joined through non-adjacent atoms are termed<br>
"bridged" rings. Each of the rings of the polycycle can be substituted with such<br>
substituents as described above, as for example, halogen, hydroxyl,<br>
alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy,<br>
carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl,<br>
phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino,<br>
dialkylamino, arylarnino, diarylamino, and alkylarylamino), acylamino (including<br>
alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino,<br>
sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonato, sulfamoyl,<br>
sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkyl, alkylaryl, or an<br>
aromatic or heteroaromatic moiety.<br>
The term "heteroatom" as used herein means an atom of any element other than<br>
carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and<br>
phosphorus.<br>
i"<br>
The term "heterocycle" or "heterocyclic system" as used herein is intended to mean a<br>
stable 5, 6 or 7-membered monocyclic or 7, 8, 9, 10 or 11- membered bicyclic<br>
heterocyclic ring which is saturated or partially unsaturated.<br>
The terms "carbocyclic" or "heterocyclic" further include spiro compounds, which<br>
denote a bicyclic compound in which the two rings have one atom in common and<br>
the atom may be carbon or a heteroatom.<br>
The term "amino acids" includes naturally and unnaturally occurring amino acids<br>
found in proteins such as glycine, alanine, valine, cysteine, leucine, isoleucine,<br>
serine, threonine, methionine, glutamic acid, aspartic acid, glutamine, asparagine,<br>
lysine, arginine, proline, histidine, phenylalanine, tyrosine, and tryptophan. Amino<br>
acid analogs include amino acids with lengthened or shortened side chains or variant<br>
side chains with appropriate functional groups. Amino acids also include D and L<br>
stereoisomers of an amino acid when the structure of the amino acid admits of<br>
stereoisomeric forms. The term "dipeptide" includes two or more amino acids linked<br>
together. Preferably, dipeptides are two amino acids linked via a peptide linkage.<br>
Particularly preferred dipeptides include, for example, alanine-alanine and glycinealanine.<br>
It will be noted that the structure of some of the compounds of this invention includes<br>
asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single<br>
enantiomers, diastereomeric mixtures and individual diastereomers. All such<br>
isomeric forms of these compounds are expressly included in this invention. Each<br>
stereogenic carbon may be of the R or S configuration. It is to be understood<br>
accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and<br>
diastereomers) are included within the scope of this invention, unless indicated<br>
otherwise. Such isomers can be obtained in substantially pure form by classical<br>
separation techniques and by stereochemically controlled synthesis.<br>
The invention further pertains to pharmaceutical compositions for treating obesity<br>
and obesity associated disorders in a mammal. The pharmaceutical composition<br>
includes a therapeutically effective amount of a compound of the invention and a<br>
pharmaceutically acceptable carrier. It is to be understood, that all of the<br>
compounds described below are included for therapeutic treatment. It is to be<br>
further understood that the compounds of the invention can be used alone or in<br>
combination with other compounds of the invention or in combination with additional<br>
therapeutic compounds, such as antibiotics, antiinflammatories, or anticancer<br>
agents, for example.<br>
The term "antibiotic" is art recognized and is intended to include those substances<br>
produced by growing microorganisms and synthetic derivatives thereof, which<br>
eliminate or inhibit growth of pathogens and are selectively toxic to the pathogen<br>
while producing minimal or no deleterious effects upon the infected host subject.<br>
Suitable examples of antibiotics include, but are not limited to, the principle classes<br>
of aminoglycosides, cephalosporins, chloramphenicols, fuscidic acids, macrolides,<br>
penicillins, polymixins, tetracyclines and streptomycins.<br>
The term "antiinflammatory" is art recognized and is intended to include those agents<br>
which act on body mechanisms, without directly antagonizing the causative agent of<br>
the inflammation such as glucocorticoids, aspirin, ibuprofen, NSAIDS, etc.<br>
The term "anticancer agent" is art recognized and is intended to include those agents<br>
which diminish, eradicate, or prevent growth of cancer cells without, preferably,<br>
adversely affecting other physiological functions. Representative examples include<br>
cisplatin and cyclophosphamide.<br>
When the compounds of the present invention are administered as Pharmaceuticals,<br>
to humans and mammals, they can be given per se or as a pharmaceutical<br>
composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of<br>
active ingredient in combination with a pharmaceutically acceptable carrier.<br>
The phrase "pharmaceutically acceptable carrier" as used herein means a<br>
pharmaceutically acceptable material, composition or vehicle, such as a liquid or<br>
solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying<br>
or transporting a compound(s) of the present invention within or to the subject such<br>
that it can performs its intended function. Typically, such compounds are carried or<br>
transported from one organ, or portion of the body, to another organ, or portion of the<br>
body. Each carrier must be "acceptable" in the sense of being compatible with the<br>
other ingredients of the formulation and not injurious to the patient. Some examples<br>
of materials which can serve as pharmaceutically acceptable carriers include:<br>
sugars, such as lactose, glucose and sucrose; starches, such as corn starch and<br>
potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose,<br>
ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc;<br>
excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil,<br>
cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols,<br>
such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and<br>
polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering<br>
agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid;<br>
pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer<br>
solutions; and other non-toxic compatible substances employed in pharmaceutical<br>
formulations.<br>
As set out above, certain embodiments of the present compounds can contain a<br>
basic functional group, such as amino or alkylamino, and are, thus, capable of<br>
forming pharmaceutically acceptable salts with pharmaceutically acceptable acids.<br>
The term "pharmaceutically acceptable salts" in this respect, refers to the relatively<br>
non-toxic,inorganic and organic acid addition salts of compounds of the present<br>
invention. These salts can be prepared in situ during the final isolation and<br>
purification of the compounds of the invention, or by separately reacting a purified<br>
compound of the invention in its free base form with a suitable organic or inorganic<br>
acid, and isolating the salt thus formed. Representative salts include the<br>
hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate,<br>
oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate,<br>
maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate,<br>
lactobionate, and laurylsulphonate salts and the like. (See, e.g., Berge et al. (1977)<br>
"Pharmaceutical Salts", J. Pharm. Sci. 66:1-19).<br>
In other cases, the compounds of the present invention may contain one or more<br>
acidic functional groups and, thus, are capable of forming pharmaceutically<br>
acceptable salts with pharmaceutically acceptable bases. The term<br>
"pharmaceutically acceptable salts" in these instances refers to the relatively nontoxic,<br>
inorganic and organic base addition salts of compounds of the present<br>
invention. These salts can likewise be prepared in situ during the final isolation and<br>
purification of the compounds, or by separately reacting the purified compound in its<br>
free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate<br>
of a pharmaceutically acceptable metal cation, with ammonia, or with a<br>
pharmaceutically acceptable organic primary, secondary or tertiary amine.<br>
Representative alkali or alkaline earth salts include the lithium, sodium, potassium,<br>
calcium, magnesium, and aluminum salts and the like. Representative organic<br>
amines useful for the formation of base addition salts include ethylamine,<br>
diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the<br>
like.<br>
The term "pharmaceutically acceptable esters" refers to the relatively non-toxic,<br>
esterified products of the compounds of the present invention. These esters can be<br>
prepared in situ during the final isolation and purification of the compounds, or by<br>
separately reacting the purified compound in its free acid form or hydroxyl with a<br>
suitable esterifying agent. Carboxylic acids can be converted into esters via<br>
treatment with an alcohol in the presence of a catalyst. Hydroxyl containing<br>
derivatives can be converted into esters via treatment with an esterifying agent such<br>
as alkanoyl halides. The term is further intended to include lower hydrocarbon<br>
groups capable of being solvated under physiological conditions, e.g., alkyl esters,<br>
methyl, ethyl and propyl esters. (See, for example, Berge era/., supra.)<br>
The invention further contemplates the use of prodrugs which are converted in vivo<br>
to the therapeutic compounds of the invention (see, e.g., R.B. Silverman, 1992, "The<br>
Organic Chemistry of Drug Design and Drug Action", Academic Press, Chapter 8).<br>
Such prodrugs can be used to alter the biodistribution (e.g., to allow compounds<br>
which would not typically enter the reactive site of the protease) or the<br>
pharmacokinetics of the therapeutic compound. For example, a carboxylic acid<br>
group, can be esterified, e.g., with a methyl group or an ethyl group to yield an ester.<br>
When the ester is administered to a subject, the ester is cleaved, enzymatically or<br>
non-enzymatically, reductively or hydrolytically, to reveal the anionic group. An<br>
anionic group can be esterified with moieties (e.g., acyloxymethyl esters) which are<br>
cleaved to reveal an intermediate compound which subsequently decomposes to<br>
yield the active compound. In another embodiment, the prodrug is a reduced form of<br>
a sulfate or sulfonate, e.g., a thiol, which is oxidized in vivo to the therapeutic<br>
compound. Furthermore, an anionic moiety can be esterified to a group which is<br>
actively transported in vivo, or which is selectively taken up by target organs. The<br>
ester can be selected to allow specific targeting of the therapeutic moieties to<br>
particular reactive sites, as described below for carrier moieties.<br>
The compounds of the invention may comprise water-soluble prodrugs which are<br>
described in WO 99/33815, International Application No. PCT/US98/04595, filed<br>
March 9, 1998 and published July 8, 1999. The entire content of WO 99/33815 Is<br>
expressly incorporated herein by reference. The water-soluble prodrugs are<br>
metabolized in v/Voto an active drug, e.g., by esterase catalyzed hydrolysis.<br>
Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and<br>
magnesium stearate, as well as coloring agents, release agents, coating agents,<br>
sweetening, flavoring and perfuming agents, preservatives and antioxidants can also<br>
be present in the compositions.<br>
Examples of pharmaceutically acceptable antioxidants include: water soluble<br>
antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium<br>
metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl<br>
palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin,<br>
propyl gallate, alpha-tocopherol, and the like; and metal chelating agents, such as<br>
citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric<br>
acid, and the like.<br>
Formulations of the present invention include those suitable for oral, nasal, topical,<br>
transdermal, buccal, sublihgual, rectal, vaginal and/or parenteral administration. The<br>
formulations may conveniently be presented in unit dosage form and may be<br>
prepared by any methods well known in the art of pharmacy. The amount of active<br>
ingredient which can be combined with a carrier material to produce a single dosage<br>
form will generally be that amount of the compound which produces a therapeutic<br>
effect. Generally, out of one hundred per cent, this amount will range from about 1<br>
per cent to about ninety-nine percent of active ingredient, preferably from about 5 per<br>
cent to about 70 per cent, most preferably from about 10 per cent to about 30 per<br>
cent.<br>
Methods of preparing these formulations or compositions include the step of bringing<br>
into association a compound of the present invention with the carrier and, optionally,<br>
one or more accessory ingredients. In general, the formulations are prepared by<br>
uniformly and intimately bringing into association a compound of the present<br>
invention with liquid carriers, or finely divided solid carriers, or both, and then, if<br>
necessary, shaping the product.<br>
Formulations of the invention suitable for oral administration may be in the form of<br>
capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose<br>
and acacia or tragacanth), powders, granules, or as a solution or a suspension in an<br>
aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion,<br>
or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and<br>
glycerin, or sucrose and acacia) and/or as mouth washes and the like, each<br>
containing a predetermined amount of a compound of the present invention as an<br>
active ingredient. A compound of the present invention may also be administered as<br>
a bolus, electuary or paste.<br>
In solid dosage forms of the invention for oral administration (capsules, tablets, pills,<br>
dragees, powders, granules and the like), the active ingredient is mixed with one or<br>
more pharmaceutically acceptable carriers, such as sodium citrate or dicalcium<br>
phosphate, and/or any of the following: fillers or extenders, such as starches,<br>
lactose, sucrose, glucose, mannitol, and/or silicic acid; binders, such as, for example,<br>
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or<br>
acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar,<br>
calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and<br>
sodium carbonate; solution retarding agents, such as paraffin; absorption<br>
accelerators, such as quaternary ammonium compounds; wetting agents, such as,<br>
for example, acetyl alcohol and glycerol monostearate; absorbents, such as kaolin<br>
and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate,<br>
solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and coloring<br>
agents. In the case of capsules, tablets and pills, the pharmaceutical compositions<br>
may also comprise buffering agents. Solid compositions of a similar type may also<br>
be employed as fillers in soft and hard-filled gelatin capsules using such excipients<br>
as lactose or milk sugars, as well as high molecular weight polyethylene glycols and<br>
the like.<br>
A tablet may be made by compression or molding, optionally with one or more<br>
accessory ingredients. Compressed tablets may be prepared using binder (for<br>
example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent,<br>
preservative, disintegrant (for example, sodium starch glycolate or cross-linked<br>
sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets<br>
may be made by molding in a suitable machine a mixture of the powdered<br>
compound moistened with an inert liquid diluent.<br>
The tablets, and other solid dosage forms of the pharmaceutical compositions of the<br>
present invention, such as dragees, capsules, pills and granules, may optionally be<br>
scored or prepared with coatings and shells, such as enteric coatings and other<br>
coatings well known in the pharmaceutical-formulating art. They may also be<br>
formulated so as to provide slow or controlled release of the active ingredient therein<br>
using, for example, hydroxypropylmethyl cellulose in varying proportions to provide<br>
the desired release profile, other polymer matrices, liposomes and/or microspheres.<br>
They may be sterilized by, for example, filtration through a bacteria-retaining filter, or<br>
by incorporating sterilizing agents in the form of sterile solid compositions which can<br>
be dissolved in sterile water, or some other sterile injectable medium immediately<br>
before use. These compositions may also optionally contain opacifying agents and<br>
may be of a composition that they release the active ingredient(s) only, or<br>
preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed<br>
manner. Examples of embedding compositions which can be used include polymeric<br>
substances and waxes. The active ingredient can also be in micro-encapsulated<br>
form, if appropriate, with one or more of the above-described excipients.<br>
Liquid dosage forms for oral administration of the compounds of the invention<br>
include pharmaceutically acceptable emulsions, microemulsions, solutions,<br>
suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage<br>
forms may contain inert dilutents commonly used in the art, such as, for example,<br>
water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol,<br>
isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,<br>
propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn,<br>
germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene<br>
glycols and fatty acid esters of sorbitan, and mixtures thereof.<br>
Besides inert clHutents, the oral compositions can also include adjuvants such as<br>
wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring,<br>
perfuming and preservative agents.<br>
Suspensions, in addition to the active compounds, may contain suspending agents<br>
as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and<br>
sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agaragar<br>
and tragacanth, and mixtures thereof.<br>
Formulations of the pharmaceutical compositions of the invention for rectal or vaginal<br>
administration may be presented as a suppository, which may be prepared by mixing<br>
one or more compounds of the invention with one or more suitable nonirritating<br>
excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a<br>
suppository wax or a salicylate, and which is solid at room temperature, but liquid at<br>
body temperature and, therefore, will melt in the rectum or vaginal cavity and release<br>
the active compound.<br>
Formulations of the present invention which are suitable for vaginal administration<br>
also include pessaries, tampons, creams, gels, pastes, foams or spray formulations<br>
containing such carriers as are known in the art to be appropriate.<br>
Dosage forms for the topical or transderrnal administration of a compound of this<br>
invention include powders, sprays, ointments, pastes, creams, lotions, gels,<br>
solutions, patches and inhalants. The active compound may be mixed under sterile<br>
conditions with a pharmaceutically acceptable carrier, and with any preservatives,<br>
buffers, or propellants which may be required.<br>
The ointments, pastes, creams and gels may contain, in addition to an active<br>
compound of this invention, excipients, such as animal and vegetable fats, oils,<br>
waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols,<br>
silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.<br>
Powders and sprays can contain, in addition to a compound of this invention,<br>
excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium sii'cate?<br>
and polyamide powder, or mixtures of these substances. Sprays can additionally<br>
contain customary propellants, such as chlorofluorohydrocarbons and volatile<br>
unsubstituted hydrocarbons, such as butane and propane.<br>
Transdermal patches have the added advantage of providing controlled delivery of a<br>
compound of the present invention to the body. Such dosage forms can be made by<br>
dissolving or dispersing the compound in the proper medium. Absorption enhancers<br>
can also be used to increase the flux of the compound across the skin. The rate of<br>
such flux can be controlled by either providing a rate controlling membrane or<br>
dispersing the active compound in a polymer matrix or gel.<br>
An appropriate buffer system (e.g., sodium phosphate, sodium acetate or sodium<br>
borate) may be added to prevent pH drift under storage conditions.<br>
Pharmaceutical compositions of this invention suitable for parenteral administration<br>
comprise one or more compounds of the invention in combination with one or more<br>
pharmaceutically acceptable sterile isotonic aqueous or nonaqueous solutions,<br>
dispersions, suspensions or emulsions, or sterile powders which may be<br>
reconstituted into sterile injectable solutions or dispersions just prior to use, which<br>
may contain antioxidants, buffers, bacteriostats, solutes which render the formulation<br>
isotonic with the blood of the intended recipient or suspending or thickening agents.<br>
Examples of suitable aqueous and nonaqueous carriers which may be employed in<br>
the pharmaceutical compositions of the invention include water, ethanol, polyols<br>
(such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable<br>
mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such<br>
as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating<br>
materials, such as lecithin by the maintenance of the required particle size in the<br>
case of dispersions, and by the use of surfactants.<br>
These compositions may also contain adjuvants such as preservatives, wetting<br>
agents, emulsifying agents and dispersing agents. Prevention of the action of<br>
microorganisms may be ensured by the inclusion of various antibacterial and<br>
antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the<br>
like. It may also be desirable to include isotonic agents, such as sugars, sodium<br>
chloride, and the like into the compositions. In addition, prolonged absorption of the<br>
injectable pharmaceutical form may be brought about by the inclusion of agents<br>
which delay absorption such as aluminum monostearate and gelatin.<br>
In some cases, in order to prolong the effect of a drug, it is desirable to slow the<br>
absorption of the drug from subcutaneous or intramuscular injection. This may be<br>
accomplished by the use of a liquid suspension of crystalline or amorphous material<br>
having poor water solubility. The rate of absorption of the drug then depends upon its<br>
rate of dissolution which, in turn, may depend upon crystal size and crystalline form.<br>
Alternatively, delayed absorption of a parenterally-administered drug form is<br>
accomplished by dissolving or suspending the drug in an oil vehicle.<br>
Injectable depot forms are made by forming microencapsule matrices of the subject<br>
compounds in biodegradable polymers such as polylactide-polyglycolide. Depending<br>
on the ratio of drug to polymer, and the nature of the particular polymer employed,<br>
the rate of drug release can be controlled. Examples of other biodegradable<br>
polymers include poly(orthoesters) and poly(anhydrides). Depot injectable<br>
formulations are also prepared by entrapping the drug in liposomes or<br>
microemulsions which are compatible with body tissue.<br>
The preparations of the present invention may be given orally, parenterally, topically,<br>
or rectally. They are of course given by forms suitable for each administration route.<br>
For example, they are administered in tablets or capsule form, by injection,<br>
inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion<br>
or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral<br>
administration is preferred.<br>
The phrases "parenteral administration" and "administered parenterally" as used<br>
herein means modes of administration other than enteral and topical administration,<br>
usually by injection, and includes, without limitation, intravenous, intramuscular,<br>
intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal,<br>
intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular,<br>
subcapsular, subarachnoid, intraspinal and ihtrasternal injection and infusion.<br>
The phrases "systemic administration," "administered systematically/1 "peripheral<br>
administration" and "administered peripherally" as used herein mean the<br>
administration of a compound, drug or other material other than directly into the<br>
central nervous system, such that it enters the patient's system and, thus, is subject<br>
to metabolism and other like processes, for example, subcutaneous administration.<br>
These compounds may be administered to humans and other animals for therapy by<br>
any suitable route of administration, including orally, nasally, as by, for example, a<br>
spray, rectally, intravaginally, parenterally, intracisternally and topically, as by<br>
powders, ointments or drops, including buccally and sublingually.<br>
Regardless of the route of administration selected, the compounds of the present<br>
invention, which may be used in a suitable hydrated form, and/or the pharmaceutical<br>
compositions of the present invention, are formulated into pharmaceutically<br>
acceptable dosage forms by conventional methods known to those of skill in the art.<br>
Actual dosage levels of the active ingredients in the pharmaceutical compositions of<br>
this invention may be varied so as to obtain an amount of the active ingredient which<br>
is effective to achieve the desired therapeutic response for a particular patient,<br>
composition, and mode of administration, without being toxic to the patient.<br>
The selected dosage level will depend upon a variety of factors including the activity<br>
of the particular compound of the present invention employed, or the ester, salt or<br>
amide thereof, the route of administration, the time.of administration, the rate of<br>
excretion of the particular compound being employed, the duration of the treatment,<br>
other drugs, compounds and/or materials used in combination with the particular<br>
compound employed, the age, sex, weight, condition, general health and prior<br>
medical history of the patient being treated, and like factors well known in the<br>
medical arts.<br>
A physician or veterinarian having ordinary skill in the art can readily determine and<br>
prescribe the effective amount of the pharmaceutical composition required. For<br>
example, the physician or veterinarian could start doses of the compounds of the<br>
invention employed in the pharmaceutical composition at levels lower than that<br>
required in order to achieve the desired therapeutic effect and gradually increase the<br>
dosage until the desired effect is achieved.<br>
In general, a suitable daily dose of a compound of the invention will be that amount<br>
of the compound which is the lowest dose effective to produce a therapeutic effect.<br>
Such an effective dose will generally depend upon the factors described above.<br>
Generally, intravenous and subcutaneous doses of the compounds of this invention<br>
for a patient, when used for the indicated analgesic effects, will range from about<br>
0.0001 to about 200 mg per kilogram of body weight per day, more preferably from<br>
about 0.01 to about 150 mg per kg per day, and still more preferably from about 0.2<br>
to about 140 mg per kg per day.<br>
If desired, the effective daily dose of the active compound may be administered as<br>
two, three, four, five, six or more sub-doses administered separately at appropriate<br>
intervals throughout the day, optionally, in unit dosage forms.<br>
While it is possible for a compound of the present invention to be administered<br>
alone, it is preferable to administer the compound as a pharmaceutical composition.<br>
The present invention also pertains to packaged pharmaceutical compositions for<br>
treating obesity or obesity associated disorders in a mammal. The packaged<br>
pharmaceutical compositions include a container holding a therapeutically effective<br>
amount of at least one compound of the invention and instructions for using the<br>
compound for treating obesity or an obesity associated disorder in the mammal.<br>
The features and details of the invention will now be more particularly described and<br>
pointed out in the claims. It is to be understood that the particular embodiments of<br>
the invention are shown by way of illustration and not as limitations of the invention.<br>
The principle features of this invention can be employed in various embodiments<br>
without departing from the scope of the invention.<br>
The invention is further illustrated by the following examples which in no way should<br>
be construed as being further limiting. The contents of all references, pending patent<br>
applications and published patent applications, cited throughout this application,<br>
including those referenced in the background section, are hereby incorporated by<br>
reference. It should be understood that the models used throughout the examples<br>
are accepted models and that the demonstration of efficacy in these models is<br>
predictive of efficacy in humans.<br>
This invention will be better understood from the Experimental Details which follow.<br>
However, one skilled in the art will readily appreciate that the specific methods and<br>
results discussed are merely illustrative of the invention as described more fully in<br>
the claims which follow thereafter.<br>
Compounds in the examples are labeled with whole numbers if the compound<br>
appears in the table above and as X.Y, where X is the example number and Y is an<br>
index starting at 1 in each example, if they do not appear in the above table.<br>
•rt<br>
Experimental Details<br>
All non-aqueous reactions requiring anhydrous conditions were performed<br>
under a positive pressure of nitrogen (N£) in oven-dried glassware, which had been<br>
cooled under N£. All solvents for anhydrous reactions were purchased from Aldrich.<br>
The removal of solvents refers to evaporation in vacua on a rotary evaporator<br>
followed by evacuation to constant sample weight (
chromatography were purchased HPLC grade. All reagents employed were of<br>
American Chemical Society (ACS) grade or finer. Air sensitive reagents were<br>
handled under an atmosphere of dry N2-<br>
Where possible all reactions were followed by thin layer chromatography<br>
(TLC) and visualized using UV fluorescence, 3% KMnO4 (aqueous) staining, and/or<br>
dodecamolybdophosphoric acid. Commercial thin layer and preparative layer<br>
chromatography plates were Si250F and SiSOOF, respectively, from J. T. Baker.<br>
Flash chromatography was performed using 40 urn 'Baker' silica gel from J. T.<br>
Baker. All solvent mixtures are listed as volume ratios.<br>
Melting points are uncorrected and were determined on a Mel-Temp II<br>
(Laboratory Devices, USA) using open capillary tubes. Mass spectra (MS) were<br>
recorded on a Platform 2 Micromass instrument. Nuclear magnetic resonance<br>
(NMR) spectra were measured on a Varian 200 instrument in the specified solvent<br>
with tetramethylsilane (TMS) as internal standard for 1H NMR. For 13C NMR<br>
spectra, the deuterated solvent peak was used as the reference with its position set<br>
relative to TMS.<br>
LCMS Methods: Method A=LC1 method; Method B=Polar method; Method<br>
C=Polar_Short method; Method D=Strong_Nonpolar<br>
General Procedure: Amides/Esters<br>
a. Route A. The aminothiophene was synthesized using a known protocol<br>
(McKibben, B.P., Cartwell, C.H., Castelhano, A.L Tetrahedron Lett. 1999, 40, 5471-<br>
5474). Amide protection with trifluoroacetic anhydride followed by TFA deprotection<br>
and treatment with sodium carbonate generates the amino acid. Attempts to<br>
deprotect with TFA without amide protection results in decarboxylation. The amino<br>
acid was reacted with various acid chlorides, and chloroformates to afford the<br>
thienoxazinones in moderate yields (Scheme 1).<br>
Scheme 1<br>
BnO^-^<br>
Et2NH, pyr Bn0<br>
Bn°<br>
,<br>
Sulfur<br>
1)TFA,DCM<br>
(70%)<br>
DBU.pyr BnO L<br>
95% 20-70%<br>
b. Route B.. In general, reacting the f-Bu protected amino acid directly with a<br>
chloroformate or an isocyanate followed by TFA deprotection of the M3u ester and<br>
treatment with thionyl chloride gives the corresponding thienoxazinones in higher<br>
yields (Scheme 2)<br>
Scheme 2<br>
BnO<br>
6<br>
g I • o<br>
. V^A.,-J<c dbu dcm sl y bnv o-1 o a> 11<br>
3 S^NH. °^ Ll n o S-^MU<br>
N * r* T<br>
/-.^^VTT*- or ° A \ / n<br>
A; 50-80 %<br>
H2,Pd(OH)2<br>
EtOAo (95%)<br>
1) TFA, DCM<br>
1) R,R2YH, EDCI,<br>
HOBt, DMAP, DCM<br>
(95%)<br>
2) TFA, DCM<br>
(95%) CO<br>
A(-h<br>
(90%)<br>
Derivation at the 5-position was achieved through either transesterification of<br>
methyl acetoacetate with various alcohols prior to thiophene formation or benzyl<br>
deprotection of the diester, followed by EDC coupling with various alcohols and<br>
amines to generate esters or amides, respectively.<br>
Example 1: General Procedure tor Amino-Thiophene formation<br>
5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl<br>
ester. (1.1) To a suspension of benzyl acetoacetate (20.0 g, 104.1 mmol), t-butyl<br>
cyanoacetate (14.7 g, 104.1 mmol), sulfur (3.5 g, 109.3 mmol) and pyridine (120 ml)<br>
was added diethyl amine dropwise. After 2 days, the "black solution was<br>
concentrated under reduced pressure, dissolved in EtaO and filtered through silica.<br>
The eluent was then concentrated. Chromatography (silica, 7:1 hexane/EtOAc)<br>
yielded 25.58g (71%)of a orange oil which slowly crystallizes upon standing: 1HNMR<br>
(CDCI3) 1-58 (s, 9H), 2.70 (s, 3H), 5.27 (s, 2H), 7.38 (m, 5H). 1H NMR was<br>
consistent with published data.<br>
5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester 4-fert-butyl<br>
ester. (1.2) The same method as for the preparation of 5-amino-3-methyl-thiophene-<br>
2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus,<br>
cyclization of fert-butyl cyanoacetate (10.3 mL, 72.0 mmol), heptyl acetoacetate<br>
(13.7 g, 68.0 mrnol), and sulfur (4.4 g, 0.14 mol) in pyridine (80 ml) with added<br>
diethylamine (7.1 ml, 68.0 mmol) afforded 18.4 g thiophene (76%) of an oil after<br>
column Chromatography (10:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.47 (bs, 2H),<br>
4.19 (t, 2H, J= 6.6 Hz), 2.67 (s, 3H), 1.80-1.50 (m, 2H), 1.57 (s, 9H), 1.30 (bs, 8H),<br>
0.89 (t,3H, J=6.6Hz).<br>
5-Amino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl ester 4-ferf-butyl<br>
ester. (1.3) The same method as for the preparation of 5-amino-3-methyl-thiophene-<br>
2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester was employed. Thus,<br>
cyclization of fert-butyl cyanoacetate (6.2 mL, 43.0 mmol), octyl acetoacetate (8.5 g,<br>
41.0 mmol), and sulfur (2.6 g, 82.0 mmol) in pyridine (50 mL) with added<br>
diethylamine (4.3 ml, 41.0 mmol) afforded 10.3 g thiophene (68%) of an oil after<br>
column chromatography (10:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 6.63 (s, 2H),<br>
4.14 (t, 2H, J= 6.6 Hz), 2.63 (s, 3H), 1.72-1.50 (m, 2H), 1.52 (s, 9H), 1.22 (bs, 10H),<br>
0.83 (t, 3H, J= 6.8 Hz). 13C NMR (CDCI3) 5 165.9, 165.4, 163.0, 147.9, 109.6,<br>
108.0, 81.0, 64.4, 31.7, 29.1, 28.6, 28.4, 25.9, 22.5, 16.2, 14.0.<br>
Example 2: General Procedure for Cyclization From Chloroformate and Aminoacid<br>
2-Dodecyloxy-5-methyl-4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid<br>
benzyl ester (6) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-<br>
dicarboxylic acid 2-benzyl ester (1.00 g, 3.43 mmol) in pyridine (20 ml) was added<br>
dodecyl chloroformate (2.80 ml, 2.56 g, 10.3 mmol). The reaction was stirred at 0<br>
SC for 0.5 h, then solvent was removed under reduced pressure. The product was<br>
purified by column chromatography (10:1; hexanes:EtOAc) to give 169mg (10%) of<br>
a solid: 1H NMR (CDCI3) 8 7.50-7.25 (m, 5H), 5.35 (s, 2H), 4.17 (t, 2H, J = 6.6 Hz),<br>
2.87 (s, 3H), 1.70-1.40 (m, 2H), 1.40-1.00 (m, 18H), 0.88 (t, 3H, J= 6.4 Hz). MS (El):<br>
486.4 (m++H).<br>
5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzyl ester (5) The same method as for the preparation of 2-dodecyloxy-5-<br>
methyl-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid benzyl. ester was<br>
employed: 1H NMR (CDCI3) 8 7.53-7.25 (m, 5H), 5.33 (s, 2H), 4.44 (t, 2H, J= 6.6<br>
Hz), 2.83 (s, 3H), 1.80 (quint, 2H, J = 6.6 Hz), 1.26 (bs, 10H), 0.88 (t, 3H, J = 6.6<br>
Hz).<br>
2-Hexadecyloxy-5-methyl-4-oxo-4H-thienot2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzyl ester (7) The same method as for the preparation of 2-dodecyloxy-5-methyl-<br>
4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed: 1H<br>
NMR (CDCI3) 5 7.50-7.25 (m, 5H), 5.34 (s, 2H), 4.44 (t, 2H, J= 6.6 Hz), 2.83 (s, 3H),<br>
1.80 (quint, 2H, J= 6.6 Hz), 1.26 (bs, 26H), 0.88 (t, 3H, J = 6.6 Hz).<br>
Example 3: General Procedure for Cyclization From Acyl Chloride and Aminoacid<br>
2-Heptyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl<br>
ester (1) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-dicarboxylic acid<br>
2-benzyl ester (200 mg, 0.69 mmol) in pyridine (5 mL) was added octanoyi chloride<br>
(352 |j.L, 2.56 g, 10.3 mmol). The reaction was stirred at 0 BC for 0.5 h, then let<br>
warm to RT and stirred for 3.5 h. The solvent was removed under reduced<br>
pressure. The mixture was diluted in EtOAc, washed with H2O. The organic fraction<br>
was dried (MgSO4), and concentrated in vacuo. The product was purified by column<br>
chromatography (9:1; hexanes:EtOAc) to give 48 mg (18%) of a solid: ): 1H NMR<br>
(CDCla) 6 7.32-7.48 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 1.90-<br>
1.70 (m, 2H), 1.45-1.20 (m, 8H), 0.98-0.80 (m, 3H).<br>
5-Methyl-4-oxo-2-pentadecyl-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzyl ester (3) The same method as for the preparation of 2-nepty!-5-methyl-4-<br>
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed.<br>
Thus, cyclization with hexadecanoyl chloride (476 mL, 2.06 mmol) yielded 56 mg<br>
product (16%) after oil after column chromatography (9:1; hexanes:EtOAc): 1H*NMR<br>
(CDCI3) 6 7.30-7.55 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 2.00-<br>
1.70 (m, 2H), 1.50-1.0 (m, 24H), 1.00-0.90 (m, 3H).<br>
2-Undecyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzyl ester (2) The same method as for the preparation of 2-heptyl-5-methyl-4-<br>
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid benzyl ester was employed.<br>
Thus, cyclization with dodecanoyl chloride (476 mL, 2.06 mmol) yielded 77 mg<br>
product (24%) after oil after column chromatography (9:1; hexanes:EtOAc): 1H NMR<br>
(CDCI3) 5 7.30-7.50 (m, 5H), 5.35 (s, 2H), 2.86 (s, 3H), 2.69 (t, 2H, J = 7.2 Hz), 1.90-<br>
1.70 (m, 2H), 1.50-1.20 (m, 16H), 1.00-0.90 (m, 3H).<br>
Example 4: Genera! Procedure for Acylation with Chlorformate of Diester<br>
Ph\-o<br>
3-Methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-<br>
benzyl ester 4-ferf-butyl ester. (4.1) To a stirring solution of 5-amino-3-<br>
methoxymethyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl ester<br>
(1.16 g, 3.06 mmol) in pyridine (15 ml) was added octyl chloroformate (0.9 mL, 886<br>
mg, 4.6 mmol). The reaction was stirred at 0 9C for 1 h, then solvent was removed<br>
under reduced pressure. The product was purified by column chromatography<br>
(10:1; hexanes:EtOAc) to give 1.27 g (78%) of a solid: 1H NMR (CDCI3) 8 10.51 (s,<br>
1H), 7.32 (m, 5H), 5.12 (s, 2H), 4.19 (t, 2H, J = 6.6 Hz), 3.81 (s, 3H), 3.76 (s, 2H),<br>
1.68 (quint, 2H, J = 6.6 Hz), 1.45 (s, 9H), 1.44-1.21 (m, 10H), 0.89 (t, 3H, J = 5.8<br>
Hz). MS (El): 533.9 (m+).<br>
3-Methyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl<br>
ester 2-octyl ester. (4.2) The same method as for the preparation of 3-<br>
methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-benzyl<br>
ester 4-fert-butyl ester was employed. Thus, acylation with octyl chloroformate<br>
(0.171 ml, 168 mg, 0.87 rnmol) afforded 80 mg of a solid (26%) after column<br>
chromatography (9:1; hexanes:EtOAc): 1H NMR (CDCIa) 8 10.86 (s, 1H), 4.23 (t,<br>
2H, J = 6.6Hz), 2.67 (s, 3H), 1.80-1.40 (m, 4H), 1.57 (s, 9H), 1.42-1.08 (m, 20H),<br>
0.89 (t, 3H, J = 6.6 Hz). MS (El): 526.0 (m+).<br>
3-Methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-ferfbutyl<br>
ester 2-heptyl ester. (4.3) To a stirring solution of 5-amino-3-methylthiophene-<br>
2,4-dicarboxylic acid 2-heptyl ester 4-tert-butyl ester (5.0 g, 14.0 mmol)<br>
and DBU (5.3 ml, 5.4 g, 35.0 mmol) in CH2CI2 (100 mL) was added heptyl<br>
chloroformate (5.0 ml, 5,0 g, 28.0 mmol). The reaction was stirred at room<br>
temperature for 20 h, and then solvent was removed under reduced pressure. The<br>
product was purified by column chromatography (9:1; hexanes:EtOAc) to give 3.1 g<br>
(45%) of a solid: 1H NMR (CDCI3) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6Hz), 2.67 (s,<br>
3H), 1.80-1.40 (m, 4H), 1.57 (s, 9H), 1.42-1.08 (m, 16H), 0.89 (t, 3H, J= 6.6 Hz).<br>
5-Benzyloxycarbonylamino-3-methyl-thiophene-2,4-dicarboxyllc acid 4-fertbutyl<br>
ester 2-octyi ester. (4.4) The same method as for the preparation of 3-<br>
methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester<br>
2-heptyl ester was employed. Thus, acylation with benzyl chloroformate (0.154 mL,<br>
185 mg, 1.1 mmol) afforded 138 mg of a solid (52%) after column chromatography<br>
(10:1; hexanes:EtOAc): Mp 65.0-66.0 aC; 1H NMR (CDCI3) 6 10.97 (s, 1H), 7.50-<br>
7.30 (m, 5H), 5.28 (d, 2H, J = 4.8 Hz), 4.23 (t, 2H, J = 6.6 Hz), 2.72 (s, 3H), 1.80-<br>
1.55 (m, 2H), 1.58 (s, 9H), 1.28 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz).<br>
4-Methyl-2-octyIoxycarbonylamino-thiophene-3-carboxylic acid ethyl ester.<br>
(4.5) The same method as for the preparation of 3-methyl-5-<br>
heptyioxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-heptyl<br>
ester was employed. Thus, acylation with octyl chlorofbrmate (1.06 ml, 1.04 g, 5.4<br>
mmol) afforded 254 mg of an oil (28%) after column chromatography (9:1;<br>
hexanes:EtOAc): 1H NMR (CDCI3) 6 10.53 (s, 1H), 6.31 (s, 1H), 4.34 (q, 2H, J= 6.8<br>
Hz), 4.12 (t, 2H, J= 6.6 Hz).2.34 (s, 3H), 1.67 (bs, 2H), 1.37 (quint, 3H, J= 6.8 Hz),<br>
1.28 (bs, 10H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 341.9 (m+).<br>
5-/soPropoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 4-fertbutyl<br>
ester 2-octyl ester. (4.6) The same method as for the preparation of 3-<br>
methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester<br>
2-heptyl ester was employed. Thus, acylation with /so-propy! chloroformate in<br>
toluene (0.54 mL, 0.54 mmol) afforded 117 mg of a solid (95%) after column<br>
chromatography (9:1; KexanesrEtOAc): 1H NMR (CDCl3) 8 10.82 (s, 1H), 5.30 (s,<br>
1H), 5.08 (sept, 1H, J = 6.2 Hz), 4.23 (t, 2H, J = 6.6 Hz), 2.73 (s, 3H), 1.80-1.60 (m,<br>
2H), 1.60 (s, 9H), 1.34 (d, 6H, J= 6.2 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J= 6.6 Hz).<br>
5-/so-Butoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 4-fertbutyl<br>
ester 2-octyl ester. (4.7) The same method as for the preparation of 3-<br>
methyl-5-heptyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester<br>
2-heptyl ester was employed. Thus, acylation with /so-butyl chloroformate (0.07 mL,<br>
74.0 mg, 0.54 mmol) afforded 98 mg of a solid (77%) after column chromatography<br>
(9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.86 (s, 1H), 4.23 (t, 2H, J = 6.6 Hz),<br>
4.04 (d, 2H, J = 6.6 Hz), 2.73 (s, 3H), 2.02 (nonet, 1H, J = 6.6 Hz), 1.80-1.50 (m,<br>
2H), 1.06 (s, 9H), 1.28 (bs, 10H), 1.00 (d, 6H, J = 6.6 Hz), 0.88 (t, 3H, J= 6.2 Hz).<br>
Example 5: General Procedure for Acylation with Isocyanate of Diester<br>
Reaction<br>
O H<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-<br>
octyl ester. (5.1) To a stirring solution of 5-amino-3-methyl-thiophene-2,4-<br>
dicarboxylic acid 2-octyl ester 4-tert-butyl ester (348 mg, 0.94 mmol) and DBU (0.35<br>
mL, 360 mg, 2.4 mmol) in CH2CI2 (10 mL) was added octyl isocyanate (0.166 mL,<br>
146 mg, 0.94 mmol). The reaction was stirred RT for 16 h, and then solvent was<br>
removed under reduced pressure. The product was purified by column<br>
chromatography (5:1; hexanes:EtOAc) to give 431 mg of a solid (87%): Mp 92.0-<br>
94.0 BC; 1H NMR (CDCI3) 5 12.30 (s, 1H), 8.64 (s, 1H), 5.30 (t, 1H, J= 6.0 Hz), 4.25<br>
(t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1 .90-1 .50 (m, 4H), 1 .61 (s,<br>
9H), 1 .28 (bs, 20H), 0.88 (m, 6H). MS (El): 525.1 (m+).<br>
o<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-<br>
fert-butyl ester. (5.2) The same method as for the preparation of 3-methyl-5-(3-<br>
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was<br>
employed. Thus, acylation with octyl isocyanate (3.83 mL, 3.37 g, 21.7 mmol)<br>
afforded 3.42 g of a solid (38%) after column chromatography (9:1; hexanes:EtOAc):<br>
Mp 119.0-120.0SC; 1H NMR (CDCI3) 8 11.03 (s, 1H), 7.50-7.20 (m, 5H), 5.27 (s, 2H),<br>
5.03 (vt, 1H), 3.29 (q, 2H, J = 6.6 Hz), 2.71 (s, 3H), 1.63-1.40 (m, 2H), 1.57 (s, 9H),<br>
1.26 (bs, 10H), 0.87 (t, 3H, J- 6.6 Hz). MS (El): 502.8 (m+).<br>
o<br>
3-Methyl-5-(3-tetradecyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester<br>
4-tert-butyl ester. (5.3) The same method as for the preparation of 3-methyl-5-(3-<br>
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was<br>
employed. Thus, acylation with tetradecyl isocyanate (0.33 ml, 287 mg, 1.2 mmol)<br>
afforded 253 mg of a solid (36%) after column chromatography (9:1;<br>
hexanes:EtOAc): Mp 104.5-106.0SC; 1H NMR (CDCI3) 6 11.04 (s, 1H), 7.50-7.20 (m,<br>
5H), 5.27 (S, 2H), 5.14 (t, 1H, J = 6.2 Hz), 3.29 (q, 2H, J = 6.2 Hz), 2.71 (s, 3H),<br>
1.65-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 22H), 0.88 (t, 3H, J = 6.0 Hz). MS (El):<br>
587.1 (m+).<br>
5-(3-Hexadecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl<br>
ester 4-fert-butyl ester. (5.4) The same method as for the preparation of 3-methyl-<br>
5-(3-octyl-ureido)-thiophene-2,4-dicarbQxylic acid 4-tert-butyl ester 2-octyl ester was<br>
employed. Thus, acylation with hexadecyl isocyanate (0.37 mL, 321 mg, 1.2 mmol)<br>
afforded 218 mg of a solid (30%) after column chromatography (9:1;<br>
hexanes-.EtOAc): Mp 104.0-105.09C; 1H NMR (CDCI3) 8 11.04 (s, 1H), 7.50-7.20 (m,<br>
5H), 5.27 (s, 2H), 5.14 (t, 1H, J = 6.2 Hz), 3.29 (q, 2H, J = 6.2 Hz), 2.71 (s, 3H),<br>
1.65-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 26H), 0.88 (t, 3H, J= 6.0 Hz). MS (El):<br>
615.1 (m*).<br>
5-(3-Dodecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester<br>
4-tert-butyl ester. (5.5) The same method as for the preparation of 3-methyl-5-(3-<br>
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester 2-octyl ester was<br>
employed. Thus, acylation with decyl isocyanate (0.29 mL, 254 mg, 1.2 mmol)<br>
afforded 265 mg of a solid (40%) after column chromatography (9:1;<br>
hexanes-.EtOAc): Mp 106.8-108.0SC). 1H NMR (CDCI3) 8 11.04 (s, 1H), 7.45-7.26<br>
(m, 5H), 5.27 (s, 2H), 5.24 (t, 1H, J= 5.6 Hz), 3.28 (q, 2H, J= 6.6 Hz), 2.72 (s, 3H),<br>
1.60-1.40 (m, 2H), 1.57 (s, 9H), 1.25 (bs, 18H), 0.88 (t, 3H, J = 6.4 Hz). MS (El):<br>
559.0 (m+).<br>
Example 6: General Procedure TFA Deprotection at C-2<br>
Ph,v-o<br>
3-Methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-<br>
benzyl ester. (6.1) To a stirring solution of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-fert-butyl<br>
ester (0.60 mg, 0.11 mmol) in CH2CI2 (1.0 ml) was added TFA (1.0 ml). The<br>
reaction was stirred at room temperature for 12 hrs, then solvent was removed<br>
under reduced pressure to give a solid. The product was taken on without further<br>
purification: 1H NMR (CDCI3) 8 11.98 (s, 1H), 10.09 (s, 1H), 7.45-7.20 (m, 5H), 5.14<br>
(s, 2H), 4.22 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.82 (s, 2H), 1.70 (quint, 2H, J = 6.6<br>
Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J = 5.6 Hz).<br>
o<br>
(,0<br>
3-Methoxymethyl-5-octyloxycarbonylamino-thiophene-2,4-dicarboxylic acid 2-<br>
octyl ester. (6.2) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded 64 mg of a solid (68%) aftei<br>
column chromatography (5:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 10.56 (s, 1H),<br>
4.27 (t, 2H, J = 6.5 Hz), 4.25 (t, 2H, J = 6.5 Hz), 2.81 (s, 3H), 1.80-1.53 (m, 4H),<br>
1.50-1.15 (m, 20H), 0.89 (t, 3H, J = 6.5 Hz). MS (El): 469.9 (m+).<br>
5-Heptyloxycarbonylamino-3-methoxymethyl-thiophene-2,4-dicarboxylic acid<br>
2-heptyl ester. (6.3) The same method as for the preparation of 3-methoxymethyl-<br>
5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded 2.7 g of a solid (96%) after<br>
tritration with hexanes: 1H NMR (CDCI3) 5 10.53 (s, 1H), 4.26 (t, 4H, J = 6.6 Hz),<br>
2.81 (s, 3H), 1.90-1.58 (m, 4H), 1.60-1.12 (m, 16H), 0.89 (t, 3H, J= 6.6 Hz). MS (El):<br>
441.9 (m+).<br>
5-Benzyloxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl<br>
ester. (6.4) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: Mp 148.0-149.5 BC; 1H NMR (CDCI3) 8 10.56 (bs, 2H), 7.50-7.30 (m,<br>
5H), 5.30 (d, 2H, J = 4.8 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.79 (s, 3H), 1.83-1.60 (m,<br>
2H), 1.29 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz).<br>
0<br>
5-/SD-Propoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl<br>
ester. (6.5) The same method as for the preparation of 3-methoxymethyl-5-<br>
octy!oxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was taken forward<br>
without further purification: Mp 152.0-153.0 SC; 1H NMR (CDCI3) 6 10.45 (s, 1H),<br>
5.12 (sept, 1H, J= 6.6 Hz), 4.25 (t, 2H, J = 6.6 Hz), 2.82 (s, 3H), 1.73 (quint, 2H, J =<br>
6.6 Hz), 1.38 (d, 6H, J = 6.6 Hz), 1:28 (bs, 10H), 0.89 (t, 3H, J = 6.6 Hz).<br>
o<br>
5-;soButoxycarbonylamino-3-methyl-thiophene-2,4-dicarboxylic acid 2-octyl<br>
ester. (6.6) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2;4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: 1H NMR (CDCI3) 6 10.53 (bs, 2H), 4.26 (t, 2H, J= 6.2 Hz), 4.08 (d, 2H, J<br>
= 6.6 Hz), 2.82 (s, 3H), 2.06 (nonet, 1H, J = 6.6 Hz), 1.71 (quint, 2H, J = 6.6 Hz),<br>
1 .29 (bs, 1 0H), 1 .00 (d, 6H, J = 6.6 Hz), 0.89 (t, 3H, J = 6.6 Hz).<br>
o<br>
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid.<br>
(6.7) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: 1H NMR (CDCl3) 6 10.90 (bs, 2H), 5.82-5.62 (m, In), 5.76-5.60 (m, 1H),<br>
3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.27 (bs, 20H), 0.88 (m,<br>
6H).<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-octyl ester. (6.8)<br>
The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: 1H NMR (CDCl3) 5 12.30 (s, 1H), 10.91 (bs, 2H), 5.30 (t, 1H, J== 6.0 Hz),<br>
4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s, 3H), 1.90-1.50 (m, 4H),<br>
1.28 (bs, 20H), 0.88 (m, 6H). MS (El): 468.9 (m+).<br>
BnNH<br>
5-Ben2ylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid.<br>
(6.9) The same method as for the preparation of 3-methoxymethy!-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: 1H NMR (CDCI3) 8 11.16 (s, 1H), 7.40-7.10 (m, 5H), 6.19 (t, 1H, J= 5.4<br>
Hz), 4.56 (d, 2H, J = 5A Hz), 3.25 (q, 2H, J = 6.6 Hz), 2.63 (s, 3H), 1.60-1:40 (m,<br>
2H), 1.26 (bs, 10H), 0.86 (t, 3H, J = 6.2 Hz). MS (El): 445.9 (m+).<br>
5-DimethylcarbamoyI-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid.<br>
(6.10) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: 1H NMR (CDCI3) 8 10.89 (s, 2H), 5.39 (t, 1H, J= 6.6 Hz), 3.27 (q, 2H, J<br>
= 6.6 Hz), 3.05 (s, 6H), 2.28 (s, 3H), 1.65-1.45 (m, 2H), 1.26 (s, 10H), 0.87 (t, 3H, J<br>
= 6.2 Hz). MS (El): 383.9 (m+).<br>
o<br>
O H<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester.<br>
(6.11) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: 1H NMR (CDCU) 5 10.57 (s, 1H), 7.45-7.25 (m, 5H), 5.30 (s, 1H), 4.26 (t,<br>
2H, J= 6.6 Hz), 2.81 (s, 3H), 1.72 (quint, 2H, J= 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H,<br>
J=6.6Hz).<br>
4-Methyl-5-octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid.<br>
(6.12) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification.<br>
2-(3-Hexadecyl-ureido)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic<br>
acid. (6.13) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: MS (El): 580.2 (m"").<br>
2"(3-Dodecyl-ureIdo)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid.<br>
(6.14) The same method as for the preparation of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]cicarboxylic acid 2-benzyl ester was<br>
employed. Thus, deprotection with TFA afforded a solid, which was used without<br>
purification: MS (El): 524.1 (m+).<br>
Example 7: Extra TFA Deportection<br>
o<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid. (7.1) To a stirring<br>
solution of 3-methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl<br>
ester (50.0 mg, 0.13 mmol) in CH2Cl2 (1 ml) was added TFA (1 mL). The reaction<br>
was stirred at RT for 2 h, and then solvent was removed under reduced pressure to<br>
give a solid. The product was dissolved in EtOAc, washed with sat. NaHCOs (aq.),<br>
and brine. The organic layer was dried with MgSO4, filtered, and concentrated<br>
under reduced pressure to give 10.0 mg of a solid (22%): 1H NMR (CDCI3) 8 10.45<br>
(bs, 1H), 6.27 (bs, 1H), 5.00 (bs, 1H), 3.50-3.20 (m, 2H), 2.37 (s, 3H), 1.70-1.40 (m,<br>
2H), 1.26 (bs, 10H), 0.88 (t, 3H, J= 6.2 Hz). MS (El): 312.9 (m+-COOH).<br>
Example 8: Ethyl Ester Hydrolysis<br>
4-Methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid. (8.1) To a<br>
stirring solution of 4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid<br>
ethyl ester (254 mg, 0.74 mmol) in ethanol (2 mL) and THF (2 mL) was added LiOHH2O<br>
(31 mg, 0.74 mmol). The reaction was stirred at RT for 5 days, and then<br>
solvent was removed under reduced pressure to give a solid. The product was<br>
taken on without further purification: 1H NMR (CDCl3) 8 6.02 (s, 1H), 4.07 (t, 2H, J =<br>
6.6 Hz), 2.32 (s, 3H), 1.60-1.40 (m, 2H), 1.27 (bs, 10H), 0.86 (t, 3H, J= 6.6 Hz).<br>
Example 9: General Procedure for Hydrogenolysis at C-6<br>
"<br>
5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (11)<br>
To a stirring solution of 2-dodecyloxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-<br>
carboxylic acid benzyl ester (50 mg, 0.10 mmol) in EtOAc (2 mL) was added 10%<br>
Pd/C (5 mg, 10 wt%). The reaction was charged with H2 and stirred at RT for 1 h.<br>
The reaction slurry was filtered through a plug of Celite, and the solvent was<br>
removed in vacuo. The product was taken on without further purification: 1H NMR<br>
(CDCI3) 8 4.47 (t, 2H, J= 6,2 Hz), 4.19 (bs, 1H), 2.85 (s, 3H), 1.80 (quint, 2H, J= 6.2<br>
Hz), 1.27 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 395.4 (m+).<br>
3-i\Tiethyi-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-ferf-butyl ester.<br>
(9.1) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-oxo-4/-/-<br>
thieno[2,3-dl[1,3]oxazine-6-carboxylic acid was employed. Thus, hydrogenolysis<br>
afforded a solid, which was used without purification: 1H NMR (CDCIa) 8 11.06 (s,<br>
1H), 5.14 (vt, 1H), 3.30 (q, 2H, J= 6.0 Hz), 2.71 (s, 3H), 1.70-1.40 (m, 2H), 1.59 (s,<br>
9H), 1.27 (bs, 10H), 0.87 (t, 3H, J= 6.6 Hz). MS (El): 412.8 (m+).<br>
5-(3-Dodecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 4-fert-butyl<br>
ester. (9.2) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-<br>
oxo^H-thieno^.S-c/ltl.Sloxazine-e-carboxylic acid was employed. Thus,<br>
hydrogenolysis afforded 0.198 g of a solid (98%), which was used without<br>
purification: Mp 187.0-188.52C; 1H NMR (CDCI3) 8 11.06 (s, 1H), 5.21 (bs, 1H), 3.31<br>
(q, 2H, J= 5.8 Hz), 2.72 (s, 3H), 1.65-1.40 (m, 2H), 1.60 (s, 9H), 1.26 (bs, 18H),<br>
0.88 (t, 3H, J= 6.6 Hz). MS (El): 469.0 (m+).<br>
3-Methyl-5-(3-tetradecyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl<br>
ester. (9.3) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-<br>
oxo-4/:/-thieno[2,3-dl[1,3]oxazine-6-carboxylic acid was employed. Thus,<br>
hydrogenolysis afforded 123 mg of a solid (58%), which was used without<br>
purification: Mp 176.0-178.09C; 1H NMR (CDCI3) 8 11.06 (s, 1H), 7.35 (t, 1H, J= 6.2<br>
Hz), 5.20 (bs, 1H), 3.30 (q, 2H, J= 6.2 Hz), 2.72 (s, 3H), 1.70-1.45 (m, 2H), 1.59 (s,<br>
9H), 1.25 (bs, 22H), 0.88 (t, 3H, J= 6.6 Hz). MS (El): 497.0 (m*).<br>
o<br>
5-(3-Hexadecyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 4-fert-butyl<br>
ester. (9.4) The same method as for the preparation of 2-dodecyloxy-5-methyl-4-<br>
oxo-4/-/-thieno[2,3-d][1,3]oxazine-6-carboxylic acid was employed. Thus,<br>
hydrogenolysis afforded a solid, which was used without purification: Mp 187.5-<br>
189.02C; 1H NMR (CDCI3) 5 11.07 (s, 1H), 5.18 (bs, 1H), 3.29 (q, 2H, J= 6.2 Hz),<br>
2.72 (s, 3H), 1.70-1.45 (m, 2H), 1.60 (s, 9H), 1.25 (bs, 26H), 0.88 (t, 3H, J= 6.6 Hz).<br>
MS (El): 525.0 (m*).<br>
Example 10: General Procedure for Amide/Ester Formation at C-6<br>
o<br>
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tertbutyl<br>
ester. (10.1) To a stirring solution of 3-methyl-5-(3-octyl-ureido)-thiophene-<br>
2,4-dicarboxylic acid 4-fert-butyl ester (185 mg, 0.46 mmol) and octyl amine (0.112<br>
ml, 87.3 mg, 0.69 mmol) in CH2CI2 (10 mL) was added EDO (133 mg, 0.69 mmol)<br>
and DMAP (2.8 mg, 0.02 mmol). The reaction was stirred at RT for 16 h, washed<br>
with H2O, 0.5N citric acid, sat. NaHCOs, and brine. The organic fraction was dried<br>
(MgSC&gt;4), filtered, and concentrated in vacua. The residue was purified by column<br>
chromatography (9:1; hexanes:EtOAc) to give 290 mg of a solid (99%): 1H NMR<br>
(CDCI3) 8 10.89 (s, 1H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H), 3.33 (q, 4H, J = 6.6<br>
Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.27 (bs, 20H), 0.88 (m, 6H). MS<br>
(El): 524.1 (m+).<br>
BnNH<br>
O<br>
5-Benzylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
fert-butyl ester. (10.2) The same method as for the preparation of 4-methyl-5-<br>
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was<br>
employed. Thus, coupling with benzyl amine (0.061 mL, 60 mg, 0.56 mmol)<br>
afforded 202 mg of a solid (99%) after by column chromatography (95:5;<br>
CHCI3:MeOH): 1H NMR (CDCI3) 8 10.90 (s, 1H), 7.40-7.20 (m, 5H), 6.05 (t, 1H, J =<br>
5.4 Hz), 5.33 (t, 1H, J - 6.6 Hz), 4.55 (d, 2H, J = 5.4 Hz), 3.26 (q, 2H, J = 6.6 Hz),<br>
2.63 (s, 3H), 1.65-1.40 (m, 2H), 1.56 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J = 6.2 Hz).<br>
MS (El): 502.0 (m+).<br>
o<br>
5-Dimethylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
ferf-butyl ester. (10.3) The same method as for the preparation of 4-methyl-5-<br>
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was<br>
employed. Thus, coupling with a 40% solution of dimethyl amine in HaO (0.063 ml_,<br>
0.56 mmol) afforded 174 mg of a solid (99%) after by column chromatography (95:5;<br>
CHCI3:MeOH): 1H NMR (CDCI3) 5 10.78 (s, 1H), 5.39 (t, 1H, J = 6.6 Hz), 3.27 (q,<br>
2H, J= 6.6 Hz), 3.05 (s, 6H), 2.28 (s, 3H), 1.65-1.45 (m, 2H), 1.56 (s, 9H), 1.26 (s,<br>
10H), 0.87 (t, 3H, J= 6.2 Hz). MS (El): 440.0 (m+).<br>
2-(3-Dodecyl-ureido)-4-methyl-5-octylcarbamoyl-thlophene-3-carboxylic acid<br>
fert-butyl ester. (10.4) The same method as for the preparation of 4-methyl-5-<br>
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid te/t-butyl ester was<br>
employed. Thus, coupling with octyl amine (0.111 mL, 87.0 mg, 0.69 mmol)<br>
afforded 205 mg of a solid (81%) after by column chromatography (9:1;<br>
hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.74 (t, 1H, J = 5.4 Hz), 5.47 (t,<br>
1H, J = 6.2 Hz), 3.32 (vsext, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55<br>
(s, 9H), 1.26 (bs, 28H), 0.88 (t, 6H, J= 6.6 Hz). MS (El): 580.2 (m+).<br>
o<br>
4-Wlethyl-5-octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid<br>
ferf-butyl ester. (10.5) The same method as for the preparation of 4-methyl-5-<br>
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was<br>
employed. Thus, coupling with octyl amine (0.112 mL, 87.3 mg, 0.69 mmol)<br>
afforded 290 mg of a solid (99%) after by column chromatography (9:1;<br>
hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.74 (t, 1H, J = 5.4), 5.44 (bs,<br>
1H), 3.33 (vsext, 4H, J= 6.2 Hz), 2.61 (s, 3H), 1.60-1.40 (m, 4H), 1.56 (s, 9H), 1.26<br>
(bs, 32H), 0.88 (t, 6H, J= 6.6 Hz). MS (El): 608.1 (m+).<br>
o<br>
2-(3-Hexadecyl-ureido)-4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid<br>
tert-butyl ester. (10.6) The same method as for the preparation of 4-methyl-5-<br>
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid terf-butyl ester was<br>
employed. Thus, coupling with octyl amine (0.080 mL, 62.0 mg, 0.50 mmol)<br>
afforded 195 mg of a solid (93% from BnOOC) after by column chromatography<br>
(9:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 10.90 (s, 1H), 5.73 (t, 1H, J= 5.4), 5.35<br>
(bs, 1H), 3.33 (vsext, 4H, J= 6.2 Hz), 2.61 (s, 3H), 1.65-1.40 (m, 4H), 1.56 (s, 9H),<br>
1.26 (bs, 36H), 0.88 (t, 6H, J = 6.6 Hz). MS (El): 636.2 (m+).<br>
2-Heptyl-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid hexyl<br>
ester (4) The same method as for the preparation of 4-methyl-5-octylcarbamoyl-2-<br>
(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was employed. Thus,<br>
coupling with octyl alcohol (0.125 mL, 1.50 mmol) afforded 20 mg of a solid (21%)<br>
after by Prep. TLC (9:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 4.29 (t, 2H, J= 6.6 Hz),<br>
2.84 (s, 3H), 2.87 (t, 2H, J= 7.2 Hz), 2.00-1.60 (m, 4H), 1.15-1.60 (m, 24H), 1.15-<br>
0.70 (m, 6H).<br>
Example 11: General Procedure for Cyclization with EDCI<br>
Ph,<br>
\-0<br>
5-Methoxy-2-octyloxy-4-oxo-4H-thieno[2,3-c/l[1,3]oxazine-6-carboxylic acid<br>
benzyl ester (112) To a stirring solution of 3-methoxymethyl-5-<br>
octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl ester (27 mg, 0.056<br>
mmol) in CH2CI2 (1,0 ml) was added EDC (16.0 mg, 0.084 mmol). The reaction<br>
was stirred at RT for 16 h, washed with H2O and brine. The organic fraction was<br>
dried (MgSO4), filtered, and concentrated in vacua. The residue was purified by<br>
column chromatography (5:1; hexanes:EtOAc) to give 7.0 mg of a solid (27%): 1H<br>
NMR (CDCI3) 5 7.42-7.27 (m, 5H), 5.16 (s, 2H), 4.38 (t, 2H, J= 6.6 Hz), 3.89 (s, 3H),<br>
3.85 (s, 2H), 1.78 (quint, 2H, J = 6.6 Hz), 1.50-1.10 (m, 10H), 0.89 (t, 3H, J = 6.6<br>
Hz). MS(EI):461.9(m+H+).<br>
5-Methyl-2-octyloxy-4-oxo-4H-thieno[2,3-c/][1,3]oxazine-6-carboxylic acid octyl<br>
ester (9) The same method as for the preparation of 5-methoxy-2-octyloxy-4-oxo-<br>
4H-thieno{2,3-d)[1I3]oxazine-6-carboxylic acid benzyl ester was employed. Thus,<br>
cyclization afforded 15 mg of a solid (24%) after by column chromatography (9:1;<br>
hexanes:EtOAc): Mp 58.5-60.22C; 1H NMR (CDCI3) 5 4.45 (t, 2H, J = 6.6 Hz), 4.29<br>
(t, 2H, J= 6.6 Hz), 2.80 (s, 3H), 1.88-1.70 (m, 4H), 1.29 (bs, 20H), 0.89 (t, 6H, J =<br>
6.6 Hz). MS(EI):451.8(m+).<br>
Example 12: General Procedure for Cyclization with SOCI2<br>
5-Methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid<br>
heptyl ester (10) To a stirring solution of 5-heptyloxycarbonylamino-3-<br>
methoxymethyl-thiophene-2,4-dicarboxylic acid 2-heptyl ester (2.7 g, 6.1 mmol) in<br>
pyridine (65 ml_) was added thionyl chloride (0.88 ml_, 1.4 g, 12.0 mmol). The<br>
reaction was stirred RT for 0.5 h, and concentrated in vacuo. The residue was<br>
dissolved in CHCI3, washed with H2O, 0.5 N citric acid, sat. NaHC03, and brine.<br>
The organic fraction was dried (MgSO4), filtered, and concentrated in vacuo. The<br>
residue was purified by column chromatography (20:1; hexanes:EtOAc) to give 2.6 g<br>
of a solid (99%): 1H NMR (CDCI3) 6 4.45 (t, 2H, J = 6.6 Hz), 4.29 (t, 2H, J= 6.6 Hz),<br>
2.80 (s, 3H), 1.78 (dquint, 4H, J= 13.2, 6.6 Hz), 1.58-1.18 (bs, 16H), 0.90 (t, 6H, J =<br>
7.0 Hz); 13C NMR (CDCI3) 5 168.9, 162.1, 158.3, 154.0, 144.1, 121.4, 113.9, 71.1,<br>
65.4, 31.6, 31.6, 28.8, 28.7, 28.6, 28.2, 25.9, 25.5, 22.5, 14.6, 14.0; MS (El): 423.9<br>
2-Benzyloxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octyl ester (113) The same method as for the preparation of 5-methyl-2-heptyloxy-<br>
4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 11.0 mg of a solid (10%) after by column chromatography<br>
(20:1; hexanes:EtOAc): 1H NMR (CDCI3) 8 7.55-7.30 (m, 5H), 5.48 (s, 2H), 4.29 (t,<br>
2H, J= 6.6 Hz), 2.82 (s, 3H), 1.75 (quint, 2H, J= 6.6 Hz), 1.29 (bs, 10H), 0.89 (t, 3H,<br>
J=6.6Hz).<br>
2-/so-Propoxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octyl ester (12) The same method as for the preparation of 5-methyl-2-heptyloxy-4-<br>
oxo-4H-thieno[2,3-cf)[1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 108 mg of a solid (98%) after by column chromatography<br>
(20:1; hexanes:EtOAc): Mp 47.5-48.0sC; 1H NMR (CDCI3) 5 5.31 (sept, 1H, J = 6.2<br>
Hz), 4.29 (t, 2H, J= 6.6 Hz), 2.81 (s, 3H), 1.75 (quint, 2H, J = 6.6 Hz), 1.44 (d, 6H, J<br>
= 6.2 Hz), 1.29 (bs, 10H), 0.89 (t, 3H, J = 6.4 Hz); MS (El): 381.9 (m+).<br>
2-/so-Butoxy-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octyl ester (114) The same method as for the preparation of 5-methyl-2-hepty!oxy-<br>
4-oxo-4H-thieno[2,3-dj[1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 15 mg of a solid (25%) after by column chromatography<br>
(20:1; hexanes:EtOAc): 1H NMR (CDCI3) 6 4.31 (q, 2H, J= 6.6 Hz), 4023 (d, 2H, J =<br>
6.6 Hz), 2.82 (s, 3H), 2.13 (nonet, 1H, J= 6.6 Hz), 1.73 (quint, 2H, J = 6.6 Hz), 1.29<br>
(bs, 10H), 1.03 (d, 6H, J= 6.6 Hz), 0.89 (t, 3H, J= 6.6 Hz); MS (El): 395.9 (m+).<br>
5-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazln-4-one (23) The same method as for<br>
the preparation of 5-methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-o][1,3]oxazine-6-<br>
carboxylic acid heptyl ester was employed. Thus, cyclization afforded 44 mg of an<br>
oil (20%) after by column chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3)<br>
8 6.59 (s, 1H), 4.41 (t, 2H, J = 6.6 Hz), 2.46 (s, 3H), 1.80 (quint, 2H, J = 6.6 Hz),<br>
1.29 (bs, 10H), 0.89 (t, 3H, J= 6.6 Hz); MS (El): 295.9 (m+).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octyl amide (18) The same method as for the preparation of 5-methyl-2-heptyloxy-4-<br>
oxo-4/-/-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 106 mg of a solid (52% from 4-methyl-5-octylcarbamoyl-2-<br>
(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester) after by column<br>
chromatography (95:5; CHCI3:MeOH): Mp 152.0-152.8SC; 1H NMR (CDCI3) 8 5.70<br>
(bs, 1H), 5.06 (bs, 1H), 3.42 (q, 6H, J = 6.2 Hz), 2.71 (s, 3H), 1.70-1.42 (m, 4H),<br>
1.54 (s, 9H), 1.28 (bs, 20H), 0.89 (t, 6H, J= 6.6 Hz); MS (El): 450.5 (m+1).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octyl ester (20) The same method as for the preparation of 5-methyl-2-heptyloxy-4-<br>
oxo-4H-thieno[2,3-c(][1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 229 mg of a solid (67% from t-Bu ester) after by column<br>
chromatography (20:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.20 (bs, 1H), 4.26 (t,<br>
2H, J= 6.6 Hz), 3.51-3.40 (m, 2H), 2.78 (s, 3H), 1.85-1.48 (m, 4H), 1.28 (bs, 20H),<br>
1.00-0.80 (m, 6H); MS (El): 451.0 (m+).<br>
BnNH<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzylamide (21) The same method as for the preparation of 5-methyl-2-<br>
heptyloxy-4-oxo-4H-thieno[2,3-d|[1,3]oxazine-6-carboxylic acid heptyl ester was<br>
employed. Thus, cyclization afforded 75.0 mg of a solid (49% from 3-methyl-5-(3-<br>
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester) after by column<br>
chromatography (95:5; CHCI3:MeOH): 1H NMR (CDCI3) 6 7.40-7.26 (m, 5H), 6.03 (t,<br>
1H, J= 5.4 Hz), 5.20 (bs, 1H), 4.62 (d, 2H, J= 5.4 Hz), 3.50-3.30 (m, 2H), 2.72 (s,<br>
3H), 1.73-1.43 (m, 2H), 1.28 (bs, 10H), 0.88 (t, 3H, J = 6.6 Hz). MS (El): 427.9 (m+).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxa2ine-6-carboxylic acid<br>
dimethylamide (22) The same method as for the preparation of 5-methyl-2-<br>
heptyloxy-4-oxo-4H-thieno[2,3-c(l[1,3]oxazine-6-carboxylic acid heptyl ester was<br>
employed. Thus, cyclization afforded 17.0 mg of a solid (13% from 3-methyl-5-(3-<br>
octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester) after by column<br>
chromatography (1:1 to 1:5; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.22 (bs, 1H), 3.41<br>
(q, 2H, J= 5.4 Hz), 3.08 (s, 6H), 2.41 (s, 3H), 1.62 (quint, 2H, J =6.6 Hz), 1.28 (bs,<br>
10H), 0.88 (t, 3H, J= 6.2 Hz); MS (El): 365.9 (m'+).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyllc acid<br>
benzyl ester (16) The same method as for the preparation of 5-methyl-2-heptyloxy-<br>
4-oxo-4H-thieno[2,3-cfl[1l3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 108 mg of a solid (63% from 3-methyl-5-(3-octyl-ureido)-<br>
thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-tert-butyl ester) after by column<br>
chromatography (9:1; hexanes:EtOAc): Mp 153.5-154.05C; 1H NMR (CDCI3) 8 7.50-<br>
7.30 (m, 5H), 5.44 (bs, 1H), 5.32 (s, 2H), 3.42 (q, 2H, J= 6.2 Hz), 2.79 (s, 3H), 1.78-<br>
1.50 (m, 2H), 1.27 (bs, 10H), 0.88 (t, 3H, J = 6.4 Hz); MS (El): 428.9 (m+).<br>
2-Heptylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzyl ester (17) The same method as for the preparation of 5-methyl-2-heptyloxy-<br>
4-oxo-4H-thieno[2,3-o(j[1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 12 mg of a solid; 1H NMR (CDCI3) 8 7.50-7.30 (m, 5H),<br>
5.32 (s, 2H), 5.24 (bs, 1H), 3.42 (q, 2H, J= 6.2 Hz), 2.79 (s, 3H), 1.78-1.50 (m, 2H),<br>
1.27 (bs, 8H), 0.88 (t, 3H, J= 6.4 Hz); MS (El): 414.8 (m+).<br>
2-Dodecylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octylamide (24) The same method as for the preparation of 5-methyl-2-heptyloxy-4-<br>
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 56 mg of a solid (32% from 2-(3-decyl-ureido)-4-methyl-5-<br>
octylcarbarnoyl-thiophene-3-carboxylic acid ferf-butyl ester) after by column<br>
chromatography (9:1 to 5:1; hexanes:EtOAc): Mp 137.1-138.0eC; 1H NMR (CDCI3)<br>
6 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J= 6.6 Hz), 2.71 (s, 3H), 1.75-1.45 (m,<br>
4H), 1.27 (bs, 28H), 0.89 (t, 6H, J= 6.0 Hz); MS (El): 506.1 (m+).<br>
5-Methyl-4-oxo-2-tetradecylamino-4H-thieno[2,3-d]t1,3]oxazine-6-carboxylic<br>
acid octylamide (25) The same method as for the preparation of 5-methyl-2-<br>
heptyloxy^-oxo^H-thieno^.S-cfJtl.Sloxazine-e-carboxylic acid heptyl ester was<br>
employed. Thus, cyclization afforded 25 mg of a solid (19% from 4-methyl-5-<br>
octylcarbamoyl-2-(3-tetradecyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester)<br>
after by column chromatography (5:1; hexanes:EtOAc): Mp145.0-145.89C; 1H NMR<br>
(CDCla) 6 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J= 6.6 Hz), 2.71 (s, 3H), 1.75-<br>
1.45 (m, 4H), 1.27 (bs, 32H), 0.89 (t, 6H, J = 6.0 Hz); MS (El): 534.1 (m4).<br>
2-Hexadecylamino-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxync<br>
acid octylamide (26) The same method as for the preparation of 5-methyl-2-<br>
heptyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was<br>
employed. Thus, cyclization afforded 24 mg of a solid (14% from 2-(3-hexadecylureido)-<br>
4-methyl-5-octylcarbamoyl-thiophene-3-carboxylic acid ferf-butyl ester) after<br>
by column chromatography (5:1; hexanes:EtOAc): Mp 146.3-147.OeC; 1H NMR<br>
(CDClg) 8 5.74 (bs, 1H), 5.30 (bs, 1H), 3.42 (q, 4H, J = 6.6 Hz), 2.71 (s, 3H), 1.75-<br>
1.45 (m, 4H), 1.27 (bs, 36H), 0.89 (t, 6H, J= 6.0 Hz); MS (El): 562.1 (m+).<br>
N H<br>
5-MethyI-4-oxo-2-(4-phenoxy-phenylamino)-4H-thieno[2,3-d][1,3]oxazine-6-<br>
carboxylic acid octyl ester (19) The same method as for the preparation of 5-<br>
methyl-a-heptyloxy^-oxo^H-thieno^.S-c/in.SJoxazine-e-carboxylic acid heptyl ester<br>
was employed. Thus, cyclization afforded a solid, which was purified by<br>
recrystalization from EtOAc/Hexanes to give 25 mg of a solid (24%): 1H NMR<br>
(CDClg) 6 7.50 (d, 2H, J= 8.8 Hz), 7.25-7.45 (m, 2H), 7.40-6.90 (m, ,5H), 4.27 (t, 2H,<br>
J = 6.6 Hz), 2.81 (s, 3H), 1.73 (dt, 2H, J = 6.6 Hz), 1.27 (m, 10H), 0.89 (t, 3H, J = 6.0<br>
Hz).<br>
2-Heptyloxy-5-methyl-4-oxo-4H-thieno[2,3-dJ[1,3]oxazine-6-carboxylic acid<br>
benzyl ester (8) The same method as for the preparation of 5-methyl-2-heptyloxy-4-<br>
oxo-4H-thieno[2,3-ad[1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 116 mg of a solid (63%) after by column chromatography<br>
(4:1; hexanes:EtOAc): 1H NMR (CDCl3) 6 7.50-7.30 (m, 5H), 5.33 (s, 2H), 4.44 (t,<br>
2H, J = 6.2 Hz), 1.90-1.70 (m, 2H), 1.45-1.15 (m, 10H), 1.00-0.80 (m, 3H).<br>
5-Wlethyl-2-octyloxy-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
octylamlde (15) The same method as for the preparation of 5-methyl-2-heptyloxy-4-<br>
oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid heptyl ester was employed.<br>
Thus, cyclization afforded 44.0 mg of a solid (44%) after by column chromatography<br>
(4:1; hexanes:EtOAc): 1H NMR (CDCI3) 5 5.90-5.70 (m, 1H), 4.43 (t, 2H, J = 6.6 Hz),<br>
3.42 (q, 2H, J = 6.6 Hz), 2.72 (s, 3H), 1.90-1.70 (m, 2H), 1.70-1.50 (m, 2H), 1.50-<br>
1.15 (m, 20H), 0.95-0.80 (m, 6H).<br>
Example 13: Carbamate/Urea Intermediates<br>
4-Wlethyl-2-(3-octyl-ureido)-5-[(pyridin-4-ylmethyl)-carbamoyl]-thlophene-3-<br>
carboxylic acid tert-butyl ester (13.1) The compound was purified by column<br>
chromatography (100% EtOAc) to yield 175 mg (70%) of a white foam.: (70%). 'H<br>
NMR (CDCI3, 200MHz) 8 0.86 (m, 3H), 1.25 (brs, 10H), 1.56 (brs, 11H), 2.64 (s,<br>
3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.56 (d, 2H, J= S.BHz), 5.16 (t, 1H, J=<br>
5.4Hz), 6.17 (t, 1H, J= 5.8HZ), 7.24 (d, 2H, J= 5.8Hz), 8.54 (d, 2H, J= 5.8Hz), 10.94<br>
4-Methyl-5-[methyl-(6-methyl-pyridin-2-ylmethyl)-carbamoyl]-2-(3-octyl-ureido)-<br>
thiophene-3-carboxylic acid tert-butyl ester (13.2): (84%). 'H NMR (CDCI3,<br>
200MHz) 8 0.87 (m, 3H), 1.25 (brs, 10H), 1.56 (brs, 11H), 2.32 (s, 3H), 2.52 (s, 3H),<br>
3.01 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.74 (s, 2H), 4.95 (t, 1H, J= 5.4Hz),<br>
7.03 (d, 2H, J=7.8Hz), 7.55 (t, 1H, J=7.6Hz), 10.75 (s, 1H)<br>
5-[Ethyl-(2-pyridin-2-yl-ethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-<br>
thiophene-3-carboxylic acid tert-butyl ester (13.3): (99%). 'H NMR (CDCI3,<br>
200MHz) 8 0.87 (m, 3H), 1.11 (t, 3H, J= 7.0Hz), 1.25 (brs, 10H),.1.56 (brs, 11H),<br>
2.20 (s, 3H), 3.09 (t, 2H, J= 7.0Hz), 3.26 (m, 4H), 3.80 (t, 2H, J= 7.0Hz), 5.08 (t, 1H,<br>
J= 5.0HZ), 7.15 (m, 2H), 7.59 (ddd, 1H, J= 7.6Hz, J= 7.6Hz, J= 1.4Hz), 8.51 (d, 1H,<br>
J=4.4Hz), 10.76 (S.1H)<br>
5-(Benzyloxycarbonylmethyl-carbamoyl)-4-methyl-2-(3-octyl-ureldo)-thiophene-<br>
3-carboxylic acid tert-butyl ester (13.4): (95%). 1H NMR (CDCI3l 200MHz) 8 0.86<br>
(m, 3H), 1.25 (brs, 10H), 1.58 (brs, 11H), 2.56 (s, 3H), 3.25 (dt, 2H, J= 6.2Hz, J =<br>
6.6Hz), 4.21 (d, 2H, J= 5.4Hz), 5.21 (s, 2H), 5.49 (brs, 1H), 6.51 (t, 1H, J= 5.6Hz),<br>
7.36(8, 5H), 10.71 (s,1H)<br>
5-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-4-methyl-2-(3-octylureido)-<br>
thiophene-3-carboxylic acid tert-butyl ester (13.5): (97%). 'H NMR<br>
(CDCl3, 200MHz) 8 0.87 (brs, 3H), 1.27 (brs, 10H), 1.57 (s, 11H), 2.30 (s, 3H), 2.83<br>
(t, 2H, J= 5.8Hz), 3.29 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.80 (m, 8H), 4.69 (s, 2H), 4.87<br>
(t, 1H, J=5.6Hz), 6.55 (s, 1H), 6.60 (s, 1H), 10.83 (s, 1H)<br>
5-(3,4-Dimethoxy-benzylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophener3-<br>
carboxylic acid tert-butyl ester (13.6): (97%). 'H NMR (CDCI3, 200MHz) 5 0.86<br>
(brs, 3H), 1.25 (brs, 10H), 1.56 (s, 11H), 2.63 (s, 3H), 3.25 (dt, 2H, J= 6.2Hz, J=<br>
6.6H2), 3.86 (s, 6H), 4.47 (d, 2H, J= 5.6Hz), 5.05 (t, 1H, J= 5.8Hz), 5.95 (t, 1H, J=<br>
S.OHz), 6.84 (m, 3H), 10.90 (s, 1H)<br>
5-(2-Acetylamino-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.7): (58%). 'H NMR (CDCI3, 200MHz) 8 0.87<br>
(s, 3H), 1.27 (brs, 10H), 1.57 (brs, 11H), 2.04 (s, 3H), 2.60 (s, 3H), 3.29 (dt, 2H, J=<br>
6.2Hz, J= 6.6Hz), 3.50 (m, 4H), 4.90 (brs, 1H), 6.29 (brm, 2H), 10.92 (s, 1H)<br>
5-[4-(lsopropylcarbamoyl-methyl)-piperazine-1-carbonyl]-4-methyl-2-(3-octylureido)-<br>
thiophene-3-carboxylic acid tert-butyl ester (13.8): (61%). 'H NMR<br>
(CDCI3, 200MHz) 5 0.86 (brs, 3H), 1.10-1.28 (m, 16H), 1.56 (s, 11H), 2.29 (s, 3H),<br>
2.51 (s, 4H), 2.99 (s, 3H), 3.27 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.63 (s, 4H), 4.10 (m,<br>
1H), 5.05 (brs, 1H), 6.81 (d, 1H, J= S.OHz), 10.79 (s, 1H)<br>
3-Methyl-5-(3-octyl-thioureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester<br>
4-tert-butyl ester (13.9): 'H NMR (CDCI3l 200MHz) 6 0.88 (m, 3H), 1.28 (brs,<br>
10H), 1.59 (m, 11H), 2.72 (s, 3H), 3.47 (m, 2H), 5.30 (s, 2H), 6.31 (brs, 1H), 7.36 (m,<br>
5H).<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-yl-methyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.10). The reaction was passed through a plug<br>
of silica gel with ethyl acetate to yield 13.10, 3.42 g (94% crude yield) of an off white<br>
solid.<br>
5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.11) white solid (97% yield): 'H NMR (CDCI3,<br>
200MHz) 5 0.86 (t, 3H, J= 6.6 Hz), 1.24-1.27 (m, 10H), 1.54 (bs, 11H), 2.61 (s, 3H),<br>
3.26 (dt, 2H, J= 6.4, 5.8 Hz), 4.54 (d, 2H, J= 5.4 Hz), 5.31 (bs, 1H), 6.02 (t, 1H, J =<br>
5.3 Hz), 6.27 (1H, dd, J= 11.4, 3.2 Hz), 6.30, (d, 1H, J = 3.2 Hz), 7.34 (s, 1H), 10.89<br>
(bs, 1H). UC NMR (CDCIa) 6 14.0, 16.0, 22,6, 26.8, 28.4, 29.1, 29.2, 29.9, 31.7,<br>
36.9, 40.8, 82.3, 107.6, 110.4, 112.9, 118.7, 140.5, 142.3, 151.0, 152.7, 153.6,<br>
163.2, 166.4. MS (ES+) 491.95 (M+1), 493.00 (M+2).<br>
4-Wlethyl-2-(3-octyl-ureido)-5-[(2-pyridin-3-yl-ethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.12) white solid (73% yield): 'H NMR (CDCI3)<br>
200MHz) 8 0.85 (t, 3H, J= 6.6 Hz), 1.21-1.28 (m, 10H), 1.52 (bs, 11H), 2.54 (s, 3H),<br>
2.89 (t, 2H, J= 6.9 Hz), 3.27 (dt, 2H, J= 6.4, 6.2 Hz), 3.61 (dt, 2H, J= 6.6, 6.2 Hz),<br>
5.69 (bs, 1H), 5.92 (t, 1H, J= 5.9 Hz), 7.23 (dd, 1H, J = 6.2, 5.2 Hz), 7.55, (ddd, 1H,<br>
J = 7.6, 1.8, 1.8 Hz), 8.46 (d,1H,J = 4.8 Hz), 8.47(8, 1H), 10.81 (bs, 1H). 13C NMR<br>
(CDCI3) 5 14.0, 15.9, 22.6, 26.8, 28.3, 29.1, 29.2, 29.9, 31.7, 33.0, 40.7, 40.9, 82.2,<br>
112.7, 118.9, 123.5, 134.4, 136.3, 139.9, 147.9, 150.1, 152.6, 153.6, 163.7, 166.3.<br>
MS (ES+) 516.98 (M+1), 518.05 (M+2).<br>
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-<br>
thiophene-3-carboxylic acid tert-butyl ester (13.13) yellow oil (80% yield): 'H.<br>
NMR (CDCI3, 200MHz) 5 0.84 (t, 3H, J = 6.4 Hz), 1.22 (bs, 12H), 1.53 (m, 15H),<br>
2.25, (s, 3H), 2.33-2.52 (m, 8H), 3.23 (dt, 2H, J = 6.6, 6.4 Hz), 3.57 (bs, 2H), 5.63<br>
(bs, 1H), 10.73 (bs, 1H). MS (ES+) 592.07 (M+1), 593.13 (M+2).<br>
5-(3-Hexyl-3-methyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl<br>
ester 4-tert-butyl ester (13.14). 1H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 6.4<br>
Hz), 1.25-1.32 (m, 6H), 1.58 (s, 11H), 2.72 (s, 3H), 3.04 (s, 3H), 3.36 (t, 2H, J = 7.7<br>
Hz), 5.26 (s, 2H), 7.27-7.43 (m, 5H), 11.53 (bs, 1H). I3C NMR (CDCI3) 8 13.9, 15.8,<br>
22.5, 26.3, 27.7, 28.3, 31.4, 34.4, 49.3, 65.8, 82.3, 113.1, 115.2, 127.9, 128.4, 136.1,<br>
145.5,153.6,156.6,163.0, 166.7. MS (ES+) 557 (M+68).<br>
5-[3-(1 -Butyl-pentyl)-ureido]-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl<br>
ester 4-tert-butyl ester (13.15). 'H NMR (CDCI3, 200MHz) 80.86 (t, 6H, J = 6.6<br>
Hz), 1.25-1.31 (m, 12H), 1.55 (s, 9H), 2.70 (s, 3H), 3.58-3.78 (m, 1H), 5.04 (bd, 1H, J<br>
= 8.8 Hz), 5.25 (S, 2H), 7.27-7.41 (m, 5H), 10.98 (bs, 1H). "C NMR (CDCI3) 8 13.9,<br>
14.0, 15.8, 22.6, 22.7, 28.0, 28.1, 28.3, 35.1, 35.6, 65.9, 82.3, 112.8, 115.2, 127.9,<br>
128.4,136.1,145.5,153.1,156.3, 163.0,166.4,186.4. MS (ES+) 585 (M+68).<br>
5-(3,3-Dioctyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester<br>
81<br>
4-fert-butyl ester (13.16). 'H NMR (CDCI3l 200MHz) 80.87 (t, 6H, J = 6.6 Hz),<br>
1.26-1.30 (m, 20H), 1.58 (bs, 13H), 2.72 (s, 3H), 3.32 (t, 4H, J = 7.7 Hz), 5.25 (s,<br>
2H), 7.28-7.43 (m, 5H), 11.58 (bs, 1H). 13C NMR (CDCI3) 8 14.0, 15.8, 22.6, 26.9,<br>
28.3, 28.5, 29.2, 29.3, 31.8, 47.9, 65.9, 82.3, 113.0, 115.1, 127.9, 128.0, 128.5,<br>
136.1, 145.6, 153.3, 156.7, 163.0, 166.7.<br>
5-lsobutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
tert-butyl ester (13.17). MS (ES): m/z 467.9 [MH+]. 1H NMR (CDCI3, 200 MHz): 8<br>
= 0.83 (m, 9H), 1.26-1.57 (m, 20H), 1.87 (m, 1H, 6.6 Hz), 2.62 (s, 3H), 3.16-3.30 (m,<br>
4H), 5.11 (brs, 1H), 5.64 (m, 1H).<br>
5-(2,2-Dimethyl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.18). MS (ES): m/z 481.7 [MH+]. 1H NMR<br>
(CDCI3, 200 MHz): 5 = 0.83 (m, 9H), 1.26-1.57 (m, 23H), 2.62 (s, 3H), 3.16-3.30 (m,<br>
4H), 5.11 (brs, 1H), 5.64 (m, 1H).<br>
5-[(2,3-Dihydro-benzofuran-5-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-<br>
thiophene-3-carboxylic acid tert-butyl ester (13.19). MS (ES): m/z 543.87 [MH+].<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-2-ylmethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.20) The same method as for the preparation of<br>
4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl<br>
ester was employed. Thus, coupling with 2-(aminomethyl)pyridine (31.5 mg, 0.36<br>
mmol) afforded 86.9 mg of a solid (71%) after by column chromatography (EtOAc):<br>
1H NMR (CDCI3) 8 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 11H), 2.64 (s,<br>
3H), 3.29 (dt, 4H, J = 6.7, 6.6 Hz), 4.68 (d, 2H, J = 5.8H.Z), 4.91 (m, TH), 7.02 (m,<br>
1H), 7.35-7.10 (m, 1H), 7.65 (t, 1H, J = 8.0Hz), 8.53 (d, 1H, J = 5.0 Hz), 10.92 (s,<br>
1H); MS (El): cal'd 502.86, exp 502.94 (MH+).<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.21) The same method as for the preparation of<br>
4-methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl<br>
ester was employed. Thus, coupling with 3-(aminomethyl)pyridine (31.5 mg, 0.36<br>
mmol) afforded 93.1 mg of a solid (76%) after by column chromatography (EtOAc):<br>
1H NMR (CDCl3) 5 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.70-1.45 (m, 11H), 2.65 (s,<br>
3H), 3.29 (dt, 4H, J= 6.7, 6.6 Hz), 4.57 (d, 2H, J = 5.6Hz), 4.89 (m, 1H), 6.05 (t, 1H,<br>
J = 7.0, 5.0HZ), 7.68 (d, 1H, J = 7.0Hz), 8.53 (d, 1H, J = 5.0 Hz), 8.58 (s, 1H), 10.92<br>
(s, 1H); MS (El): cal'd 502.86, exp 502.94 (MH+).<br>
5-Dibutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
tert-butyl ester (13.22) The same method as for the preparation of 4-methyl-5-<br>
octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fert-butyl ester was<br>
employed. Thus, coupling with dibutylamine (37.6 mg, 0.36 mmol) afforded 56.9 mg<br>
of a solid (45%) after by column chromatography (8:2; hexanes:EtOAc): 1H NMR<br>
(CDCI8) 5 0.87 (m, 9H), 1.18-1.40 (m, 14H), 1.45-1.68 (m, 15H), 2.23 (s, 3H), 3.20-<br>
3.46 (m, 6H), 5.11 (m, 1H), 10.74 (s, 1H); MS (El): caPd 523.77, exp 524.02 (MH+).<br>
5-(4-Benzyl-piperidine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.23): 'H NMR (CDCI3, 200MHz) 8 0.87 (s, 3H),<br>
1.26 (brs, 11H), 1.56 (bra, 15H), 2.27 (s, 3H), 2.54 (d, 2H, J = 6.6Hz), 2.80 (m, 2H),<br>
3.27 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 4.20 (m, 2H), 5.06 (t, 1H, J = 5.2Hz), 7.05-7.30<br>
(m, 5H), 10.77 (s, 1H); MS (ES) 570.1 (M+1)<br>
8<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester 2-<br>
(1-butyl-pentyl) ester (13.24): (60%). 'H NMR (CD3OD, 200MHz) 5 0.89 (s, 9H),<br>
1.32 (s, 18H), 1.60 (s, 15H), 2.69 (s, 3H), 3.19 (t, 2H, J = 6.4Hz), 5.00 (p, 1H, J =<br>
6Hz), 10.95 (s, 1H); MS (ES) 539.2 (M+1)<br>
4-Methyl-2-(3-octyl-ureido)-5-(3-phenoxy-propylcarbamoyl)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.25): (55%).'H NMR (CDCI3, 400MHz) 5 0.88<br>
(m, 3H), 1.27 (m, 10H), 1.55 (m, 11H), 2.07 (m, 2H), 2.62 (s, 3H), 3.30 (dt, 2H, J =<br>
5.6Hz, J = 7.2Hz), 3.59 (dt, 2H, J = 5.6Hz, J = 6.4Hz), 4.07 (t, 2H, J = 5.6Hz), 4.82<br>
(brs, 1H), 6.14 (brs, 1H), 6.95 (m, 3H), 7.25 (m, 2H), 10.95 (s, 1H); MS (ES) 545.95<br>
(M)<br>
5-(1-Butyl-pentylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic<br>
acid tert-butyl ester (13.26): (92%). 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 9H),<br>
1.29 (m, 18H), 1.56 (s, 11H), 2.61 (s, 3H), 3.29 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 4.02<br>
(brs, 1H), 5.04 (t, 1H, J = 5.6Hz), 5.40 (d, 1H, J = 8.8Hz), 10.91 (s, 1H)<br>
5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid ferf-butyl ester (13.27): MS (ES+) 491.88 (M+1).<br>
4-Methyl-2-(3-octyl-ureido)-5-(thlazol-2-ylcarbamoyl)-thlophene-3-carboxylic<br>
acid ferf-butyl ester (13.28): MS (ES+) 494.84 (M+1).<br>
4-Methyl-2-(3-octyl-ureido)-5-(2-pyridin-3-yl-ethylcarbamoyl)-thiophene-3-<br>
carboxylic acid ferf-butyl ester (13.29): MS (ES+) 516.93 (M+1).<br>
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-<br>
thiophene-3-carboxylic acid fert-butyl ester (13.30): MS (ES+) 592.04 (M+1).<br>
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-plperazine-1-carbonyl)-thlophene-3-<br>
carboxylic acid ferf-butyl ester (13.31): MS (ES+) 556.94 (M+1).<br>
5-([1,4']Bipiperidinyl-1'-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.32): MS (ES+) 563.01 (M+1).<br>
5-(3-lmidazol-1-yl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid terf-butyl ester (13.33): MS (ES+) 519.95 (M+1),<br>
5-Dihexylcarbamoyi-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
tert-butyl ester (13.34): (40%). 1H NMR (CD3CI, 200MHz) 8 0.85 (s, 9H), 1.24 (s,<br>
22H), 1.56 (s, 15H), 2.24 (s, 3H), 3.31 (m, 6H), 4.83 (t, 1H, J = 5.2Hz), 10.76 (S, 1H);<br>
MS(ES) 580.21 (M+1)<br>
5-Dioctylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
tert-butyl ester (13.35): (65%). 'H NMR (CD3Cl, 200MHz) 8 0.86 (m, 9H), 1.23 (s,<br>
32H), 1.56 (s, 15H), 2.25 (s, 3H), 3.31 (m, 6H), 4.80 (t, 1H, J = 5.6Hz), 10.77 (s, 1H);<br>
MS (ES) 637.00 (M+1)<br>
5-Cyclohexylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic<br>
acid tert-butyl ester (13.36): (75%). 1H NMR (CD3CI, 200MHz) 8 0.87 (t, 3H, J =<br>
6.4Hz), 1.26 (m, 16H), 1.56 (m, 15H), 2.60 (s, 3H), 3.28 (dt, 2H, J = 6.6Hz, J =<br>
6.2Hz), 3.88 (m, 1H), 4.97 (t, 1H, J = 5.4Hz), 5.57 (d, 1H, J = 7.2Hz), 10.78 (s, 1H);<br>
MS (ES) 494.12 (M+1)<br>
5-(4-Benzyl-piperazine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.37): (72%). 'H NMR (CD3CI, 200MHz) 80.87<br>
(m, 3H), 1.26 (brs, 10H), 1.56 (brs, 11H), 2.28 (s, 3H), 2.44 (brs, 4H), 3.27 (dt, 2H, J<br>
= 6.6Hz, J = 6.6Hz), 3.52 (s, 2H), 3.60 (brs, 4H), 4.88 (t, 1H, J = 5.0Hz), 7.30 (brs,<br>
5H), 10.78 (s, 1H); MS (ES) 571.16 (M--1)<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.38). The crude solid was then flashed through<br>
a plug of silica gel with ethyl acetate to yield 13.38, 3.84g (98% crude yield) of a tan<br>
solid.<br>
5-(3-DimethyIamino-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.39): MS (ES+) 496.95 (M+1).<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester 4-<br>
lerf-butyl ester (13.40). Mp 11 9.0-1 20.09C; 1H NMR (CDCI3) 8 11.03 (s, 1H), 7.50-<br>
7.20 (m, 5H), 5.27 (s, 2H), 5.03 (vt, 1H), 3.29 (q, 2H, J = 6.6 Hz), 2.71 (s, 3H), 1.63-<br>
1.40 (m, 2H), 1.57 (s, 9H), 1.26 (bs, 10H), 0.87 (t, 3H, J = 6.6 Hz). MS (El): 502.8<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-ferf-butyl ester 2-<br>
octyl ester (13.41) Mp 92.0-94.0 eC; 1H NMR (CDCI3) 6 12.30 (s, 1H), 8.64 (s, 1H),<br>
5.30 (t, 1H, J = 6.0 Hz), 4.25 (t, 2H, J = 6.4 Hz), 3.29 (q, 2H, J = 6.0 Hz), 2.74 (s,<br>
3H), 1.90-1.50 (m, 4H), 1.61 (s, 9H), 1.28 (bs, 20H), 0.88 (m, 6H). MS (El): 525.1<br>
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fertbiityl<br>
ester (13.42). 1H NMR (CDCI3) 8 10.89 (s, 1H), 5.82-5.62 (m, 1H), 5.78-5.60<br>
(m, 1H), 3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.55 (s, 9H), 1.27<br>
(bs, 20H), 0.88 (m, 6H). MS (El): 524.1 (m+).<br>
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-butylcarbamoyl)-thiophene-3-carboxylic<br>
acid tert-butyl ester (13.43): 'H NMR (CDCI3l 200MHz) 8 0.87 (m, 3H), 1.21-1.43<br>
(m, 10H), 1.57 (s, 15H), 2.60 (m, 5H), 3.24-3.43 (m, 4H), 5.22 (brs, 1H), 5.70 (t, 1H,<br>
J = 5.0HZ), 7.25 (m, 5H), 10.90 (s, 1 H).<br>
4-Methyl-2-(3-octyl-ureido)-5-(3-phenyl-propylcarbamoyl)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.44) 'H NMR (CDCI3l 200MHz) 8 0.87 (m, 3H),<br>
1.21-1.45 (m, 10H), 1.57 (s, 11H), 1.89 (tt, 2H, J = 7.4Hz, J = 7.6Hz), 2.65 (m, 5H),<br>
3.24-3.45 (m, 4H), 5.14 (brs, 1H), 5.73 (t, 1H, J = 5.2Hz), 7.17-7.31 (m, 5H), 10.90<br>
4-Methyl-2-(3-octyl-ureido)-5-(2-phenoxy-ethylcarbamoyl)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.45): 'H NMR (CDCl3, 200MHz) 8 0.87 (m, 3H),<br>
1.22-1.49 (m, 10H), 1.56 (s, 11H), 2.61 (s, 3H), 3.28 (dt, 2H, J = 6.2Hz, J = 6.6Hz),<br>
3.78 (dt, 2H, J = 5.2Hz, J = 5.4Hz), 4.09 (t,'2H, J = 5.2Hz), 5.08 (t, 1H, J = S.OHz),<br>
6.21 (t, 1 H, J = 5.4HZ), 6.29 (m, 3H), 7.28 (m, 2H), 1 0.91 (s, 1 H).<br>
5-(2-Methoxy-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.46): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H),<br>
1.27-1.45 (m, 10H), 1.57 (brs, 11H), 2.60 (s, 3H), 3.24-3.37 (m, 5H), 3.54 (m, 4H),<br>
5.05 (t, 1H, J = 5.2Hz), 6.12 (brs, 1H), 10.88 (s, 1H).<br>
5-(3-Methoxy-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid tert-butyl ester (13.47): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H),<br>
1.21-1.49 (m, 10H), 1.57 (brs, 11H), 1.83 (tt, 2H, J = 5.8Hz, J = 6.2Hz), 2.60 (s, 3H),<br>
3.24-3.35 (m, 5H), 3.49 (m, 4H), 5.13 (t, 1H, J = 5.6Hz), 6.31 (t, 1H, J = 5.6Hz),<br>
10.90(s,<br>
5-((Benzo(1,3)dioxol-5-ylmethyl)-carbamoyl)-4-methyl-2-(3-octyl-ureido)-<br>
thiophene-3-carboxyHc acid tert-butyl ester (13.48): 'H NMR (CDCI3, 200MHz) 8<br>
0.87 (m, 3H), 1.26-1.43 (brs, 10H), 1.57 (brs, 11H), 2.63 (s, 3H), 3.27 (dt, 2H, J=<br>
6.2HZ, J= 6.6HZ), 4.44 (d, 2H, J = 5.6Hz), 4.92 (t, 1H, J = 5.6Hz), 5.94 (s, 2H), 6.76<br>
(s, 2H), 6.81 (s, 1H), 10.91 (s, 1H).<br>
3-Methyl-5-(1-methylheptyloxycarbonylamino)thiophene-2,4-dicarboxylic acid<br>
2-benzyl ester 4-tert-butyl ester (13.49)<br>
Light brownish oil in 82% yield as mixture of two rotatmers (2:1 ratio).<br>
'H NMR (CDCI3, 200MHz): 8 7.35-7.40 (m, 5H), 6.49 (brs, 1H), 5.25 and 5.28 (s, 2H),<br>
4.70-4.80 and 4.80-5.05 (m, 1H), 2.68 and 2.73 (s, 3H), 1.50-1.61 (m, 9H), 1.20-1.40<br>
(m, 8H), 0.87(m, 3H).<br>
3-Methyl-5-[3-(1-methylheptyl)ureido]thiophene-2,4-dicarboxylic acid 2-benzyl<br>
ester 4-fert-butyl ester (13.50)<br>
Light yellow oil in 99% yield as mixture of two rotatmers.<br>
'H NMR (CDCIS, 200MHz): 5 11.00 (brs, 1H), 7.29-7.43 (m, 5H), 5.24 and 5.26 (s,<br>
2H), 4.60 and 4.68 (brs, 1H), 3.80-3.95 (brs, 1H), 3.45-3.90 (m, 1H), 2.65 and 2.70<br>
(s, 3H), 1.55 and 1.57 (s, 9H), 1.40-1.50(m, 2H), 1.20-1.40 (m, 8H), 1.17 (d, 2H, J =<br>
6.6Hz), 1.09(d, 1H, J= 6.2HZ), 0.80-0.95(m, 3H).<br>
Example 14: Acid Intermediates<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-4-ylmethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid (14.1): (99%). 'H NMR (CD3OD, 200MHz) 8 0.86 (m, 3H), 1.25<br>
(brs, 10H), 1.56 (m, 2H), 2.64 (s, 3H), 3.28 (m, 2H), 4.56 (d, 2H, J= 5.8Hz) 7.24 (d,<br>
2H, J= 5.8HZ), 8.54 (d, 2H, J= 5.8Hz)<br>
4-Methyl-5-[methyl-(6-methyl-pyridin-2-ylmethyl)-carbamoyl]-2-(3-octyl-ureido)-<br>
thiophene-3-carboxylic acid (14.2): (99%). 'H NMR (CD3OD, 200MHz) 6 0.86 (m,<br>
3H), 1.28 (brs, 10H), 1.50 (brs, 2H), 2.38 (s, 3H), 2.50 (s, 3H), 3.04 (s, 3H), 3.17<br>
(brs, 2H), 4.74 (s, 2H), 7.15 (m, 2H), 7.55 (t, 1 H, J= 7.6Hz)<br>
5-[Ethyl-(2'pyridin-2-yl-ethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-<br>
thiophene-3-carboxylic acid (14.3): (99%). 'H NMR (CD3OD, 200MHz) 8 0.85 (m,<br>
3H), 1.20 (brs, 13H), 1.49 (brs, 2H), 2.20 (s, 3H), 3.19 (m, 4H), 3.41 (m, 2H), 3.83<br>
(brs, 2H), 7.38 (m, 2H), 7.84 (t, 1 H, J= 7.2Hz), 8.49 (d, 1 H, J= 3.6Hz)<br>
5-(Benzyloxycarbonylmethyl-carbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-<br>
3-carboxylic acid (14.4): (99%). 1H NMR (CD3OD, 200MHz) 6 0.86 (m, 3H). 1.28<br>
(brs, 10H), 1.50 (brs, 2H), 2.57 (s, 3H), 3.18 (m, 2H), 4.09 (s, 2H), 7.31 (brs, 5H)<br>
3-Methyl-5-(3-octyl-thioureido)-thiophene-2,4-dicarboxylic acid 2-benzyl ester<br>
(14.5): (99%). 'H NMR (CD3OD, 200MHz) 8 0.89 (brs, 3H), 1.29 (brs, 10H), 1.61<br>
(brs, 2H), 2.74 (s, 3H), 3.48 (brs, 2H), 5.29 (s, 2H), 7.38 (m, 5H).<br>
4-Wlethyl-2-(3-octyl-ureido)-5-[(pyridin-3-yl-methyl)-carbamoyI]-thiophene-3-<br>
carboxylic acid (14.6) Thiophene (3.42 g, 6.8 mmol) was dissolved in 40 mL<br>
CH2CI2. Trifluoroacetic acid (10 mL) was added slowly and the reaction was stirred<br>
for 4h at rt. The reaction was concentrated in-vacuo. The residue was dissolved in<br>
methanol and saturated NaHCO3 was added until pH~7. The solution was<br>
concentrated in vacuo and then resuspended in hot ethyl acetate. The insoluble<br>
salts were filtered and the filtrate was concentrated in vacuo to yield 14.6, 2.19 g<br>
(72% crude yield) of a tan solid.<br>
5-[(Furan-2-yl-methyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.7) white solid (73% yield): 'H NMR (CD3OD, 200MHz) 8 0.90<br>
(t, 3H, J= 6.4 Hz), 1.30-1.39 (m, 10H), 1.50-1.60 (m, 2H), 2.56 (s, 3H), 3.20 (t, 2H, J<br>
= 6.9 Hz), 4.49 (s, 2H), 6.27 (1H, d, J = 3.0 Hz), 6.35 (dd, 1H, J = 3.2, 1.8 Hz), 7.34<br>
(d, 1H, J =1.8 Hz). MS (ES+) 435.76 (M+1), 436.66 (M+2).<br>
4-Methyl-2-(3-octyl-ureido)-5-[(2-pyridin-3-yl-ethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid (14.8) light pink solid (100% yield): 'H NMR (CD3OD, 200MHz) 8<br>
0.90 (t, 3H, J= 9.9 Hz), 1.32 (bs, 10H), 1.51-1.60 (m, 2H), 2.58 (s, 3H), 2.96 (t, 2H, J<br>
= 7.0 Hz), 3.20 (t, 2H, J = 6.7 Hz), 3.59 (t, 2H, J = 7.0 Hz), 7.39 (dd, 1 H, J = 7.8, 4.8<br>
Hz), 7.78 (d, 1H, J=7.8 Hz), 8.39 (d, 1H, J=4.8 Hz), 8.46 (s, 1H). MS (ES-) 458.92<br>
(M-1).<br>
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-<br>
thiophene-3-carboxylic acid (14.9) peach solid (80% yield): MS (ES-) 534.04 (M-<br>
1).<br>
5-(3-Hexyl-3-methyl-ureido)-3-methyl-thiophene-2,4-dicarboxyi«c ackti 2-benzyl<br>
ester (14.10) light pink solid (100% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J<br>
= 6.4 Hz), 1.25-1.31 (m, 6H), 1.58-1.62 (m, 2H), 2.78 (s, 3H), 3.05 (s, 3H), 3.36 (t,<br>
13C 2H, J = 7.5 Hz), 5.29 (s, 2H), 7.29-7.44 (m, 5H), 10.39 (bs, 1H), 11.18 (bs, 1H).<br>
NMR (CDCI3) 5 13.9, 15.4, 22.4, 26.3, 27.7, 31.4, 34.7, 49.7, 66.4, 110.8, 116.4,<br>
127.9, 128.1, 128.5, 135.7, 146.1, 153.5, 158.6, 162.9, 171.3. MS (ES+) 432.74<br>
(M+1).<br>
5-(3,3-Dioctyl-ureido)-3-methyl-thiophene-2,4-dicarboxylic acid 2-benzyl ester<br>
(14.11) light pink solid (84% yield): 1H NMR (CDCI3, 200MHz) 6 0.86 (t, 6H, J = 6.6<br>
Hz), 1.26-1.30 (m, 20H), 1.63 (bs, 4H), 2.80 (s, 3H), 3.33 (t, 4H, J = 7.0 Hz), 5.28 (s,<br>
2H), 7.30-7.43 (m, 5H), 11.20 (s, 1H), 11.92 (bs, 1H).<br>
5-lsobutylcarbamoyl-4-methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
(14.12). MS (ES): m/z411.8 [MH+].<br>
5-(2,2-Dimethyl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.13). MS (ES): m/z 425.8 [MH+]. 1H NMR (CDCI3) 200 MHz): D<br>
= 1.26-1.57 (m, 23H), 2.62 (s, 3H), 3.16-3.30 (m, 4H), 5.11 (brs, 1H), 5.64 (m, 1H).<br>
O<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-2-ylmethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid (14.14) The same method as for the preparation of 3-<br>
methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl<br>
ester was employed. Thus, deprotection with TFA afforded a solid, which was used<br>
without purification: 1H NMR (CDCI3 + 1 drop of CD3OD) 8 0.86 (m, 3H), 1.32-1.20<br>
(m, 10H), 1.60-1.32 (m, 2H), 2.59 (s, 3H), 3.22 (dt, 4H, J= 6.7, 6.6 Hz), 4.76 (s, 2H),<br>
7.40-7.15 (m, 2H), 7.76 (t, 1H, J = 7.9Hz), 8.53 (d, 1H, J = 5.0 Hz).<br>
4-Methyl-2-(3-octyl-ureido)-5-[(pyridin-3-ylmethyl)-carbamoyl]-thiophene-3-<br>
carboxylic acid (14.15) The same method as for the preparation of 3-<br>
methoxymethyl-5-octyloxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-benzyl<br>
ester was employed. Thus, deprotection with TFA afforded a solid, which was used<br>
without purification: 1H NMR (CDCI3+1 drop of CD3OD) 8 0.82 (m, 3H), 1.45-1.20 (m,<br>
10H), 1.70-1.45 (m, 2H), 2.02 (m, 3H), 2.92 (m, 2H), 4.39 (m, 1H), 7.11 (m, 1H), 7.55<br>
(m, 1H), 8.31 (m, 1H), 8.49 (m, 1H).<br>
5-(4-Benzyl-piperidine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.16): (100%). 'H NMR (CD3OD, 200MHz) 8 0. 87 (s, 3H), 1.26<br>
(brs, 11H), 1.56 (brs, 6H), 2.27 (s, 3H), 2.54 (d, 2H, J = 6.6Hz), 2.90 (m, 2H), 3.27 (t,<br>
2H, J = 6.6Hz), 4.20 (brs, 2H), 7.05-7.30 (rn, 5H)<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 2-(1-butyl-pentyl)<br>
ester (14.17): (95%). 1H NMR (CD3OD, 400MHz) 8 0.89 (m, 9H), 1.33 (m, 18H),<br>
1.50-1.70 (m, 6H), 2.73 (s, 3H), 3.19 (t, 2H, J = 6.6Hz), 5.02 (m, 1H)<br>
5-(1-Butyl-pentylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thlophene-3-carboxylic<br>
acid (14.18): (100%). 'H NMR (CDCI3, 200MHz) S 0.87 (m, 9H), 1.29 (m, 18H),<br>
1.56 (s, 6H), 2.52 (s, 3H), 3.35 (t, 2H, J = 6.6Hz), 3.90 (brs, 1H)<br>
4-Methyl-2-(3-octyl-ureido)-5-(3-phenoxy-propylcarbamoyl)-thiophene-3-<br>
carboxylic acid (14.19): (100%). 1H NMR (CD3OD, 200MHz) 8 0.89 (m, 3H), 1.32<br>
(s, 10H), 1.55 (brs, 2H), 2.06 (tt, 2H, J = 6.0Hz, J = 6.0Hz), 2.55 (s, 3H), 3.19 (t, 2H,<br>
J = 7.0Hz), 3.51 (t, 2H, J = 6.8Hz), 6.90 (m, 3H), 7.24 (m, 2H).<br>
4-Methyl-2-(3-octyl-ureido)-5-(pyridin-3-ylmethyl)-carbamoyl)-thiophene-3-<br>
carboxyllc acid (14.20):. 14.20,110 mg (100% crude yield) of a tan solid.<br>
5-(3-Dimethylamino-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.21): MS (ES-) 438.70 (M-1).<br>
5-[(Furan-2-ylmethyl)-carbamoyl]-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.22): MS (ES-) 434.03 (M-1).<br>
4-Methyl-2-(3-octyl-ureido)-5-(thiazol-2-ylcarbamoyl)-thiophene-3-carboxylic<br>
acid (14.23): MS (ES-) 436.23 (M-1).<br>
4-Methyl-2-(3-octyl-ureido)-5-(2-pyridin-3-yl-ethylcarbamoyl)-thiophene-3-<br>
carboxylic acid (14.24): MS (ES-) 459.03(M-1).<br>
4-Methyl-2-(3-octyl-ureido)-5-[4-(2-piperidin-1-yl-ethyl)-piperazine-1-carbonyl]-<br>
thiophene-3-carboxylic acid (14.25): MS (ES-) 534.20 (M-1).<br>
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-piperazine-1-carbonyl)-thiophene-3-<br>
carboxylic acid (14.26): MS (ES-) 499.03 (M-1).<br>
5-([1,4']Bipiperidinyl-1'-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.27): MS (ES-) 505.08 (M-1).<br>
5-(3-lmida2ol-1-yl-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.28): MS (ES-) 462.09 (M-1).<br>
3-Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-fert-butyl ester<br>
(14.29) 1H NMR (CDCI3) 8 11.06 (s, 1H), 5.14 (vt, 1H), 3.30 (q, 2H, J= 6.0 Hz), 2.71<br>
(s, 3H), 1.70-1.40 (m, 2H), 1.59 (s, 9H), 1.27 (bs, 10H), 0.87 (t, 3H, J= 6.6 Hz). MS<br>
(El): 412.8 (m+).<br>
2-Dodecyloxy-5-methyl-4-oxo-4W-thieno[2,3-cf][1,3]oxazine-6-carboxylic acid<br>
(14.30) 1H NMR (CDCIa) 6 4.47 (t, 2H, J= 6.2 Hz), 4.19 (bs, 1H), 2.85 (s, 3H), 1.80<br>
(quint, 2H, J= 6.2 Hz), 1.27 (bs, 18H), 0.88 (t, 3H, J= 6.6 Hz). MS (Ei): 395.4 (m+).<br>
4-Methyl-5-octylcarbamoyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid<br>
(14.31) 1H NMR (CDCh) 8 10.90 (bs, 2H), 5.82-5.62 (m, 1H), 5.78-5.60 (m, 1H),<br>
3.33 (q, 4H, J = 6.6 Hz), 2.61 (s, 3H), 1.70-1.40 (m, 4H), 1.27 (bs, 20H), 0.88 (m,<br>
6H).<br>
3-Methoxymethyl-5-octvioxycarbonylamino-thiophene[2,4]dicarboxylic acid 2-<br>
benzyl ester (14.32) 1H NMR (CDCI3) 8 11.98 (s, 1H), 10.09 (s, 1H), 7.45-7.20 (m,<br>
5H), 5.14 (s, 2H), 4.22 (t, 2H, J = 6.6 Hz), 3.85 (s, 3H), 3.82 (s, 2H), 1.70 (quint, 2H,<br>
J = 6.6 Hz), 1.28 (bs, 10H), 0.88 (t, 3H, J = 5.6 Hz).<br>
5-(4-(lsopropylcarbamoyl-methyl)-piperazine-1-carbonyl)-4-methyl-2-(3-octylureido)-<br>
thiophene-3-carboxylic acid (14.33): 'H NMR (CDCI3) 200MHz) 8 0.89<br>
(brs, 3H), 1.15-1.34 (m, 16H), 1.56 (m, 2H), 2.37 (s, 3H), 3.05-3.49 (m, 10H), 3.95<br>
(m, 1H).<br>
5-((Benzo(1,3)dioxol-5-ylrr,ethyl)-carbamoyl)-4-methyl-2-(3-octyl-ureido)-<br>
thiophene-3-carboxylic acid (14.34): 'H NMR (CDCI3, 200MHz) 8 0.86 (m, 3H),<br>
.1.32-1.45 (m, 10H), 1.53 (rr, 2H), 2.56 (s, 3H), 3.19 (m,2H), 4.4 (d, 2H, J = 6.0Hz),<br>
5.91 (s, 2H), 6.80 (m, 3H).<br>
5-(3,4-Dlmethoxy-benzylcarbamoyl)-4-methylT2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.35): 'H NMR (CDCI3, 200MHz) 8 0.88 (brs, 3H), 1.31-1.45 (m,<br>
10H), 1.56 (m, 2H), 2.56 (s, SH), 3.18 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 3.80 (s, 3H), 3.82<br>
(s, 3H), 4.43 (s, 2H), 6.89 (s, 2H), 6.97 (s, 1H).<br>
S-te^-Dimethoxy-S^-dihydro-IH-isoquinoline^-carbonylH-methyl^-ta-octylureido)-<br>
thiophene-3-carboxylic acid (14.36): 'H NMR (CDCI3l 200MHz) 8 0.89<br>
(m, 3H), 1.31-1.45 (m, 10H), 1 51 (brs, 2H), 2.31 (s, 3H), 2.85 (t, 2H, J = 6.0Hz), 3.18<br>
(t, 2H, J = 7.0Hz), 3.79 (m, 8H), 6.71 (s, 1H), 6.74 (s,1H).<br>
4-Methyl-2-(3-octyl-ureido)-5-(4-phenyl-butylcarbamoyl)-thiophene-3-carboxylic<br>
acid (14.37): 'H NMR (CDCI3) 200MHz) 8 0.89 (brs, 3H), 1.26-1.45 (m, 10H), 1.59<br>
(m, 6H), 2.54 (s, 3H), 2.65 (t, 2H, J = 7.0Hz)', 3.19 (m, 4H), 7.21 (m, 5H).<br>
4-Methyl-2-(3-octyl-ureldo)-5-(3-phenyl-propylcarbamoyl)-thiophene-3-<br>
carboxylic acid (14.38): 'H NMR (CDCI3, 200MHz) 8 0.89 (m, 3H), 1.25-1.45 (m,<br>
10H), 1.57 (brs, 2H), 1.89 (tt, 2H, J = 7.4Hz, J = 7.6Hz), 2.55 (s, 3H), 3.17-3.39 (m,<br>
4H), 7.23 (m, 5H).<br>
4-Methyl-2-(3-octyl-ureido)-5-(2-phenoxy-ethylcarbamoyl)-thiophene-3-<br>
carboxylic acid (14.39): 'H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.25-1.41 (m,<br>
10H), 1.56 (brs, 2H), 2.56 (s, 3H), 3.19 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 3.71 (dt, 2H, J<br>
= 5.2HZ, J = 5.4Hz), 4.12 (t, 2H, J = 5.2Hz), 6.95 (m, 3H), 7.25 (m, 2H).<br>
5-(2-Methoxy-ethylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.40): 'H NMR (CDCI3l 200MHz) 5 0.89 (brs, 3H), 1.25-1.43 (m,<br>
10H), 1.53 (m, 2H), 2.56 (s, 3H), 3.19 (t, 2H, J =7.0Hz), 3.37 (s, 3H), 3.51 (m, 4H).<br>
5-(3-Methoxy-propylcarbamoyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (14.41): 'H NMR (CDCI3, 200MHz) 8 0.89 (brs, 3H), 1.27-1.44 (m,<br>
10H), 1.51 (brs, 2H), 1.84 (tt, 2H, J = 6.2Hz, J = 6.6Hz), 2.56 (s, 3H), 3.19 (t, 2H, J =<br>
7.0Hz), 3.34 (s, 3H), 3.39 (t, 2H, J = 7.0Hz), 3.49 (t, 2H, J = 6.2Hz).<br>
0 O<br>
5-Methyl-2-(1-methyiheptyloxy)-4-pxo-4H-thieno[2,3-c/Ioxa2ine-6-carboxylic<br>
acid benzyl ester (14.42)<br>
Light yellow oil in 32% yield.<br>
'HNMR (CDCI3, 200MHz): 8 10.70 (brs, 1H), 8.31 (brs, 2H), 7.29-7.43 (m, 5H), 5.27<br>
(S, 2H), 3.45-3.90 (m, 1H), 2.75 (s, 3H), 1.40-1.60(m, 2H), 1.10-1.40 (m, 11H), 0.85<br>
(t, 3H, J=6.6Hz).<br>
3-Methyl-5-[3-(1-methylheptyl)ureido]thiophene-2,4-dicarboxylic acid 2-benzyl<br>
ester (14.43)<br>
Light brownish solid in 99% yield.<br>
'HNMR (CDCI3, 200MHz): 8 10.52 (s, 1H), 9.00(brs, 1H), 7.35-7.39 (m, 5H), 5.28 (s,<br>
2H), 4.70-5.05 (m, 1H), 2.79 (s, 3H), 1.42-1.62(m, 2H), 1.10-1.40 (m, 8H), 0.87(t, 3H,<br>
J= 6.6Hz), MS (ES) [M'-l] 444.96.<br>
5-(4-Benzyl-piperazine-1-carbonyl)-4-methyl-2-(3-octyl-ureido)-thiophene-3-<br>
carboxylic acid (37) 1H NMR (DMSO, 200MHz) 8 0.83 (brm, 3H), 1.18-1.41 (brm,<br>
12H), 2.26 (s, 3H), 2.33 (brs, 4H), 2.99 (dt, 2H, J = 5.8Hz, J = 5.8Hz), 3.29 (s, 2H),<br>
3.43 (brm, 4H), 7.21-7.41 (m, 5H)<br>
Example 15: Thienoxazinones<br>
[(5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carbonyl)-<br>
amino]-acetic acid benzyl ester (48): 'H NMR (CDCI3) 200MHz) 6 0.88 (m, 3H),<br>
1.30 (brs, 10H), 1.61 (m, 2H), 2.74 (s, 3H), 3.42 (dt, 2H, J= 6.2Hz, J= 7.0Hz), 4.25<br>
(d, 2H, J= 5.0Hz), 5.08 (brs, 1H), 5.23 (s, 2H), 6.29 (brs, 1H), 7.37 (s, 5H)<br>
O<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
(pyridin-4-ylmethyl)-amide (55): (15%). 'H NMR (CDCI3, 200MHz) 5 0.88 (brs,<br>
3H), 1.25 (brs, 10H), 1.55 (brs, 2H), 2.75 (s, 3H), 3.38 (dt, 2H, J= 6.4Hz, J= 6.6Hz),<br>
4.60 (d, 2H, J= 5.8Hz), 6.17 (s, 1H), 7.24 (s, 2H), 8.54 (d, 2H, J= 5.8Hz)<br>
5-iv"iethyi-2-ociyiamhio-4-oxo-4K-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
methyl-(6-methyl-pyridin-2-ylmethyl)-amide (49): (20%). 'H NMR (CDCI3,<br>
200MHz) 5 0.86 (m, 3H), 1.26 (brs, 10H), 1.58 (m, 2H), 2.45 (s, 3H), 2.52 (s, 3H),<br>
3.06 (s, 3H), 3.38 (dt, 2H, J= 6.4Hz, J= 6.6Hz), 4.73 (s, 2H), 5.28 (brs, 1H), 7.05 (d,<br>
2H, J= 7.6Hz), 7.56 (t, 1H, J= 7.8Hz)<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyllc acid<br>
ethyl-(2-pyridin-2-yl-ethyl)-amide (51): (58%). 'H NMR (CDCI3, 200MHz) 5 0.87<br>
(m, 3H), 1.14 (t, 3H, J= 7.0Hz), 1.26 (brs, 10H), 1.59 (m, 2H), 2.31 (s, 3H), 3.10 (t,<br>
2H, J= 7.0HZ), 3.38 (dt, 4H, J= 6.2Hz, J= 7.0Hz), 3.84 (t, 2H, J= 7.6Hz), 5.26 (brs,<br>
1H), 7.14 (m, 2H), 7:59 (ddd, 1H, J= 7.4Hz, J= 7.6Hz, J= 1.6Hz), 8.52 (d, 1H, J=<br>
4.4HZ)<br>
5-Methyl-2-octy!amino-4-oxo-4H-thieno[2,3-d][1,3]thiazlne-6-carboxylic acid<br>
benzyl ester (56): 'H NMR (CD3OD, 200MHz) 6 0.87 (brs, 3H), 1.27 (brs, 10H),<br>
1.61 (m, 2H), 2.82 (s, 3H), 3.45 (dt, 2H, J= 6.2Hz, J= 6.6Hz), 5.31 (s, 2H), 5.42 (brs,<br>
1H), 7.35 (m,5H)<br>
2-(Hexyl-methyl-amino)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-<br>
carboxylic acid benzyl ester (57): 'H NMR (CDCI3, 200MHz) 5 0.89 (t, 3H, J= 6.6<br>
Hz), 1.30 (bs, 6H), 1.58-1.64 (m, 2H), 2.77 (s, 3H), 3.11 (s, 3H), 3.47-3.50 (m, 2H),<br>
5.29 (s, 2H), 7.30-7.44 (m, 5H). MS (ES+) 414.70 (M+1).<br>
2-(1-Butyl-pentylamino)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-<br>
carboxylic acid benzyl ester (59). 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 6H, J = 6.4<br>
Hz), 1.22-1.40 (bs, 8H), 1.48-1.66 (m, 4H), 2.79 (s, 3H), 3.90-4.00 (m, 1H), 5.32 (s,<br>
2H), 5.77 (d, J= 8.4 Hz), 7.31-7.45 (m, 5H).<br>
0<br>
2-Dioctylamino-5-methyl-4-oxo-4H-thleno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
benzyl ester (60) 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 6H, J = 6.6 Hz), 1.26-1.37 (m,<br>
20H), 1.58-1.64 (m, 4H), 2.79 (s, 3H), 3.39-3.53 (m, 4H), 5.31 (s, 2H), 7.29-7.45 (m,<br>
5H).oo \—/ \_N<br>
0<br>
0<br>
5-Methyl-2-octylamino-6-[4-(2-piperidm-1-yl-ethyl)-piperazine-1-carbonyllthleno[<br>
2,3-d][1,3]oxazin-4-one (53) MS (ES): m/z 517.9 [MH+]. 1H NMR (CDCI3,<br>
200 MHz): 5 = 0.87-1.59 (m, 9H), 1.18-1.59 (m, 14H), 2.54 (s, 3H), 2.23-2.51 (rff,<br>
4H), 3.34 (dt, 2H, J = 7 Hz), 3.61 (m, 3H), 5.21 (brs, 1H)<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
(furan-2-ylmethyl)-amide (52) MS (ES): nVz417.3 [MH+].<br>
1H NMR (CDCI3, 200 MHz): 5 = 1.18-1.41 (m, 14H), 2.67 (s, 3H), 3.43 (t, 2H, J = 8.4<br>
Hz), 4.48 (m, 2H, J = 5.6 Hz), 5.12 (brs, 1H), 6.02-6.57 (m, 3H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyIic acid (2-<br>
pyridin-3-yl-cthyl)-amide (50) MS (ES): m/z 443.5 [MH+]. 1H NMR (CDCI3, 200<br>
MHz): 8 = 1.25-1.68 (m, 14H), 2.60 (s, 3H), 2.99 (t, 2H, J = 7.4 Hz), 3.39 (dt, 2H, J =<br>
6.6 Hz), 5.25 (brs, 1H), 5.77 (s, 1H), 7.25 (m, 2H), 7.61 (d, 1H, J = 19.4 Hz), 8.51 (m,<br>
1H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
isobutyl-amide (54). MS (ES): m/z 393.8 [MH+].<br>
1H NMR (CDCIs, 200 MHz): 6 = 0.84-0.88 (m, 20H), 0.95-0.99(d, 6H, ), 1.41 (m,<br>
14H), 2.67 (s, 3H), 3.43 (t, 2H, J = 8.4 Hz), 4.48 (m, 2H, J = 5.6 Hz), 5.12 (brs, 1H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-dl[1,3]oxazine-6-carboxylic acid<br>
(2,2-dimethyl-propyl-amide (58). MS (ES): m/z 407.86 [MH+]. 1H NMR (CDCI3, 200<br>
MHz): 8 = 0.84-0.93 (m, 14H), 0.96 (s, 9H), 2.72 (s, 3H), 3.24 (s, 2H), 3.42 (m, 2H, J<br>
= 6.2 Hz), 5.12 (brs, 1H), 5.76 (brs, 1H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
dibutylamide (36). The same method as for the preparation of 5-methyl-2-<br>
heptyloxy-4-oxo-4H-thieno[2,3-c(][1,3]oxazine-6-carboxylic acid heptyl ester was<br>
employed. Thus, cyclization afforded 20 mg of a solid after column chromatography<br>
(7:3; hexanes:EtOAc) (40% from tert-butyl ester): 1H NMR (CDCI3) 5 0.88 (m, 9H),<br>
1.18-1.40 (m, 14H), 1.45-1.68 (m, 6H), 2.37 (s, 3H), 3.30-3.46 (rn, 6H), 5.19 (br s,<br>
1H); MS (El): caPd 449.66, exp 449.95 (MH+).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
(pyridin-3-ylmethyl)amide (35). The same method as for the preparation of 5-<br>
methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-afl[1,3]oxazine-6-carboxylic acid heptyl ester<br>
was employed. Thus, cyclization afforded 46 mg of a solid (36.6% from tert-butyl<br>
ester) after tritration: 1H NMR (CDCI3) 6 0.87 (m, 3H), 1.42-1.20 (m, 10H), 1.68-1.45<br>
(m, 2H), 2.72 (s, 3H), 3.41 (dt, 4H, J= 6.7, 6.6 Hz), 4.62 (d, 2H, J = 6.0Hz), 5.15 (m,<br>
fOt)<br>
1H), 6.07 (m, 1H), 7.38-7.20 (m, 1H), 7.70 (d, 1H, J = 8.6Hz), 8.65-8.52 (m, 2H);<br>
(El): cal'd 428.56, exp 428.88 (MH+).<br>
5-Methyl-2-octyIamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
(pyridin-2-ylmethyl)amide (34). The same method as for the preparation of 5-<br>
methyl-2-heptyloxy-4-oxo-4H-thieno[2,3-ad[1,3]oxazine-6-carboxylic acid heptyl ester<br>
was employed. Thus, cyclization afforded 46 mg of a solid (36.6% from tert-butyl<br>
ester) after tritration: 1H NMR (CDCI3) 6 0.87 (m, 3H), 1.45-1.20 (m, 10H), 1.80-1.50<br>
(m, 2H), 2.79 (s, 3H), 3.41 (dt, 4H, J= 6.7, 6.6 Hz), 4.72 (d, 2H, J = 4.4Hz), 5.25 (m,<br>
1H), 7.45-7.18 (m, 2H), 7.69 (t, 1H, J = 7.6Hz), 8.55 (d, 1H, J = 4.6 Hz); MS (El):<br>
cal'd 428.56, exp 428.88 (MH+).<br>
6-(4-Ben2yl-piperidine-1-carbonyl)-5-methyl-2-octylamino-thieno[2,3-<br>
d][1,3]oxazin-4-one (43)<br>
1H NMR (CDCIs, 200MHz) 6 0.88 (brs, 3H), 1.27 (brs, 11H), 1.54-1.70 (m, 6H),<br>
2.40 (s, 3H), 2.57 (d, 2H, J = 7'.OHz), 2.86 (m, 2H), 3.40 (dt,. 2H, J = 6.4Hz, J =<br>
6.4Hz), 4.20 (brs, 2H), 5.09 (s, 1H), 7.11-7.35 (m, 5H); MS (ES) 496.69 (M+1).<br>
fet<br>
5-Methyl-2-octyIamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid 1 -<br>
butyl-pentyl ester (39): (73%). 'H NMR (CDCI3, 200MHz) 6 0.89 (s, 9H), 1.31 (s,<br>
18H), 1.61 (m, 6H), 2.78 (s, 3H), 3.42 (dt, 2H, J = 6.2Hz, J = 6.6Hz), 5.00-5.20 (m,<br>
2H); MS(ES) 465.67 (M+1)<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (1 -<br>
butyl-pentyl)-amide (45): (28%). 'H NMR (CDCI3, 200MHz) 5 0.87 (m, 9H), 1.29<br>
(m, 18H), 1.56 (s, 2H), 2.65 (s, 3H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.6Hz), 4.02 (brs,<br>
1H), 5.04 (brs, 1H), 5.40 (d, 1H, J = 8.8Hz); MS (ES) 464.6 (M+1)<br>
-octyl<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid (3-<br>
phenoxy-propyl)-amide (44): (22%). 'H NMR (CDCI3, 200MHz) 6 0.88 (m, 3H),<br>
1.27 (m, 10H), 1.55 (m, 2H), 2.07 (m, 2H), 2.62 (s, 3H), 3.40 (dt, 2H, J = 5.6Hz, J =<br>
7.2Hz), 3.65 (dt, 2H, J = 5.6Hz, J = 6.4Hz), 4.12 (t, 2H, J = 5.6Hz), 5.05 (brs, 1H),<br>
6.30 (brs, 1H), 6.95 (m, 3H), 7.25 (m, 2H); MS (ES) 471.81 (M+1)<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
cyclohexylamide (38): (21%). 'H NMR (CDCIa, 400MHz) 8 0.87 (s, 3H), 1.26 (m,<br>
16H), 1.56 (m, 6H), 2.60 (s, 3H), 3.40 (dt, 2H, J = 6.6Hz, J = 6.2Hz), 3.88 (m, 1H),<br>
5.07 (brs, 1H), 5.57 (d, 1H, J = 7.2Hz); MS (ES) 420.12 (M+1)<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
dioctylamide (41): (61%). 'H NMR (CDCI3l 400MHz) 6 0.87 (m, 9H), 1.25 (brs,<br>
30H), 1.58 (m, 6H), 2.38 (s, 3H), 3.39 (m, 6H), 5.12 (brs, 1H); MS (ES) 562.15<br>
(M+1)<br>
103<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
dihexylamide (42): (56%). 1H NMR (CDCI3l 400MHz) 8 0.87 (m, 9H), 1.27 (brs,<br>
22H), 1.56 (m, 6H), 2.38 (s, 3H), 3.40 (m, 6H), 5.05 (brs, 1H); MS (ES) 506.03<br>
(M+1).<br>
O<br>
6-(4-Benzyl-piperazine-1-carbonyl)-5-methyl-2-octylamino-thieno[2,3-<br>
d][1,3]oxazin-4-one (40): (67%). 1H NMR (CD3CI, 200MHz) 8 0.87 (t, 3H, J =<br>
5Hz), 1.27 (brs, 10H), 1.58 (brs, 2H), 2.40 (s, 3H), 2.46 (t, 4H, J = 4.8Hz), 3.39 (dt,<br>
2H, J = 6.6Hz, J = 6.6Hz), 3.52 (s, 2H), 3.62 (brs, 4H), 5.19 (brs, 1H), 7.30 (s, 5H);<br>
MS (ES) 497.11 (M+1)<br>
5-Methyl-2-octyiamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
methylamide (31): (70%, off-white solid). 'H NMR (CDCI3, 200MHz) 8 0.88 (m,<br>
3H), 1.25-1.4 (m), 1.59-1.65 (m), 2.71 (s, 3H), 2.99 (d, 3H (J=5.2)), 3.41 (q, 2H, J=7<br>
Hz), 5.32 (bs, 1H), 5.76 (bs, 1H). MS (ES+) 351.93 (M+1), 352.99 (M+2).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxyIic acid<br>
ethylamide (33): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.88 (t, 3H, J=6.5<br>
Hz), 1.21-1.31 (m, 13H), 1.59-1.65 (m, 2H), 2.71 (s, 3H), 3.36-3.53 (m, 4H), 5.27 (bs,<br>
1H), 5.72 (bs, 1H). MS (ES+) 365.95 (M+1), 367.01 (M+2).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
butylamide (32): (off-white solid). 1H NMR (CDCI3, 200MHz) 8 0.85-1.00 (m, 6H),<br>
1.28-1.50 (m, 12H), 1.53-1.63 (m, 4H), 2.70 (s, 3H), 3.41-3.43 (m, 4H), 5.53 (bs, 1H),<br>
5.78 (bs, 1H). MS (ES+) 393.98 (M+1), 395.05(M+2).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
hexylamide (27): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.88-0.89 (m, 6H),<br>
1.27-1.32 (m, 16H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.44 (bs, 1H), 5.76<br>
(bs, 1H). MS (ES+) 422.05 (M+1), 423.13 (M+2).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
decylamide (28): (off-white solid). 'H NMR (CDCI3| 200MHz) 5 0.85-0.88 (m, 6H),<br>
1.26-1.31 (m, 24H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.27 (bs, 1H), 5.73<br>
(bs, 1H). MS (ES+) 478.08 (M+1), 479.10 (M+2).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
dodecylamide (29): (off-white solid). 'H NMR (CDCI3, 200MHz) 8 0.85-0.91 (m,<br>
6H), 1.26-1.31 (m, 24H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.30 (bs, 1H),<br>
5.73 (bs, 1H). MS (ES+) 506.14 (M+1), 507.14 (M+2).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic acid<br>
hexadecylamide (30): (off-white solid). 'H NMR (CDCI3, 200MHz) 6 0.84-0.91 (m,<br>
6H), 1.26-1.32 (m, 34H), 1.61 (bs, 4H), 2.70 (s, 3H), 3.41 (2xdt, 4H), 5.21 (bs, 1H),<br>
5.72 (bs, 1H). MS (ES+) 562.19 (M+1), 563.22 (M+2).<br>
J-00<br>
6-(6,7"Dimethoxy-3,4-dihydro-1H-isoquinoline-2-carbonyl)-5-methyl-2-<br>
octylamino-thieno(2,3-d)(1,3)oxazln-4-one (65): 1H NMR (CDCI3, 200MHz) 5 0.88<br>
(brs, 3H), 1.28-1.45 (m, 10H), 1.62 (m, 2H), 2.43 (s, 3H), 2.85 (t, 2H, J = 5.6Hz), 3.41<br>
(dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.84 (m, 8H), 4.69 (s, 2H), 5.20 (brs, 1H), 6.56 (s, 1H),<br>
6.63 (s,1H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2-<br>
(3,4-dimethoxy-phenyl)-methyl)-amldc (66): !H NMR (CDCI3, 200MHz) 6 0.88<br>
(brs, 3H), 1.28-1.43 (m, 10H), 1.59 (m, 2H), 2.71 (s, 3H), 3.41 (dt, 2H, J = 6.6Hz, J =<br>
6.6Hz), 3.88 (s, 6H), 4.55 (d, 2H, J = 5.4Hz), 5.10 (brs, 1H), 5.96 (brs, 1H), 6.88 (m,<br>
3H).<br>
N-lsopropyl-2-(4-(5-methyl-2-octylamino-4-oxo-4H-thieno(2J3-d)(1,3)oxazine-6-<br>
carbonyl)-piperazin-1-yl)-acetamide (64): 'H NMR (CDCI3, 200MHz) 8 0.88 (m,<br>
3H), 1.28-1.45 (m, 16H), 1T,60 (m, 2H), 2.41 (s, 3H), 2.54 (m, 4H), 3.25 (s, 2H), 3.40<br>
(dt, 2H, J = 6.6Hz, J = 6.6Hz), 3.59 (m, 4H), 4.61 (m, 1H), 5.08 (brs, 1H).<br>
O<br>
5-Methyl-2-octylamlno-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxy!ic acid (2-<br>
benzo(1,3)dioxol-5-yl-methyl)-amide (69): 'H NMR (CDCI3&gt; 200MHz) 6 0.88 (t,<br>
3H, J = 7.0Hz), 1.27-1.45 (m, 10H), 1.60 (m, 2H), 2.71 (s, 3H), 3.44 (dt, 2H, J =<br>
6.4Hz, J = 6.4Hz), 4.51 (d, 2H, J = 5.6Hz), 5.08 (brs, 1H), 5.96 (s, 3H), 6.79 (m, 3H).<br>
0<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2-<br>
phenoxy-ethyl)-amlde (70): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 7.0Hz),<br>
1.27-1.42 (m, 10H), 1.60 (m, 2H), 2.72 (s, 3H), 3.41 (dt, 2H, J = 6.6Hz, J = 6.6Hz),<br>
3.84 (dt, 2H, J = 5.0HZ, J = 5.2Hz), 4.15 (t, 2H, J = 5.0Hz), 5.08 (brs, 1H), 6.25 (brs,<br>
1H),6.93(m, 3H), 7.30 (m, 2H).<br>
0<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (2-<br>
methoxy-ethyl)-amide (72): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.8Hz),<br>
1.28-1.45 (m, 10H), 1.61 (m, 2H), 2.71 (s, 3H), 3.93 (m, 5H), 3.58 (m, 4H), 5.08 (brs,<br>
1H), 6.15 (brs, 1H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (3-<br>
methoxy-propyl)-amide (73): 'H NMR (CDCI3( 200MHz) 6 0.88 (t, 3H, J = 6.8Hz),<br>
1.28-1.44 (m, 10H), 1.61 (m, 2H), 1.87 (tt, 2H, J = 5.8Hz, J = 6.0Hz), 2.70 (s, 3H),<br>
3.40 (m, 5H), 3.57 (m, 4H), 5.09 (brs, 1H), 6.77 (brs, 1H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazlne-6-carboxyllc acid (4-<br>
phenyl-butyl)-amide (79): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.6Hz),<br>
1.28-1.45 (m, 10H), 1.66 (m, 6H), 2.69 (m, 5H), 3.43 (m, 4H), 5.07 (brs, 1H), 5.68<br>
(brs, 1H), 7.20 (m,5H).<br>
5-Methyl-2-octylamino-4-oxo-4H-thieno(2,3-d)(1,3)oxazine-6-carboxylic acid (3-<br>
phenyl-propyl)-amide (80): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J = 6.6Hz),<br>
1.27-1.44 (m, 10H), 1.58 (m, 2H), 1.96 (tt, 2H, J = 7.0Hz, J = 7.4Hz), 2.72 (m, 5H),<br>
3.43 (m, 4H), 5.71 (brs, 1 H), 7.22 (m, 5H).<br>
1C13<br>
o N O<br>
5-Methyl-2-(1 -methyl heptyloxy)-4-oxo-4H-thieno[2,3-cf|[1,3]oxazine-B-carboxyUc<br>
acid benzyl ester (89)<br>
Light yellow oil in 22% yield.<br>
'H NMR (CDCIj, 200MHz): 6 7.31-7.50 (m, 5H), 5.34 (s, 2H), 5.18 (tq, 1H, J = 6.2,<br>
6.2Hz), 2.82 (s, 3H), 1.58-1.83(m, 2H), 1.40(d, 3H, J = 6.2Hz), 1.10-1.34 (m, 8H),<br>
0.88 (t, 3H, J=6.6Hz).<br>
O<br>
O<br>
H<br>
5-Methyl-2-(1-methylheptylamino)-4-oxo-4H-thleno[2,3-cQ[1,3]oxazine-6-<br>
carboxylic acid benzyl ester (71)<br>
Light yellow oil in 40% yield.<br>
'H NMR (CDCI,, 200MHz): 8 7.31-7.43 (m, 5H), 5.32 (s, 2H), 5.13 (d, 1H, J = 6.2Hz),<br>
4.00 (m, 1H), 2.79 (s, 3H), 1.42-1.62(m, 2H), 1.10-1.40 (m, 8H), 0.87 (t, 3H, J =<br>
6.6Hz). MS (ES) [M++1] 429.10.<br>
ooi<br>
2-(1,3-Dioctyl-ureido)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-carboxylic<br>
acid benzyl ester (13): 1H NMR (CDCI3, 200MHz): 8 9.25 (m, -1H), 7.31-7.43 (m,<br>
5H), 5.32 (s, 2H), 3.99 (m, 2H), 3.35 (dt, 2H, J= 5.6, 5.6 Hz), 2.83 (s, 3H), 1.70-1.5<br>
(m, 4H), 1.50-1.20 (m, 20H), 0.87 (m, 6H, J= 6.6Hz). MS (ES) [M++1] 583.99.<br>
2-(1,3-Diheptyl-ureido)-5-methyl-4-oxo-4H-thieno[2,3-d][1,3]oxazine-6-<br>
carboxylic acid benzyl ester (14): 'H NMR (CDCI,, 200MHz): 6 9.25 (m, 1H), 7.31-<br>
7.43 (m, 5H), 5.32 (s, 2H), 3.99 (m, 2H), 3.35 (dt, 2H, J = 5.6, 5.6 Hz), 2.83 (s, 3H),<br>
1.70-1.5 (m, 4H), 1.50-1.20 (m, 16H), 0.87 (m, 6H, J = 6.6Hz). MS (ES) [M++1]<br>
555.97.<br>
114-<br>
5-Methyl-3-octyl-1H-thieno[2,3-d]pyrimidine-2,4-dione-6-carboxylic acid<br>
octylamide (47): Compound 18 (100 mg, 0.22 mmol) was dissolved in 1.8 mL<br>
absolute ethanol. Sodium ethoxide (21% by wt in ethanol, 1.1 ml, 2.9 mmol) was<br>
added and the solution was refluxed for 1h. Once cooled to room temperature, the<br>
solution was poured into 10 ml of a 1N HCI solution. The resultant precipitate was<br>
filtered to provide 47 (116 mg) as an off-white solid (100% yield). 'H NMR (CDCI3,<br>
200MHz) 6 0.87 (m, 6H), 1.27-1.32 (m, 20H), 1.54-1.70 (m, 4H), 2.78 (s, 3H), 3.44<br>
(dt, 2H, J = 7.0, 6.2 Hz), 3.97 (t, 2H, J = 7.7 Hz), 5.86 (t, 1H, J = 5.4 Hz), 10.39 (s,<br>
1H).<br>
Example 16; Procedure for reduction of carboxylic acid: 5-Hydroxymethyl-4-<br>
methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (2) 3-<br>
Methyl-5-(3-octyl-ureido)-thiophene-2,4-dicarboxylic acid 4-tert-butyl ester (1.0g,<br>
2.40 mmol) was dissolved in 25 mL of CH2CI2 and 0.25 ml_ of DMF. Thionyl chloride<br>
added as a 2M solution in CH2CI2 (1.2 ml, 2.4 mmol) and the reaction was stirred for<br>
2h. The reaction was rotovaped to a white solid, which was dissolved in 20 mL of<br>
dioxane. Sodium borohydride (910 mg, 24.0 mmol) added and the reaction stirred<br>
for 2h. The reaction was poured into 100 mL of H2O and extracted with EtOAc. The<br>
organic layer was washed with 1N HCI (aq), H2O, dried with MgSO4) and the solvent<br>
rotovaped off. The residue was recrystalized from EtOAc/Hexanes to give 600 mg of<br>
the title compound.: (62%). 1H NMR (CDCI3, 200MHz) 8 0.87 (m, 3H), 1.26 (brs,<br>
10H), 1.57 (brs, 11H), 2.30 (s, 3H), 3.28 (dt, 2H, J= 6.2Hz, J = 6.6Hz), 4.64 (s, 2H),<br>
4.74 (t, 2H, J = 5.6Hz), 10.77 (s, 1H)<br>
Scheme 3<br>
OH<br>
oxalyl chloride<br>
DMSO, NEt3<br>
CH2CI2<br>
-78aC-»rt<br>
S, NEt3<br>
DMF<br>
rt<br>
2 days<br>
rNH,<br>
| SOCI2<br>
OH pyr:CH2CI2<br>
-R1 or<br>
NHRbase,<br>
CH2CI2<br>
X<br>
.R'<br>
Example 17: Aldehyde Intermediates<br>
For a general procedure to synthesize non-commercial aldehydes 17.1-17.4 see<br>
Yoshisuke, Tsuda et al, Chem. Pharm. Bull. 1991, 39(1), 18-22<br>
4-Phenyi-butyraldehyde (17.1) clear liquid (860 mg, 87% yield) 'H NMR (CDCI3,<br>
200MHz) 6 1.99 (tt, 2H, J= 7.8, 7.4Hz), 2.45 (dt, 2H, J= 7.0, 1.2Hz), 2.67 (t, 2H, J-.<br>
7.4Hz), 7.26 (m, 5H), 9.76 (t, 1H, J= 1.4Hz).<br>
115<br>
5-Phenyl-pentanal (17.2) clear liquid (470 mg, 48% yield) 'H NMR (CDCI3, 200MHz)<br>
6 1.67 (m, 4H), 2.45 (dt, 2H, J = 4.8, 1.8Hz), 2.64 (brs, 2H), 7.25 (m, 5H), 9.75 (t, 1H,<br>
J=1.8Hz).<br>
6-Phenyl-hexanal (17.3) pale yellow oil (2.49 g, 84% yield) 1H NMR (CDCI3,<br>
200MHz) 5 1.20-1.43(m, 4H), 1.44-1.76(m, 4H), 2.41 (dt, 2H, J=7.0, 7.6 Hz), 2.60(t,<br>
2H, J = 7.2 Hz), 7.06-7.35(m, 5H), 9.75(t, 1H, J = 1.8 Hz); MS (ES) No ionization<br>
and no LC was found<br>
5-Phenyl-heptanal (17.4) pale yellow oil (401 mg, 81% yield) 1H NMR (CDCI3,<br>
200MHz) 6 1.20-1.50(m, 2H), 1.50-1.80(m, 4H), 2.41 (dt, 2H, J = 7.0, 7.4 Hz), 2.61 (t,<br>
2H, J = 7.4 Hz), 7.00-7.20(m, 5H), 9.75(t, 1H, 2 Hz), MS (ES) No ionization and no<br>
LC was found.<br>
Example 18: Aminothlophenes<br>
2-Amino-5-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.1): 1H NMR<br>
(CDCIs) 51.54 (s, 9H), 2.24 (s, 3H), 5.65 (br d, 2H), 7.25 (s, 1H); MS (El): cal'd<br>
213.70,exp213.96(MH+).<br>
2-Amino-5-heptyl-thiophene-3-carboxyllc acid fert-butyl ester (18.2) yellow oil<br>
(5.808 g, 46% yield): 0.88 (t, 3H, J = 6.4 Hz), 1.24-1.32 (m, 8H), 1.54-1.57 (m,<br>
11H), 2.56 (t, 2H, J = 7.5 Hz), 5.69 (bs, 2H), 6.56 (s, 1H). MS (ES+) 297.<br>
For a general procedure to synthesize 2-amino-5-alkyl-thiophene-3-carboxylic acid<br>
tert-butyl esters from aldehydes, see Tinney, F. J.; et al. J. Med. Chem. 1981, 24,<br>
878-882.<br>
2-Amino-5-butyl-thiophene-3-carboxylic acid ferf-butyl ester (18.3) yellow oil<br>
(372 mg, 41% yield): 'H NMR (CDCI3, 200MHz) 6 0.91 (t, 3H, J= 7.1 Hz), 1.26-1.41<br>
(m, 4H), 1.53 (bs, 9H), 2.56 (t, 2H, J = 7.3 Hz), 5.77 (bs, 2H), 6.56 (t, 1H, J= 1.1 Hz).<br>
"C NMR (CDCI3, 50MHz) 8 13.7, 22.0, 28.4, 29.3, 33.2, 79.7, 107.7,121.8,126.3,<br>
160.4,164.9. MS (ES+) 340.4 (M+1).<br>
NH.<br>
2-Amino-5-decyl-thiophene-3-carboxylic acid tert-butyl ester (18.4) yellow oil<br>
(11.32 g, 79% yield): 'H NMR (CDCI3, 400MHz) 8 0 88 (t, 3H, J = 6.8 Hz), 1.26-1.30<br>
(m, 14H), 1.52-1.55 (m, 11H), 2.56 (t, 2H, J = 7.4 Hz), 5.68 (bs, 2H), 6.56 (s, 1H).<br>
2-Arnino-5-benzyl-thiophene-3-carboxylic acid fert-butyl ester (18.5) yellow oil<br>
(520 mg, 51% yield): 'H NMR (CDCI3, 200MHz) 6 1.53 (s, 9H), 3.89 (s, 2H), 5.71<br>
(bs, 2H), 6.66 (t, 1H, J= 1.1 Hz), 7.16-7.33 (m, 5H). 13C NMR (CDCI3, 50MHz) 5<br>
28.4, 35.9, 79.9, 107.8, 123.4, 124.7, 126.5, 128.4, 128.5, 140.0, 161.3, 164.9. MS<br>
(ES+) 289.9 (M+1).<br>
2-Amino-5-(1,3,3-trlmethyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester<br>
(18.6) yellow oil (846 mg, 79% yield): 'H NMR (CDCI3, 200MHz) 8 0.89 (s, 9H), 1.22<br>
(d, 3H, J = 7.0 Hz), 1.39 (dd, 1 H, J = 13.8, 4.6 Hz), 1.54 (s, 9H), 1.59 (dd, 1 H, J =<br>
14.0, 7.0 Hz), 2.80-2.96 (m, 1H), 5.67 (bs, 2H), 6.55 (s, 1H).<br>
2-Amino-5-(5-methoxy-1,5-dimethyl-hexyl)-thiophene-3-carboxylic acid tertbutyl<br>
ester (18.7) yellow oil (2.328 g, 80% yield): 'H NMR (CDCI3, 200MHz) 8 1.12<br>
(s, 6H), 1.22 (d, 3H, J= 6.8 Hz), 1.22-1.54 (m, 18H), 2.74 (dq, 1H, J= 7.0, 6.2 Hz),<br>
3.16 (s, 3H), 5.70 (bs, 2H), 6.57 (s, 1H). MS (ES+) 341.93 (M+1).<br>
£16<br>
2-Amino-5-(1,5-dimethyl-hex-4-enyl)-thiophene-3-carboxylic acid fert-butyl<br>
ester (18.8) yellow oil (2.029 mg, 77% yield): 'H NMR (CDCl3, 200MHz) 5 1.21 (d,<br>
3H, J = 6.6 Hz), 1.51-1.54 (m, 11 H), 1.57 (s, 3H), 1.68 (s, 3H), 1.96 (dt, 2H, J = 7.2,<br>
7.0 Hz), 2.75 (tq, 1H, J = 7.0, 6.6 Hz), 5.08 (t, 1H, J= 6.4 Hz), 5.69 (bs, 2H), 6.56 (s,<br>
1H). MS (ES+) 309.9 (M+1).<br>
2-Amino-5-phenethyl-thiophene-3-carboxylic acid fe/t-butyl ester (18.9) yellow<br>
solid (1.5 g, 85% yield) 1H NMR (CDCI3) 200MHz) 8 1.53 (s, 9H), 2.88 (s, 4H), 5.70<br>
(s, 2H), 6.59 (S, 1H), 7.26 (m, 5H)<br>
2-Amino-5-(3-phenyl-propyl)-thiophene-3-carboxyllc acid ferf-butyl ester<br>
(18.10) yellow oil (440 mg, 48% yield) 1H NMR (CDCI3, 200MHz) 8 1.54 (s, 9H),<br>
1.90 (tt, 2H, J= 7.8,7.2Hz), 2.62 (m, 4H), 5.70 (s, 2H), 6.58 (s, 1H), 7.26 (m, 5H)<br>
2-Amino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid fert-butyl ester (18.11)<br>
yellow oil (1.22 g, 67% yield) 'H NMR (CDCI3l 200MHz) 8 0.88 (bt, 2H, J= 6.6 Hz),<br>
1.16-1.31 (m, 2H), 1.54 (s, 9H), 1.57-1.74 (m, 2H), 2.52-2.70 (m, 2H), 5.69(bs, 2H),<br>
6.56 (t, 1H, J= 1.2 Hz), 7.11-7.22 (m, 3H), 7.22-7.34 (m, 2H); MS (ES) No<br>
lonization (M+1), ^method D) = 9.11min.<br>
2-Amino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid ferf-butyl ester (18.12)<br>
yellow oil (638 mg, 36% yield) 1H NMR (CDCI3, 200MHz) 8 1.21-1.50 (m, 2H), 1.50-<br>
1.76 (m, 14H), 2.44-2.72 (m, 4H), 5.69(bs, 2H), 6.56 (t, 1H, J= 1.2 Hz), 7.07-7.37<br>
(m, 5H); MS (ES) No lonization (M+1), t^method D)= No LC trace observed<br>
2-Amino-5-butyl-thiophene-3-carboxylic acid tert-butyl ester (18.13): 1H NMR<br>
(CDCI3, 200 MHz): 8 = 0.91 (t, J = 7.1 Hz, 3H), 1.10-1.80 (m, 13H), 2.56 (td, J = 0.8,<br>
7.4 Hz, 2H), 5.68 (brs, 2H), 6.56 (t, J = 1.1 Hz, 1H).<br>
2-Amino-5-isopropyl-thiophene-3-carboxylic acid tert-butyl ester (18.14): 1H<br>
NMR (CDCI3, 200 MHz): 8 = 1.23 (dd, J = 2.2, 6.8 Hz, 6H), 1.54 (s, 9H), 2.78-3.02<br>
(m, 1H), 5.68 (brs, 2H), 6.57 (d, J = 1.2 Hz, 1H).<br>
2-Amino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester (18.15): 1H NMR<br>
(CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.14-1.43 (m, 10H), 1.44-1.68 (m,<br>
11H), 2.56 (t, J = 7.1 Hz, 2H), 5.67 (bra, 2H), 6.56 (s, 1H).<br>
2-Amino-5-dodecyl-thiophene-3-carboxylic acid tert-butyl ester (18.16): 1H<br>
NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.16-1.42 (m, 18H), 1.46-1.68<br>
(m, 11 H), 2.55 (t, J = 7.5 Hz, 2H), 5.68 (brs, 2H), 6.55 (t, J = 1.2 Hz, 1 H).<br>
2-Amino-5-heptyl-4-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.17):<br>
9.561 g (61%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.6 Hz, 3H), 1.16-1.40 (m,<br>
10H, 1.55 (s, 9H), 2.12 (s, 3H), 2.41 (t, J = 7.4 Hz, 2H).<br>
2-Amino-5-octyl-4-methyl-thiophene-3-carboxylic acid tert-butyl ester (18.18):<br>
10.202 g (63%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.8 Hz, 3H), 1.20-1.38<br>
(m, 12 H), 1.55 (s, 9H), 2.12 (s, 3H), 2.41 (t, J = 7.2 Hz, 2H).<br>
113<br>
2-Amino-6-benzylthiophene-3-carboxylic acid f-butyl ester (18.19)<br>
Light yellow oil in 62% yield.<br>
'H NMR (CDCI3, 200MHz): 6 7.18-7.38 (m, 5H), 6.66 (t, 1H, J= 1.0Hz), 5.70 (brs,<br>
2H), 3.90 (s, 2H), 1 .54(s, 9H).<br>
H<br>
S" ^NH2<br>
2-Amino-6-decylthiophene-3-carboxylic acid f-butyl ester (18.20)<br>
Dark brownish oil in 74% yield.<br>
'H NMR (CDCI3&gt; 200MHz): 5 6.56 (t, 1H, J= 1.2Hz), 5.68 (brs, 2H), 2.56 (dt, 2H,<br>
7.6, 1.2Hz), 1.54(s, 9H), 1.20-1.40 (m, 8H), 0.89 (t, 3H, J = 7.6Hz).<br>
2-Amino-6-hexylthiophene-3-carboxylic acid f-butyl ester (18.21)<br>
Dark brownish oil in 99% yield.<br>
'H NMR (CDCI,, 200MHz): S 6.56 (t, 1H, J= 1.2Hz), 5.68 (brs, 2H), 2.55 (dt, 2H, J =<br>
8.0, 1.2Hz), 1.54(s, 9H), 1.20-1.40 (m, 16HO, 0.88 (t, 3H, J = 7.0Hz).<br>
Example 19: Carbamate/Urea Intermediates<br>
5-Heptyl-4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tertbutyl<br>
ester (19.1): 1H NMR (CDCI3) 50.83-0.92 (m, 6H), 1.20-1.40 (m, 18H), 1.50-<br>
1.60 (m, 11H), 1.64-1.72 (m, 2H), 2.20 (s, 3H), 2.62 (t, 2H, J = 7.6 Hz), 4.19 (t, 2H, J<br>
= 7.2 Hz); MS (El): cal'd 467.72, exp, did not ionize.<br>
5-Methyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid tert-butyl ester (19.2):<br>
1H NMR (CDCIa) 80.87 (t, 3H, J = 7.2 Hz), 1.20-1.42 (m, 10H), 1.45-1.68 (m, 11H),<br>
2.32 (s, 3H), 3.27 (dt, 2H, J = 7.2, 7.2 Hz), 4.79 (m, 1H), 6.70 (s, 1H), 10.2 (br s, 1H);<br>
MS (El): cal'd 368.5, exp 368.87 (MH+).<br>
5-Methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester<br>
(19.3): 1H NMR (CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1.20-1.42 (m, 10H), 1.55 (s, 9H),<br>
1.62-1.72 (m, 2H), 2.34 (s, 3H), 4.19 (t, 2H, J = 6.8 Hz), 6.74 (s, 1H), 10.12 (br s,<br>
1H); MS (El): cal'd 369.5, exp,.did not ionize.<br>
General Procedure for urea formation (19.4-19.6):<br>
5-Heptyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid fe/t-butyl ester (19.4)<br>
Amino-thiophene 18.2 (200 mg, 0.67 mmol) was dissolved in 3 ml_ CH2Cl2 and<br>
cooled to 0 SC. Under N2 atmosphere, DBU (0.25 ml, 1.68 mmol) was added slowly<br>
followed by octyl isocyanate (104mg, 0.67mmol). The reaction slowly warmed to rt<br>
and was stirred at room temperature for 5h. The reaction was then diluted with 20<br>
mL CHaCIa and washed with 1N HCI and brine. The organic solution was then dried<br>
with MgSCXj and concentrated in vacua. The crude mixture purified by silica gel<br>
chromatography (15:1 hexanes: ethyl acetate) to yield 19.4, 73 mg (24% yield) of an<br>
off-white solid: 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 6H, J = 6.4 Hz), 1.27-1.29 (m,<br>
18H), 1.54-1.58 (m, 13H), 2.64 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 5.8 Hz),<br>
4.85 (t, 1H, J = 5.7 Hz), 6.69 (s, 1H), 10.25 (s, 1H). MS (ES+) 453.1 (M+1).<br>
O<br>
5-Butyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester (19.5) offwhite<br>
solid (353 mg, 59% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J = 7.1 Hz),<br>
0.90 (t, 3H, J= 7.1 Hz), 1.25-1.41 (m, 12H), 1.53-1.64 (m, 13H), 2.64 (t, 2H, J = 7.5<br>
Hz), 3.27 (dt, 2H, J = 7.0, 6.2 Hz), 5.29 (t, 1H, J ~ 5.7 Hz), 6.69 (s, 1H), 10.27 (bs,<br>
1H). 13C NMR (CDCIs, 50MHz) 8 1.3.7, 14.0, 22.1, 22.6, 26.8, 28.3, 29.1, 29.2, 29.3,<br>
30.0, 31.7, 33.4, 40.8, 80.7, 110.7, 119.8, 133.0, 149.9, 153.7, 165.6.<br>
5-Benzyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid ferf-butyl ester (19.6)<br>
pale yellow solid (394 mg, 49% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 3H, J =<br>
6.4 Hz), 1.27 (bs, 10H), 1.54 (s, 11H), 3.25 (dt, 2H, J = 7.0, 5.8 Hz), 3.97 (s, 2H),<br>
4.88 (t, 1H, J= 5.6 Hz), 6.48 (t, 1H, J= 1.0 Hz), 7.16-7.32 (m, 5H), 10.26 (bs, 1H).<br>
General procedure for amide and carbamate formation (19.7-19.17):<br>
2-Dodecanoylamino-5-heptyl-thiophene-3-carboxylic acid tert-butyl ester (19.7)<br>
Amino-thiophene 18.2 (171 mg, 0.57 mmol) was dissolved in 3 ml_ CHaCIa and 2 ml<br>
pyridine. Under N2 atmosphere, lauroyl chloride (126mg, 0.57mmol) was added and<br>
the reaction was stirred at room temperature for 6h. The reaction was then diluted<br>
with 10 mL CH2CI2 and washed with water, 5% citric acid, and brine. The organic<br>
solution was then dried with MgS04 and concentrated in vacua. The crude mixture<br>
purified by silica gel chromatography (40:1 hexanes: ethyl acetate) to yield 19.7,175<br>
mg (63% yield) of a yellow oil: 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 6H, J = 6.4 Hz),<br>
1.25-1.44 (m, 24H), 1.51-1.73 (m, 13H), 2.45 (t, 2H, J=7.5 Hz), 2.67 (t, 2H, J=7.5<br>
Hz), 6.77 (s, 1H), 10.94 (bs, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 14.1, 22.5, 22.6,<br>
25.3, 28.3, 28.9, 29.0, 29.1, 29.2, 29.3, 29.4, 29.5, 29.6, 31.3, 31.7, 31.9, 36.7, 81.2,<br>
113.3, 120.1, 134.8,146.3, 165.1, 169.9.<br>
2-Octyloxycarbonylamino-5-(1.3,3-trimethyl-butyl)-thiophene-3-carboxylic acid<br>
fert-butyl ester (19.8) yellow oil (185 mg, 34% yield): 'H NMR (CDCI3, 200MHz) 8<br>
0.85-0.91 (m, 12H), 1.26-1.76 (m, 26H), 2.90-3.03 (m, 1H), 4.20 (t, 2H, J= 6.8 Hz),<br>
6.73 (s, 1H), 10.15 (bs, 1H). 13C NMR (CDCI3, 50MHz) 8 14.0, 22.6, 25.8, 26.3, 28.3,<br>
28.8, 29.1, 29.2, 29.8, 31.2, 31.8, 32.0, 52.6, 66.3, 81.2, 112.3, 118.9, 142.1, 147.7,<br>
153.3,164.9.<br>
5-(5-Methoxy-1,5-methyl-hexyl)-2-octyloxycarbonylamino-thiophene-3-<br>
carboxyiic acid fert-butyl ester (19.9) pale yellow oil: 'H NMR (CDCI3&gt; 200MHz) 5<br>
0.89 (t, 3H, J= 6.4 Hz), 1.11 (s, 6H), 1.26-1.48 (m, 19H), 1.50-1.71 (m, 11H), 2.74<br>
(dq, 1H, J = 7.0, 7.0 Hz), 3.15 (s, 3H), 4.20 (t, 2H, J= 6.6 Hz), 6.74 (s, 1H), 10.17 (s,<br>
1H). "C NMR (CDCI3l 50MHz) 8 14.0, 21.5, 22.5, 22.6, 24.9, 25.7, 28.2, 28.7, 29.1,<br>
31.7, 35.1, 39.3, 39.5, 48.9, 60.2, 66.2, 74.3, 81.. 1, 112.2, 119.3, 139.7, 147.9,<br>
153.1, 164.8.<br>
CT 0<br>
5-(1,5-Dimethyl-hex-4-enyl)-2-octyloxycarbonylamino-thiophene-3-carboxylic<br>
acid terf-butyl ester (19.10) brown oil (630 mg, 90% yield): 1H NMR (CDCI3,<br>
200MHz) 8 0.89 (t, 3H, J = 6.6 Hz), 1.26-1.42 (m, 13H), 1.55-1.73 (m, 19H), 1.96<br>
(dt, 2H, J = 7.8, 7.2 Hz), 2.86 (tq, 1H, J = 7.2, 6.6 Hz), 4.20 (t, 3H, J= 6.6 Hz), 5.08<br>
(t, 1H, J= 7.2 Hz), 6.74 (s, 1H), 10.16 (bs, 1H).<br>
H<br>
2-Octyloxycarbonylamino-5-phenethyl-thiophene-3-carboxylic acid ferf-butyl<br>
ester (19.11) white solid (740 mg, 98% yield) 'H NMR (CDCI3, 200MHz) 8 0.88 (t,<br>
3H, J= 6.6Hz), 1.28 (brs, 10H), 1.56 (s, 9H), 1.68 (m, 2H), 2.96 (s, 4H), 4.20 (t, 2H, J<br>
= 6.6Hz), 6.75 (s, 1H), 7.26 (m, 5H), 10.15 (s, 1H)<br>
2-Octyioxycarbonylamino-5-(3-phenyl-propyi)-ihiophene-3-carboxyiic aciu ierfbutyl<br>
ester (19.12) yellow oil (270 mg, 90% yield) 'H NMR (CDCI3, 200MHz) 8 0.88<br>
(t, 3H, J= 6.6Hz), 1.28 (brs, 10H), 1.64 (brs, 11H), 1.97 (tt, 2H, J = 7.8, 7.2Hz), 2.69<br>
(m, 4H), 4.20 (t, 2H, J= 6.6 Hz), 6.76 (s, 1H), 7.26 (m, 5H), 10.15 (s, 1H)<br>
2-Octyloxycarbonylamino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid tertbutyl<br>
ester (19.13) clear colorless oil (401 mg, 88% yield) 1H NMR (CDCI3, 200MHz)<br>
8 0.88 (bt, 3H, J = 6.2 Hz), 1.15-1.42 (m, 11H), 1.56 (s, 9H), 1.61-1.80 (m, 6H),<br>
2.52-2.80 (m, 4H), 4.20 (t, 2H, J = 6.6 Hz), 6.74 (s, 1H), 7.09-7.35 (m, 5H), 10.15 (s,<br>
1H); MS (ES) no ionization or LC was observed.<br>
2-Octyloxycarbonylamino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid tertbutyl<br>
ester (19.14) clear/colorless oil (331 mg, 75% yield) 1H NMR (CDCI3,<br>
200MHz), 8 0.88 (bt, 3H, J= 6.2 Hz), 1.20-1.50 (m, 14H), 1.50-1.75 (m, 15H), 2.50-<br>
2.75 (m, 4H), 4.19 (t, 2H, J = 7.0 Hz), 6.74 (t, 1H, J = 1.0 Hz), 7.08-7.36 (m, 5H); MS<br>
(ES) No LC trace and no ionization came out.<br>
5-Decyl-2-(2-methoxy-ethoxycarbonylamino)-thiophene-3-carboxylic acid tertbutyl<br>
ester (19.15) pale yellow oil (307 mg, 76% yield) 1H NMR (CDCI3, 200MHz) 8<br>
0.88 (bt, 3H, J = 6.2 Hz), 1.16-1.43 (m, 14H), 1.55 (s, 9H), 1.57-1.73 (m, 2H), 2.66<br>
(t, 2H, J = 7.8 Hz), 3.41 (s, 3H), 3.58-3.70 (m, 2H), 4.25-4.44 (m, 2H), 6.74 (s, 1H),<br>
10.27 (bs, 1H); MS (ES) 442.64 (M+1), t^method D) = 12.91min.<br>
2-(4-Butyl-phenoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid tertbutyl<br>
ester (19.16) Amino thiophene 18.4 ( 300 mg, 0.92 mmol) was dissolved in<br>
anhydrous THF (4 ml_). Under a nitrogen atmosphere was added 4-nitrophenyl<br>
chloroformate (184 mg, 0.92 mmol) and was stirred overnight at room temperature.<br>
Without any isolation of the 4-nitrophenyl carbamate intermediate the sodium salt of<br>
4-butyl phenol (200 mg, 1.26 mmol) was dropwise added to the solution of the<br>
intermediate and was stirred at room temperature for 2 hours followed by heating to<br>
40 BC for an additional hour. The sodium salt of the phenol was prepared by<br>
dissolving 4-butyl phenol (174 mg, 1.16 mmol) in anhydrous THF (3 mL) and cooling<br>
to 0 SC. Then NaH(60% dispersion in mineral oil) (45 mg, 1.16 mmol) was added to<br>
reaction mixture and stirred at 0 BC for Vfe hour and was used as stated above. The<br>
reaction mixture was partitioned between CHCI3 and H20 and separated. The H20<br>
layer was extracted again with CHCI3 (3x) and separated. The combined CHCI,<br>
layers was washed with 2M NaOH (1x), 1M HCI (1x), brine (1x) and dried with<br>
Na2SO4 filtered and concentrated resulting in 490 mg of a dark orange oil. The crude<br>
material was further purified by flash silica chromatography (2% EtOAc in Hexanes)<br>
which resulted in 241 mg of a yellow oil (50% yield). 1H NMR (CDCI3, 200MHz) 8<br>
0.83-0.93 (m, 6H), 1.19-1.45 (m, 18H), 1.47-1.72 (m, 14H), 2.55-2.75 (m, 4H), 6.80<br>
(s, 1H), 7.11 (d, 2H, J=8.8Hz), 7.19 (d, 2H, J = 8.8Hz), 10.58 (s, 1H).<br>
5-Decyl-2-(4-phenyl-butoxycarbonylamino)-thiophene-3-carboxylic acid tertbutyl<br>
ester (19.17) pale yellow oil (241 mg, 89% yield) 1H NMR (CDCI3, 200MHz) 5<br>
0.88 (t, 3H, J = 6.6 Hz), 1.26-1.38 (m, 14H), 1.56-1.70 (m, 11H), 1.99 (tt, 2H, J =<br>
12.6, 6.2 Hz), 2.66 (t, 2H, J = 7.5 Hz), 3.58 (t, 2H, J = 6.2 Hz), 4.34 (t, 2H, J = 6.2<br>
Hz), 4.50 (s, 2H), 6.75 (s, 1H), 7.24-7.34 (m, 5H), 10.16 (s, 1H). UC NMR (CDCI3,<br>
50MHz) 8 14.04, 22.60, 28.26, 28.97, 29.19, 29.23, 29.27, 29.45, 29.48, 29.51,<br>
31.25, 31.82, 63.35, 66.35, 72.96, 81.09, 112.53, 120.60, 127.48, 127.53, 128.28,<br>
133.87,138.21, 147.97, 152.97, 164.77.<br>
Example 20: Tert-butyl Ester Intermediates<br>
5-Butyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester<br>
(20.1): 1H NMR (CDCI3, 200 MHz): 8 = 0.80-1.00 (m, 6H), 1.18-1.49 (m, 12H),<br>
1.50-1.79 (m, 13H), 2.67 (t, J = 7.3 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.74 (t, J = 0.9<br>
Hz, 1H), 10.14 (brs, 1H).<br>
5-lsopropyl-2-octyloxycarbonylamJno-thlophene-3-carboxylic acid tert-butyl<br>
ester (20.2): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.16-1.46 (m,<br>
16H), 1.50-1.76 (m, 11H), 2.90-3.16 (m, 1H), 4.20 (t, J = 6.6 Hz, 2H), 6.75 (d, J =<br>
1.0Hz, 1H), 10.15 (brs, 1H).<br>
cr o<br>
5-Octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl ester<br>
(20.3): 1H NMR (CDCI3, 200 MHz): 6 = 0.79-0.98 (m, 6H), 1.18-1.46 (m, 20H),<br>
1.51-1.78 (m, 13H), 2.66 (td, J = 0.8, 7.5 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.74 (t, J<br>
= 1.1 Hz, 1H), 10.14 (brs, 1H).<br>
CT O<br>
5-Dodecyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl<br>
ester (20.4): 1H NMR (CDCI3, 200 MHz): 6 = 0.80-0.98 (m, 6H), 1.15-1.46 (m,<br>
28H), 1.52-1.78 (m, 13H), 2.66 (t, J = 7.3 Hz, 2H), 4.20 (t, J = 6.8 Hz, 2H), 6.74 (s,<br>
1H), 10.14 (brs, 1H).<br>
2-Benzyloxycarbonylamino-5-decyi-thiophene-3-carboxylic acid tert-butyl ester<br>
(20.5): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.18-1.42 (m, 14H),<br>
1.48-1.72 (rn, 11H), 2.66 (t, J = 7.5 Hz, 2H), 5.24 (s, 2H), 6.74 (s, 1H), 7.31-7.47 (m,<br>
5H), 10.25 (brs, 1H).<br>
General procedure for the preparation of tert-butyl esters 20.6-20.8 from<br>
aminothiophene 18.4 and the corresponding commercially available alcohols:<br>
To a solution of 4-butylbenzyl alcohol (0.30 mL, 1.76 mmol) in CH2Cl2 (10 ml) was<br>
added saturated NaHC03 (10 ml) and then diphosgene (0.25 ml, 2.07 mmol)<br>
dropwise. The mixture was allowed to stir vigorously at ambient temperature for 45<br>
min, and aminothiophene 18.4 (283 mg, 0.83 mmol) was added in one portion. After<br>
stirring vigorously for 2 h, the reaction mixture was diluted with EtaO (100 ml), and<br>
the organic layer was washed with saturated NaHCOs (2x20 mL), and brine (40 mL).<br>
The organic layer was dried over Na2S04 and then filtered. The filtrate was<br>
concentrated and the resulting residue was purified by flash column chromatography<br>
(40:1 Hexanes/EtOAc) to give tert-butyl ester 20.6 as a light yellow oil (416 mg,<br>
95%).<br>
2-(4-Butylbenzyloxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid tertbutyl<br>
ester (20.6): 1H NMR (CDCI3, 200 MHz): 6 = 0.82-1.00 (m, 6H). 1.18-1.46<br>
(m, 16H), 1.48-1.72 (m, 13H), 2.54-2.73 (m, 4H), 5.20 (s, 2H), 6.73 (s, 1H), 7.13-<br>
7.38 (m,4H), 10.23 (brs, 1H).<br>
5-Decyl-2-(2-p-tolyl-ethoxycarbonylamino)-thiophei'ie-3-carboxyi!c acid tertbutyl<br>
ester (20.7): 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.17-<br>
139<br>
1.42 (m, 14H), 1.49-1.72 (m, 11H), 2.32 (s, 3H), 2.66 (t, J = 7.3 Hz, 2H), 2.96 (t, J =<br>
7.1 Hz, 2H), 4.39 (t, J = 7.3 Hz, 2H), 6.74 (s, 1H), 7.08-7.19 (m, 4H), 10.14 (brs, 1H).<br>
0 0<br>
5-Decyl-2-phenethyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl<br>
ester (20.8): 1H NMR (CDCI3, 200 MHz): 5 = 0.88 (t, J = 6.4 Hz, 3H), 1.18-1.42 (m,<br>
14H), 1.50-1.72 (m, 11H), 2.66 (t, J = 7.3 Hz, 2H), 3.01 (t, J = 7.5 Hz, 2H), 4.42 (t, J<br>
= 7.3 Hz, 2H), 6.74 (s, 1H), 7.18-7.40 (m, 5H), 10.15 (brs, 1H).<br>
O<br>
4-Methyl-5-octyl-2-octyloxycarbonylamino-th1ophene-3-carboxylic acid tertbutyl<br>
ester (20.9): 2.35 g (33%). 1H NMR (CDCI3, 200 MHz): 6 0.87 (t, J = 6.6 Hz,<br>
3H), 0.88 (t, J = 7.6 Hz, 3H), 1.30-1.72 (m, 24H), 1.57 (s, 9H), 2.20 (s, 3H), 2.61 (t, J<br>
= 7.8 Hz, 2H), 4.18 (t, J = 6.6 Hz, 2H), 10.26 (s, 1H); 13C NMR (CDCI3, 75 MHz): 6<br>
12.3, 12.9, 20.9, 24.0, 24.1, 25.4, 26.7, 27.1, 27.3, 27.4, 27.5, 27.6, 29.6, 30.1, 30.1,<br>
64.5, 79.7, 111.2, 126.2, 127.1, 146.7, 151.5, 164.0.<br>
2-Butyloxycarbonylamino-5-octyl-th!ophene-3-carboxylic acid tert-butyl ester<br>
(20.10): 693 mg (92%). 1H NMR (CDCI3&gt; 200 MHz): 8 0.83 (t, J = 6.6 Hz, 3H), 0.94<br>
(t, J =7.0 Hz, 3H), 1.20-1.48 (m, 12H), 1.55 (s, 9H), 1.52-1.75 (m, 4H), 2.65 (t, J =<br>
7.0 Hz, 2H), 4.20 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s 1H).<br>
2-Hexyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid tert-butyl ester<br>
(20.11): 760 mg (98%). 1H NMR (CDCI3, 200 MHz): 80.87 (t, J = 6.6 Hz, 3H), 0.89<br>
(t, J = 6.6 Hz, 3H), 1.18-1.44 (m, 14H), 1.55 (s, 9H), 1.54-1.76 (m, 4H), 2.65 (t, J =<br>
7.0 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s, 1H).<br>
2-Dodecy!oxycarbonylamino-5-octyl-thiophene-3-carboxylic acid tert-butyl<br>
ester (20.12): 831 mg (88%). 1H NMR (CDCI3) 200 MHz): 8 0.87 (t, J = 6.6 Hz, 6H),<br>
1.051-.50 (m, 28H), 1.55 (s, 9H), 1.50-1.75 (m, 4H), 2.65 (t, J = 7.2 Hz, 2H), 4.19 (t,<br>
J = 6.6 Hz, 2H), 6.73 (t, J = 1.2 Hz, 1H), 10.14 (s, 1H).<br>
5-Decyl-2-phenyloxycarbonylamino-thiophene-3-carboxylic acid tert-butyl<br>
ester (20.13): 696 mg (84%). 1H NMR (CDCI3, 200 MHz): 80.88 (t, J = 7.0 Hz, 3H),<br>
1.20-1.36 (m, 14H), 1.52-1.66 (m, 2H), 1.59 (s, 9H), 2.67 (dt, J = 7.4, 1.2 Hz, 2H),<br>
6.78 (t, J = 1.2 Hz, 1H), 7.14-7.48 (m, 5H), 10.55 (s, 1H).<br>
2-Decyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid ferf-butyl ester<br>
(20.14): 863 mg (91%). 1H NMR (CDCI3) 200 MHz): 5 0.87 (t, J = 6.6 Hz, 6H), 1.14-<br>
1.44 (m, 24H), 1.55 (s, 9H), 1.52-1.76 (m, 4H), 2.65 (t, J = 7.2 Hz, 2H), 4.19 (t, J =<br>
6.6 Hz, 2H), 6.73 (s, 1H), 10.14 (s, 1H).<br>
CT O<br>
6-Benzyl-2-octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester<br>
(20.15)<br>
Light yellow oil in 77% yield.<br>
'H NMR (CDCI3&gt; 200MHz): 5 10.16 (s, 1H), 7.20-7.40 (m, 5H), 6.82 (s, 1H), 4.17 (t,<br>
2H, J= 6.6Hz), 3.99 (s, 2H), 1.64(q, 2H, J= 6.6Hz), 1.55(s, 9H), 1.10-1.50 (m, 10H),<br>
0.88(t,3H, J=6.6Hz).<br>
6-Hexyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester<br>
(20.16)<br>
Light yellow oil in 86% yield.<br>
1H NMR (CDCI3, 200MHz): 8 10.14 (brs, 1H), 6.74 (s, 1H), 4.19 (t, 2H, J = 6.6Hz),<br>
2.66 (t, 2H, J = 7.6Hz), 1.60-1.75(m, 2H), 1.56 (s, 9H), 1.10-1.40 (m, 18H), 0.80-<br>
0.95(m, 6H).<br>
CT O<br>
6-Decyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid f-butyl ester<br>
(20.17)<br>
Light yellow oil in 99% yield.<br>
'H NMR (CDCI3, 200MHz): 8 10.14 (brs, 1H), 6.74 (s, 1H), 4.19 (t, 2H, J = 6.6Hz),<br>
2.66 (t, 2H, J = 8.0Hz), 1.60-1.75(m, 2H), 1.56 (s, 9H), 1.08-1.40 (m, 26H), 0.80-<br>
0.95(m, 6H).<br>
O O<br>
6-Decyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic acid tbutyl<br>
ester (20.18)<br>
Light yellow oil in 99% yield.<br>
'H NMR (CDCI3, 200MHz): 8 10.10 (brs, 1H), 6.73 (s, 1H), 4.82-5.00 (m, 1H), 2.65 (t,<br>
2H, J = 7.4Hz), 1.50-1.83(m, 15H), 1.08-1.50 (m, 23H), 0.80-1.00(m, 6H).<br>
6-Heptyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic acid rbutyl<br>
ester (20.19)<br>
Light yellow oil in 78% yield.<br>
133<br>
'H NMR (CDCI,, 200MHz): 6 10.01 (brs, 1H), 6.73 (s, 1H), 4.80-5.00 (m, 1H), 2.65 (t,<br>
2H, J= 7.4Hz), 1.50-1.83(m, 13H), 1.08-1.50 (m, 17H), 0.80-1.00 (m, 6H).<br>
5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid f-butyl<br>
ester (20.20)<br>
Light brownish oil in 99% yield.<br>
1H NMR (CDCI3, 400MHz): 5 10.12 (s, 1H), 7.26-7.31 (m, 2H), 7.19-7.26 (m, 3H), 6.75<br>
(s, 1H), 4.23 (t, 2H, J = 6.4Hz), 2.73 (t, 2H, J= 7.6Hz), 2.66 (t, 2H, J= 7.2Hz), 1.98-<br>
2.07(m, 2H), 1.59-1.65(m, 2H), 1.52-1.57 (m, 11H), 1.26-1.30 (m, 12H), 0.88(t, 3H, J<br>
= 6.4Hz).<br>
5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid f-butyl<br>
ester (20.21)<br>
Light brownish oil in 98% yield.<br>
'H NMR (CDCI3I 400MHz): 5 10.11 (s, 1H), 7.26-7.31 (m, 2H), 7.18-7.26 (m, 3H), 6.74<br>
(S, 1H), 4.26 (brs, 2H), 2.67-2.70 (m, 4H), 1.70-1.80(m, 4H), 1.50-1.70(m, 11H),<br>
1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.8Hz).<br>
Example 21: Acid Intermediates<br>
5-Heptyl-4-methyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.1):<br>
May contain -10% other isomer; 1H NMR (CDCI3) 6 0.82-0.94 (m, 6H), 1.20-1.46 (m,<br>
18H), 1.50-1.66 (m, 2H), 1.66-1.80 (m, 2H), 2.28 (s, 3H), 2.64 (t, 2H, J = 7.2 Hz),<br>
4.22 (t, 2H, J = 7.0 Hz). There was another peak at 2.79 (t, J = 7.0 Hz), which may<br>
be from other isomer; MS (El): cal'd 411.61, exp, did not ionize.<br>
5-Methyl-2-octyloxycarbonylamino-th!ophene-3-carboxylic acid (21.2): 1H NMR<br>
(CDCI3) 80.88 (t, 3H, J = 7.2 Hz), 1:20-1.45 (m, 10H), 1.65-1.75 (m, 2H), 2.37 (s,<br>
3H), 4.23 (t, 2H, J = 6.8 Hz), 6.84 (s, 1H), 9.89 (s, 1H); MS (El): cal'd 313.41, exp.<br>
5-Heptyl-2-(3-octyl-ureldo)-thiophene-3-carboxylic acid (21.3) tan solid (51 mg,<br>
80% yield): 'H NMR (CDCI3, 200MHz) 8 0.87 (t, 6H, J = 5.7 Hz), 1.26 (bs, 18H),<br>
1.54-1.61 (m, 4H), 2.63 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 7.0 Hz), 5.95 (bs,<br>
1H), 6.77 (s, 1H), 10.10 (s, 1H), 11.36 (bs, 1H). "C NMR (CDCIg, 50MHz) 5 14.0,<br>
22.6, 26.8, 29.0, 29.2, 29.3, 29.4, 29.7, 31.1, 31.7, 31.8, 41.0, 88.4, 108.9, 119.6,<br>
134.2,151.9, 154.1,169.9.<br>
5-Butyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (21.4) purple oil (308 mg,<br>
100% yield): 'H NMR (CDCI3&gt; 200MHz) 6 0.87 (t, 6H, J= 5.7 Hz), 1.26 (bs, 18H),<br>
1.54-1.61 (m, 4H), 2.63 (t, 2H, J = 7.5 Hz), 3.26 (dt, 2H, J = 7.0, 7.0 Hz), 5.95 (bs,<br>
1 H), 6.77 (s, 1 H), 10.10 (s, 1 H), 11.36 (bs, 1 H).<br>
5-Benzyl-2-(3-octyl-ureido)-thiophene-3-carboxylic acid (21.5) tan solid (450 mg): 'H<br>
NMR (CDCIg, 200MHz) 5 0.87 (t, 3H, J= 6.4 Hz), 1.26 (bs, 10H), 1.51 (tt, 2H, J = 12.2, 6.5<br>
Hz), 3.21 (dt, 2H, J= 6.6, 6.0 Hz), 3.96 (s, 2H), 6.33 (bs, 1H), 6.82 (s, 1H), 7.14-7.32 (m,<br>
5H), 10.16 (bs,1H).<br>
8 NH<br>
2-Dodecanoylamino-5-heptyl-thiophene-3-carboxylic acid (21.6) dark brown<br>
solid (185 mg, 100% yield): 'H NMR (CDCI3, 200MHz) 6 0.85-0.90 (m, 6H), 1.26-<br>
1.40 (m, 24H), 1.54-1.79 (m, 4H), 2.52 (t, 2H, J = 7.5 Hz), 2.71 (t, 2H, J = 7.5 Hz),<br>
6.91 (s, 1 H), 10.53 (bs, 1 H), 10.75 (s, 1 H). MS (ES-) 421.86 (M-1).<br>
5-Heptyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.7) pale<br>
yellow solid (76 mg, 54% yield): 'H NMR'(CDCI3, 200MHz) 8 0.85-0.91 (m, 6H),<br>
1.30 (bs, 18H), 1.58-1.75 (m, 4H), 2.69 (t, 2H, J = 7.5 Hz), 4.24 (t, 2H, J = 6.6 Hz),<br>
6.86 (s, 1H), 9.90 (s, 1H). MS (ES-) 395.93 (M-1).<br>
O<br>
2-Octyloxycarbonylamino-5-(1,3,3-trimethyl-butyl)-thiophene-3-carboxylic acid<br>
(21.8) waxy tan solid (190 mg, 100% yield): 'H NMR (CDCI3, 200MHz) 6 0.88-0.89<br>
(m, 12H), 1.28-1.76 (m, 17H), 2.90-3.09 (m, 1H), 4.24 (t, 2H, J= 6.6 Hz), 6.87 (s,<br>
1H), 9.85 (S, 1H), 10.34 (bs, 1H).<br>
2-(2-BenzyIoxy-ethoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid<br>
(21.9) tan solid (142 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.5 Hz), 1.23-<br>
1.27 (m, 14H), 1.58-1.69 (m, 2H), 2.69 (t, 2H, J = 7.3 Hz), 3.76 (t, 2H, J = 4.6 Hz),<br>
4.43 (t, 2H, J = 4.6 Hz), 4.61 (s, 2H), 6.88 (s, 1H), 7.28-7.38 (m, 5H), 9.99 (s, 1H),<br>
10.48. (bs, 1 H). MS (ES-) 460.06 (M-1).<br>
2-Octyloxycarbonylamino-5-phenethyl-thiophene-3-carboxylic acid (21.10)<br>
white solid (203 mg, 97% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J= 6.8Hz),<br>
1.28 (brs, 10H), 2.98 (s, 4H), 4.23 (t, 2H, J= 7.0Hz), 6.84 (s, 1H), 7.22 (m, 5H), 9.96<br>
13?<br>
0<br>
2-Octyloxycarbonylamino-5-(3-phenyl-propyl)-thiophene-3-carboxylic acid<br>
(21.11) yellow solid (175 mg, 99% yield): 'H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J<br>
= 6.8Hz), 1.28 (brs, 10H), 1.68 (m, 2H), 1.98 (tt, 2H, J= 7.8Hz, 7.2Hz), 4.23 (t, 2H, J<br>
= 7.0HZ), 6.87 (s, 1H), 7.26 (m, 5H), 9.93 (1H)<br>
o<br>
2-Octyloxycarbonylamino-5-(4-phenyl-butyl)-thiophene-3-carboxylic acid<br>
(21.12) white waxy solid (303 mg, 92% yield): 1H NMR (CD3OD, 400MHz) § 0.90 (bt,<br>
3H, J= 6.8 Hz), 1.21-1.48 (m, 12H), 1.57-1.76 (m, 6H), 2.57-2.77 (m, 4H), 4.20 (t,<br>
2H, J = 6.4 Hz), 6.82 (s, 1H), 7.08-7.32 (m, 5H). MS (ES) 430.35 (M-1), tfi(method<br>
D) = 7.74min<br>
2-Octyloxycarbonylamino-5-(5-phenyl-pentyl)-thiophene-3-carboxylic acid<br>
(21.13) off-white solid (331 mg, 90% yield): 1H NMR (CD3OD, 400MHz) 6 0.90 (bt,<br>
3H, J = 6.4 Hz), 1.23-1.45 (m, 14H), 1.58-1.75 (m, 6H), 2.59 (t, 2H, J = 7.6 Hz),<br>
2.68 (t, 2H, J = 7.2 Hz), 4.20 (t, 2H, 6.8 Hz), 6.81 (bs, 1H), 7.07-7.18 (m, 3H), 7.19-<br>
7.27 (m, 2H). MS (ES) 443.58 (M-1), tn(method D) = 8.58min<br>
5-Decyl-2-(2-methoxy-ethoxycarbonylamino)-thiophene-3-carboxylic acid<br>
(21.14) off-white solid (256 mg, 95% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (bt,<br>
3H, J = 6.2 Hz), 1.11-1.44 (m, 14H), 1.47-1.73 (m, 2H), 2.69 (t, 2H, J = 7.8 Hz),<br>
3.43 (s, 3H), 3.62-3.75 (m, 2H), 4.31-4.47 (m, 2H), 6.86 (s, 1H), 10.00 (s, 1H). MS<br>
(ES) 384.52 (M-1), t^method D) = 6.28min.<br>
2-(4-Butyl-phenoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid (21.15)<br>
tan solid (214 mg, 97% yield) 'H NMR (CD3OD, 400 MHz) 8 0.891 (bt, 3H, J = 6.8<br>
Hz), 0.949 (t, 3H, J= 7.2 Hz), 1.21-1.43 (m, 16H), 1.54-1.71 (m, 4H), 2.63 (t, 2H, J<br>
= 7.6 Hz), 2.70 (t, 2H, J= 7.2 Hz), 6.87 (s, 1H), 7.12 (d, 2H, J= 8.4 Hz), 7.23 (d, 2H,<br>
J= 8.8 Hz); MS (ES) no ionization (M-1), tR(method D) = no peak<br>
2-(3-phenoxy-propoxycarbonylamlno)-5-decyl-thiophene-3-carboxylic acid<br>
(21.16) off-white solid (137 mg, 80% yield): 1H NMR (CDCI3l 200MHz) 8 0.88 (t, 3H,<br>
J= 6.4 Hz), 1.26-1.38 (m, 14H), 1.64 (tt, 2H, J= 12.4, 7.0 Hz), 2.02 (tt, 2H, J= 12.4,<br>
6.2 Hz), 2.68 (t, 2H, J = 7.3 Hz), 3.60 (t, 2H, J = 6.2 Hz), 4.37 (t, 2H, J = 6.2 Hz),<br>
4.53 (s, 2H), 6.87 (s, 1H), 7.25-7.34 (m, 5H), 9.88 (s, 1H), 10.85 (bs, 1H).<br>
2-(4-Benzyloxy-butoxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid<br>
(21.17) off-white solid (55 mg, 55% yield): 1H NMR (CDCI3, 200MHz) 8 0.88 (t, 3H, J<br>
= 6.3 Hz), 1.26-1.38 (m, 14H), 1.61-1.82 (m, 6H), 2.68 (t, 2H, J= 7.4 Hz), 3.53 (t,<br>
2H, J = 5.8 Hz), 4.27 (t, 2H, J = 5.8 Hz), 4.50 (s, 2H), 6.86 (s, 1H), 7.25-7.33 (m,<br>
5H), 9.92(s, 1H).<br>
5-Pentyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.18): 1H<br>
NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.14-1.50 (m, 12H), 1.52-1.82 (m,<br>
4H), 2.69 (t, J = 7.5 Hz, 2H), 4.23 (t, J = 6.8 Hz, 2H), 6.59 (s, 1H), 9.88(brs, 1H).<br>
5-lsopropyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.19): 1H<br>
NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.50 (m, 16H), 1.60-1.82<br>
(m, 2H), 2.90-3.18 (m, 1H), 4.24 (t, J = 6.8 Hz, 2H), 6.87 (d, J = 1.2 Hz, 1H), 9.81<br>
(brs, 1H), 9.86 (brs, 1H).<br>
O<br>
5-Octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.20): 1H NMR<br>
(CDCI3, 200 MHz): 6 = 0.78-1.00 (m, 6H), 1.12-1.49 (m, 20H), 1.54-1.82 (m, 4H),<br>
2.68 (t, J = 7.3 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.86 (s, 1H), 9.89 (brs, 1H).<br>
5-Dodecyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.21): 1H<br>
NMR (CDCI3, 200 MHz): 8 = 0.78-0.96 (m, 6H), 1.12-1.46 (m, 28H), 1.52-1.78 (m,<br>
4H), 2.68 (t, J = 7.3 Hz, 2H), 4.23 (t, J = 6.8 Hz, 2H), 6.85 (s, 1H), 9.90 (brs, 1H).<br>
2-Benzyloxycarbonylamino-5-decyl-thlophene-3-carboxylic acid (21.22): 1H<br>
NMR (CDCI3, 200 MHz): 6 = 0.88 (t, J = 6.4 Hz, 3H), 1.14-1.44 (m, 14H), 1.50-1.74<br>
(m, 2H), 2.68 (t, J = 7.1 Hz, 2H), 5.26 (s, 2H), 6.85 (s, 1H), 7.33-7.49 (m, 5H), 9.95<br>
(brs, 1H).<br>
2-(4-Butylbenzyloxycarbonylamino)-5-decyl-thiophene-3-carboxylic acid<br>
(21.23): 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.10-1.46 (m, 16H),<br>
1.48-1.76 (m, 4H), 2.52-2.80 (m, 4H), 5.23 (s, 2H), 6.84 (s, 1H), 7.13-7.40 (m, 4H),<br>
9.93 (brs, 1H).<br>
cr o'<br>
5-Decyl-2-(2-p-tolyl-ethoxycarbonylamino)-thiophene-3-carboxylic acid (21.24):<br>
1H NMR (CDCIa, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.46 (m, 14H), 1.52-<br>
1.78 (m, 2H), 2.33 (s, 3H), 2.69 (t, J = 7.5 Hz, 2H), 3.00 (t, J = 7.3 Hz, 2H), 4.43 (t, J<br>
= 7.3 Hz, 2H), 6.87 (s, 1H), 7.08-7.22 (m, 4H), 9.91 (brs, 1H).<br>
H<br>
( T O<br>
5-Decyl-2-phenethyloxycarbonylamino-thiophene-3-carboxylic acid (21.25): 1H<br>
NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.16-1.46 (m, 14H), 1.52-1.76<br>
(m, 2H), 2.69 (t, J = 7.3 Hz, 2H), 3.05 (t, J = 7.3 Hz, 2H), 4.46 (t, J = 7.5 Hz, 2H),<br>
6.87 (s, 1H), 7.18-7.42 (m, 5H), 9.92 (brs, 1H).<br>
4-Methyl-5-octyl-2-octyloxycarbonylamino-thiophene-3-carboxylic acid (21.26):<br>
520 mg (69%). 1H NMR (CDCI3, 200 MHz): S 0.87 (t, J = 6.6 Hz, 6H), 1.16-1.62 (m,<br>
24), 2.28 (s, 3H), 2.64 (t, J = 7.2 Hz, 2H), 4.18 (t, J = 6.6 Hz, 2H), 10.26 (s, 1H).<br>
o<br>
2-Butyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid (21.27): 366 mg<br>
(67%). 1H NMR (CDCIs, 200 MHz): 6 0.87 (t, J = 6.6 Hz, 3H), 0.96 (t, J = 7.4 Hz,<br>
3H), 1.14-1.82 (m, 16H), 2.67 (t, J = 7.4 Hz, 2H), 4.24 (t, J = 6.6 Hz, 2H), 6.85 (s,<br>
1H), 9.89(8, 1H).<br>
2-Hexyloxycarbonylamino-5-octyl-thiophene-3-carboxyiic acid (21.28): 395 mg<br>
(60%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 7.0 Hz, 3H), 0.90 (t, J = 6.4 Hz,<br>
3H), 1.12-1.52 (m, 16H), 1.50-1.82 (m, 4H), 2.68 (t, J = 7.2 Hz, 2H), 4.23 (t, J = 7.0<br>
Hz, 2H), 6.68 (s, 1H), 9.88 (s, 1H).<br>
2-Dodecyloxycarbonylamlno-5-octyl-thiophene-3-carboxylic acid (21.29): 541<br>
mg (80%). 1H NMR (CDCIg, 200 MHz): 5 0.87 (t, J = 6.4 Hz, 6H), 1.12-1.50 (m,<br>
28H), 1.50-1.80 (m, 4H), 2.68 (t, J = 7.4 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.85 (s,<br>
1H), 9.89 (s, 1H).<br>
cr o<br>
5-Decyl-2-phenyloxycarbonylamino-thiophene-3-carboxylic acid (21.30): 469<br>
mg (80%). 1H NMR (CDCI3) 200 MHz): 50.87 (t, J = 6.6 Hz, 3H), 1.18-1.44 (m,<br>
14H), 1.54-1.76 (m, 2H), 2.70 (t, J = 7.2 Hz, 2H), 6.91 (s, 2H), 7.17-7.48 (m, 5H),<br>
10.27 (s,1H).<br>
Cr 0<br>
2-Decyloxycarbonylamino-5-octyl-thiophene-3-carboxylic acid (21.31): 603 mg<br>
(86%). 1H NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.2 Hz, 6H), 1.32-1.50 (m, 24H),<br>
1.52-1.82 (m, 4H), 2.67 (t, J = 7.4 Hz, 2H), 4.23 (t, J = 6.6 Hz, 2H), 6.85 (s, 1H),<br>
9.89 (S.1H).<br>
6-Benzyl-2-octyloxycarbonylamino)thiophene-3-carboxylic acid (21.32)<br>
Light yellow solid in 100% yield.<br>
'H NMR (CDCI3, 200MHz): 5 9.86 (s, 1H), 7.22-7.34 (m, 5H), 7.00(brs, 1H), 6.87 (t,<br>
1H, J= 1.0HZ), 4.21 (t, 2H, J= 6.6Hz), 4.01 (s, 2H), 1.67(q, 2H, J = 7.0Hz), 1.15-<br>
1.45 (m, 10H), 0.88(t, 3H, J = 7.0Hz).<br>
6-Hexyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid (21.33)<br>
Light yellow oil in 74% yield.<br>
'H NMR (CDCI3, 200MHz): 5 10.87 (brs, 1H), 9.83 (s, 1H), 6.86 (s, 1H), 4.24 (t, 2H, J<br>
= 6.6Hz), 2.68 (t, 2H, J = 7.2Hz), 1.60-1.80(m, 4H), 1.10-1.45 (m, 20H), 0.80-0.95(m,<br>
6H).<br>
6-Decyl-2-(octyloxycarbonylamino)thiophene-3-carboxylic acid (21.34)<br>
Light yellow solid in 100% yield.<br>
'H NMR (CDCI3, 200MHz): 5 9.89 (brs, 1H), 8.00 (brs, 1H), 6.85 (s, 1H), 4.23 (t, 2H, J<br>
= 6.6Hz), 2.68 (t, 2H, J = 7.0Hz), 1.60-1.80(m, 4H), 1.08-1.40 (m, 24H), 0.80-0.95(m,<br>
6H).<br>
6-Decyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic<br>
(21.35)<br>
Light yellow solid in 98% yield.<br>
acid<br>
'H NMR (CDCI,, 200MHz): 6 9.80 (brs, 1H), 8.24(brs, 1H), 6.73 (s, 1H), 4.82-5.00 (m,<br>
1H), 2.65 (t, 2H, J = 7.4Hz), 1.50-1.83(m, 15H), 1.08-1.50 (m, 23H), 0.80-1.00(m,<br>
6H).<br>
( T O<br>
acid 6-Heptyl-2-(1-methylheptyloxycarbonylamino)thiophene-3-carboxylic<br>
(21.36)<br>
Light yellow oil in 100% yield.<br>
'H NMR (CDCI3&gt; 200MHz): 5 9.80 (brs, 1H), 8.24(brs, 1H), 6.85 (s, 1H), 4.90-5.00 (m,<br>
1H), 2.68 (t, 2H, J = 7.6Hz), 1.50-1.83(m, 4H), 1.08-1.50 (m, 20H), 0.80-1.00 (m,<br>
6H).<br>
O O<br>
5-Decyl-2-(4-phenylpropoxycarbonylamino)thiophene-3-carboxylic acid (21.37)<br>
Light brownish solid in 100% yield.<br>
'H NMR (CDCI,, 400MHz): 5 10.4 (brs, 1H), 9.88 (s, 1H), 7.26-7.31 (m, 2H), 7.18-7.21<br>
(m, 3H), 6.87 (s, 1H), 4.27 (t, 2H, J= 6.4Hz), 2.74 (t, 2H, J = S.OHz), 2.68 (t, 2H, J =<br>
7.6Hz), 2.02-2.07(m, 2H), 1.59-1.66(m, 2H), 1.18-1.40 (m, 14H), 0.88 (t, 3H, J =<br>
6.0Hz).<br>
5-Decyl-2-(4-phenylbutoxycarbonylamino)thiophene-3-carboxylic acid (21.38)<br>
Light brownish solid in 100% yield.<br>
!H NMR (CDCI3, 400MHz): 8 12.0 (brs, 1H), 9.90 (s, 1H), 7.26-7.31 (m, 2H), 7.17-7.21<br>
(m, 3H), 6.87 (s, 1H), 4.26 (t, 2H, J= 6.4Hz), 2.67-2.70 (m, 4H), 1.70-1.80(m, 4H),<br>
1.50-1.70(m, 2H), 1.18-1.40 (m, 16H), 0.88(t, 3H, J = 6.8Hz).<br>
Example 22: Thienoxazinones<br>
6-Heptyl-5-methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (74) (May contain<br>
-10% other isomer); Mp 29-31 SC; 1H NMR (CDCI3) 6 0.82-0.96 (m, 6H), 1.20-1.50<br>
(m, 18H), 1.50-1.68 (m, 2H), 1.68-1.86 (m, 2H), 2.36 (s, 3H), 2.70 (t, 2H, J = 6.8 Hz),<br>
4.38 (t, 2H, J = 6.6 Hz) Another peak at 2.83 (t, J = 6.7 Hz), which may be from other<br>
isomer; MS (El): cal'd 393.59, exp, did not ionize.<br>
6-Methyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (22.1): 1H NMR (CDCI3)<br>
80.88 (t, 3H, J = 7.2 Hz), 1.20-1.45 (m, 10H), 1.55 (s, 9H), 1.70-1.84 (m, 2H), 2.46<br>
(s, 3H), 4.39 (t, 2H, J = 6.6 Hz), 6.93 (s, 1H); MS (El): cal'd 295.5, exp.<br>
6-Heptyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (61): off-white solid (38 mg,<br>
801% yield): 'H NMR (CDCI3, 200MHz) 5 0.87 (t, 6H, J = 6.4 Hz), 1.27-1.30 (m,<br>
18H), 1.58-1.67 (m, 4H), 2.71 (t, 2H, J= 7.3 Hz), 3.38 (dt, 2H, J= 7.0, 6.2 Hz), 5.45<br>
(68,11-0,6.84(8,1^.<br>
6-Butyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (63): off-white solid (162 mg,<br>
55% yield): mp 93.0-94.0 eC. 'H NMR (CDCI3, 200MHz) 5 0.88 (t, 3H, J= 6.4 Hz),<br>
0.93 (t, 3H, J = 7.3 Hz), 1.27-1.48 (m, 12H), 1.56-1.71 (m, 4H), 2.72 (t, 2H, J = 7.5<br>
Hz), 3.39 (dt, 2H, J = 7.0, 6.2 Hz), 5.73 (bs, 1H), 6.§5 (t, 1H, J= 1.1 Hz). MS (ES+)<br>
337.23 (M+1).<br>
6-Benzyl-2-octylamino-thieno[2,3-d][1,3]oxazin-4-one (62): off-white solid (182<br>
mg, 55% 2-step yield): mp 123.0-124.0 BC. 'H NMR (CDCI3, 200MHz) 6 0.87 (t, 3H,<br>
J= 6.4 Hz), 1.26-1.28 (m, 10H), 1.51 (tt, 2H, J= 13.6, 6.5 Hz), 3.36 (dt, 2H, J = 7.0,<br>
6.6 Hz), 4.02 (s, 2H), 5.81 (bs, 1H), 6.85 (s, 1H), 7.20-7.35 (m, 5H). MS (ES+)<br>
371.18 (M+1).<br>
6-Heptyl-2-undecyl-thieno[2,3-d][1,3]oxazin-4-one (67): yellow oil (97 mg, 55%<br>
yield): 'H NMR (CDCI3, 200MHz) 5 0.85-0.91 (m, 6H), 1.26-1.32 (m, 24H), 1.66-<br>
1.83 (m, 4H), 2.69 (t, 2H, J= 7.7 Hz), 2.82 (t, 2H, J= 7.5 Hz), 7.06 (s, 1H). 13C NMR<br>
(CDCI3, 50MHz) 8 14.0, 14.1, 22.5, 22.6, 26.2, 28.8, 28.9, 29.0, 29.2, 29.3, 29.4,<br>
29.5, 30.4, 31.0, 31.7, 31.9, 34.7, 117.8, 118.6, 144.3, 155.6, 162.2, 165.2.<br>
6-Heptyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (68): yellow oil (36 mg, 50%<br>
yield): 1H NMR (CDCI3, 200MHz) 8 0.85-0.93 (m, 6H), 1.29-1.48 (m, 18H), 1.61-<br>
1.87 (m, 4H), 2.77 (t, 2H, J = 7.5 Hz), 4.41 (t, 2H, J = 6.6 Hz), 6.97 (t, 1H, J = 1.1<br>
Hz).<br>
2-Octyloxy-6-(1,3,3-trimethyl-butyl)-thIeno[2,3-d][1,3]oxazin-4-one (78): colorless<br>
oil (92 mg, 51% yield): 'H NMR (CDCI3, 200MHz) 8 0.88-0.89 (m, 12H), 1.30-1.83<br>
(m, 17H), 3.04-3.13 (m, 1H), 4.41 (t, 2H, J = 6.6 Hz), 6.98 (s, 1H). "C NMR (CDCI3,<br>
50MHz) 8 14.0, 22.6, 25.6, 26.2, 28.3, 29.1, 29.8, 31.3, 31.7, 32.8, 52.6, 70.5, 113.2,<br>
116.5, 149.4,154.5,156.9,165.3. MS (ES+) 380.01 (M+1).<br>
(83): pale yellow oil (3 mg): 'H NMR (CDCI3, 200MHz) 8 0.89 (t, 3H, J = 6.6 Hz),<br>
1.11 (s, 6H), 1.26-1.67 (m, 19H), 1.77 (dt, 2H, J= 7.0, 6.6 Hz), 2.96 (dq, 1H, J = 7.2,<br>
7.0 Hz), 3.15 (S, 3H), 4.40 (t, 2H, J^ 6.6 Hz), 6.98 (s, 1H). MS (ES+) 424.03 (M+1).<br>
6-(1,5-Dimethyl-hex-4-enyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one and 6-<br>
(1,5-Dimethyl-hex-5-enyl)-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (2:1 mixture<br>
of isomers) (81): colorless oil (16 mg): MS (ES+) 391.95, 391.97 (M+1).<br>
O<br>
Trifluoro-acetic acid 1,1-dimethyl-5-(2-octyloxy-4-oxo-4H-thieno[2,3-<br>
d][1,3]oxazin-6-yl)-hexyl ester (82): colorless oil (61 mg): 'H NMR (CDCI3,<br>
200MHz) 8 0.89 (t, 3H, J= 6.6 Hz), 1.26-1.69 (m, 8H), 1.76-1.88 (m, 4H), 2.97 (dq,<br>
1H, J = 7.0, 6.8 Hz), 4.41 (t, 2H, J = 6.6 Hz), 6.98 (s, 1H). "C NMR (CDCI3,<br>
100MHz) 8 14.2, 21.5, 22.7, 22.8, 25.7, 25.8, 28.5, 29.3, 31.9, 35.8, 38.7, 40.3, 70.8,<br>
89.1, 113.6, 114.6 (q, CF3, J = 285.9 Hz), 117.3, 117.4, 146.8, 154.7, 156.4 (q,<br>
COCF3, J= 40.9 Hz), 157.3, 165.8. MS (ES+) 505.93 (M+1).<br>
2-(2-Benzyloxy-ethoxy)-6-decy1-thieno[2,3-d][1,3]oxazin-4-one (97): yellow oil<br>
(68 mg, 50% yield): 'H NMR (CDCI3, 400MHz) 8 0.88 (t, 3H, J= 6.8 Hz), 1.26-1.32<br>
(m, 14H), 1.66 (tt, 2H, J = 14, 7.6 Hz), 2.76 (t, 2H, J = 7.6 Hz), 3.81 (t, 2H, J = 4.4<br>
Hz), 4.57 (t, 2H, J = 4.6 Hz), 4.60 (s, 2H), 6.95 (s, 1H), 7.25-7.34 (m, 5H). 13C NMR<br>
(CDCI3l 100MHz) 5 14.0, 22.6, 28.8, 29.2, 29.3, 29.4, 29.5, 30.2, 30.9, 31.8, 67.1,<br>
69.3, 73.3, 113.7, 118.2, 127.6, 127.7, 128.4, 137.6, 141.3, 154.2, 156.7, 165.2.<br>
490<br>
2-Octyloxy-6-phenethyl-thieno[2,3-d][1,3]oxazin-4-one (103): clear oil (84 mg,<br>
88% yield) 'H NMR (CDCI3l 200MHz) 8 0.89 (t, 3h, J = 6.8Hz), 1.28-1.43 (m, 10H),<br>
1.79 (tt, 2H, J = 7.6Hz, J = 7.2Hz), 2.98 (t, 2H, J = 7.2Hz), 3.10 (t, 2H, J = 7.6Hz),<br>
4.39 (t, 2H, J = 6.8Hz), 6.95 (s, 1H), 7.17-7.31 (m, 5H).<br>
2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][1,3]oxazin-4-one (104): white solid<br>
(72 mg, 75% yield) 'H NMR (CDCI3, 200MHz) 80.88 (t, 3H, J = 6.6Hz), 1.21-1.50 (m,<br>
10H), 1.79 (tt, 2H, J = 7.0Hz, J = 6.6Hz), 2.01 (tt, 2H, J = 7.8Hz, J = 7.2Hz), 2.69 (t,<br>
2H, J = 7.6Hz), 2.80 (t, 2H, J = 7.2Hz), 4.40 (t, 2H, J = 6.6Hz), 6.98 (s, 1H), 7.16-<br>
7.35 (m, 5H).<br>
2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][1,3]oxazin-4-one (92): pale yellow oil<br>
(218 mg, 78% yield) 'H NMR (CDCI3, 200MHz) 8 0.887 (bt, 3H, 6.2 Hz), 1.08-1.52<br>
(m, 10H), 1.60-1.90 (m, 6H), 2.54-2.72 (m, 2H), 2.72-2.88 (m, 2H), 4.40 (t, 2H, J =<br>
6.6 Hz), 6.95 (s, 1H), 7.09-7.38 (m, 5H); MS (ES) 414.59 (M+1), tn(method D) =<br>
9.71 min.<br>
131<br>
2-Octyloxy-6-(5-phenyl-pentyl)-thieno[2,3-d][1,3]oxazin-4-one (93): Pale yellow<br>
oil (223 mg, 94% yield) 1H NMR (CDCI3, 200MHz) 8 0.887 (bt, 3H, J = 6.2 Hz),<br>
1.20-1.50 (m, 12H), 1.57-1.88 (m, 6H), 2.61 (t, 2H, J = 7,4 Hz), 2.76 (t, 2H, J = 6.8<br>
Hz), 4.40 ( t, 2H, J = 6.6 Hz), 6.95 (t, 1H, J = 1 Hz), 7.08-7.35 (m, 5H); MS (ES)<br>
428.62 (M+1), tfl(method D) = 10.69min.<br>
6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][1,3]oxazin-4-one (96): off-white<br>
waxy solid (195 mg, 83% yield); m.p. = 38-41 SC; 1H NMR (CDCI3, 200MHz) 8 0.879<br>
(bt, 3H, J = 6.2 Hz), 1.06-1.43 (m, 14H), 1.52-1.78 (m, 2H), 2.76 (t, 3H, J= 7.0 Hz),<br>
3.43 (s, 3H), 3.62-3.82 (m, 2H), 4.44-4.64 (m, 2H), 6.96 (s, 1H); MS (ES) 368.52<br>
(M+1), tfl(method D) = S.OOmin.<br>
2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one (102): light yellow<br>
solid (145 mg, 79% yield); m.p. = 55-58 SC; 1H NMR (CDCI,, 400 MHz) 8 0.878 (t,<br>
3H, J= 6.0 Hz), 0.946 (t, 3H, J = 7.6 Hz), 1.18-1.45 (m, 18H), 1.55-1.71 (m, 4H),<br>
2.64 (t, 2H, J = 7.6 Hz), 2.76 (t, 2H, J = 7.6 Hz), 6.99 (s, 1H), 7.15 (d, 2H, J = 8.4<br>
Hz), 7.24 (d, 2H, J= 8.4 Hz); MS (ES) 442.64 (M+1), t, (method D) = 12.19min.<br>
o<br>
2-(3-Benzyloxy-propoxy)-6-decyI-thieno[2,3-d][1,3]oxazin-4-one (109): colorless<br>
oil (115 mg, 87% yield): 'H NMR (CDCI3, 200 MHz) 8 0.88 (t, 3H, J= 6.6 Hz), 1.26-<br>
1.38 (m, 14H), 1.67 (tt, 2H, J= 14.4, 7.4 Hz), 2.09 (tt, 2H, J= 12.4, 6.2 Hz), 2.76 (t,<br>
2H, J= 7.4 Hz), 3.62 (t, 2H, J = 6.2 Hz), 4.51 (s, 2H), 4.53 (t, 2H, J= 6.4 Hz), 6.96 (t,<br>
1H, J = 1.1 Hz), 7.24-7.33 (m, 5H). "C NMR (CDCI3, 100MHz) 5 14.04, 22.61,<br>
28.78, 28.83, 29.22, 29.23, 29.44, 29.50, 30.25, 30.90, 31.82, 65.93, 67.46, 73.06,<br>
113.59,118.14,127.60,128.31, 133.09,141.18,154.30, 156.73, 165.54.<br>
2-(3-Benzyloxy-butyloxy)-6-decyl-thieno[2,3-d][1,3]oxazin-4-one (111): colorless<br>
oil (19 mg, 36% yield): 'H NMR (CDCI3, 200 MHz) 8 0.88 (t, 3H, J = 6.4 Hz), 1.26-<br>
1.38 (m, 14H), 1.63-1.99 (m, 14H), 2.76 (t, 2H, J= 7.7 Hz), 3.54 (t, 2H, J= 6.2 Hz),<br>
4.44 (t, 2H, J= 6.2 Hz), 4.51 (s, 2H), 3.96 (t, 1H, J= 1.0 Hz), 7.28-7.35 (m, 5H).<br>
N o<br>
6-Butyl-2-octyloxy-thleno[2,3-d][1,3]oxazln-4-one (75): MS (ES/SIR): m/z 338.49<br>
[MH4]. 1H NMR (CDCI3, 200 MHz): 8 = 0.78-1.03 (m, 6H), 1.15-1.53 (m, 12H),<br>
1.54-1.90 (m, 4H), 2.77 (t, J = 7.5 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.96 (t, J = 0.8<br>
Hz, 1H).<br>
6-lsopropy!-2-octy!oxy-thieno[2,3-d][1,3]oxazin-4-one (76): MS (ES/SIR): m/z<br>
324.46 [MH4]. 1H NMR (CDCI3, 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.18-1.52 (m,<br>
16H), 1.70-1.88 (m, 2H), 2.98-3.22 (m, 1H), 4.40 (t, J = 6.6 Hz, 2H), 6.98 (d, J = 1.0<br>
Hz, 1H).<br>
6-Octyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (85): 1H NMR (CDCI3, 200<br>
MHz): 6 = 0.80-1.00 (m, 6H), 1.12-1.52 (m, 20H), 1.57-1.90 (m, 4H), 2.76 (td, J<br>
1.0, 7.6 Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.95 (t, J = 1.1 Hz, 1H).<br>
N O<br>
6-Dodecyl-2-octyloxy-thieno[2,3-d][1,3]oxazin-4-one (88): 1H NMR (CDCI3&gt; 200<br>
MHz): 5 = 0.80-0.98 (m, 6H), 1.16-1.52 (m, 28H), 1.58-1.88 (m, 4H), 2.76 (t, J = 7.2<br>
Hz, 2H), 4.40 (t, J = 6.6 Hz, 2H), 6.95 (s, 1H).<br>
2-Benzyloxy-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one (105): MS (ES/SIR): m/z<br>
400.56 [MH+].1H NMR (CDCI3, 400 MHz): 8 = 0.88 (t, J = 6.8 Hz, 3H), 1.17-1.42 (m,<br>
14H), 1.67 (quint., J = 7.4 Hz, 2H), 2.77 (t, J = 7.1 Hz, 2H), 5.44 (s, 2H), 6.96 (s, 1H),<br>
7.33-7.49 (m, 5H).<br>
15 *2-(4-Butylbenzyloxy)-6-Decyl-thieno[2,3-d][1,3]oxazin-4-one (106): 1H NMR<br>
(CDCI3, 200 MHz): 8 = 0.78-1.02 (m, 6H), 1.12-1.47 (m, 16H), 1.50-1.77 (m, 4H),<br>
2.62 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.6 Hz, 2H), 5.40 (s, 2H), 6.96 (s, 1H), 7.20 (d, J<br>
= 8.0 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H).<br>
6-Decyl-2-(2-p-tolyl-ethoxyHhieno[2,3-d][1,3]oxazin-4-one (107): 1H NMR<br>
(CDCI3) 200 MHz): 8 = 0.88 (t, J = 6.6 Hz, 3H), 1.14-1.46 (m, 14H), 1.56-1.78 (m,<br>
2H), 2.32 (s, 3H), 2.76 (t, J = 7.4 Hz, 2H), 3.06 (t, J = 7.0 Hz, 2H), 4.58 (t, J = 7.0 Hz,<br>
2H), 6.95 (t, J = 1.1 Hz, 1H), 7.07-7.22 (m, 4H).<br>
6-Decyl-2-phenethyloxy-thieno[2,3-d][1,3]oxazin-4-one (108): 1H NMR (CDCI3,<br>
200 MHz): 8 = 0.88 (t, J = 6.4 Hz, 3H), 1.14-1.46 (m, 14H), 1.56-1.76 (m, 2H), 2.76<br>
(t, J = 7.2 Hz, 2H), 3.11 (t, J = 7.0 Hz, 2H), 4.60 (t, J = 7.0 Hz, 2H), 6.95 (s, 1H),<br>
7.18-7.42 (m,5H).<br>
455<br>
3-Methyl-6-octyl-2-octyloxy-5H-thieno[2,3-b]pyridin-4-one (87): 51 mg (60%).<br>
m.p. 369C. 1H NMR (CDCI3, 200 MHz): 8 0.88 (t, J = 6.6 Hz, 6HO, 1.10-1.94 (m,<br>
24H), 2.35 (s, 3H), 2.69 (t, J = 7.2 Hz, 2H), 4.38 (t, J = 7.0 Hz, 2H); 13C NMR (CDCI3,<br>
75 MHz): 5 11.1, 12.3, 20.9, 23.9, 25.7, 26.6, 27.3, 27.4, 27.5, 27.6, 29.4, 30.0, 30.1,<br>
68.6, 11.5, 126.9, 132.0, 153.1, 155.1, 162.9.<br>
2-Butoxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (95): 265 mg (93%). 1H NMR<br>
(CDCI3, 200 MHz): 8 0.86 (t, J = 6.6 Hz, 3H), 0.96 (t, J = 7.2 Hz, 3H), 1.14-1.88<br>
(m,16H), 2.74 (t, J = 7.4 Hz, 2H), 4.39 (t, J = 6.6 Hz, 2H), 6.93 (s, 1H); 13C NMR<br>
(CDCI3, 75 MHz): S 11.9, 12.3, 17.2, 20.9, 27.2, 27.4, 27.5, 28.6, 29.2, 30.1, 68.5,<br>
101.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS (SIR): 338.48 (M+1).<br>
2-Hexyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (94): 312 mg (94%). 1H NMR<br>
(CDCI3, 200 MHz): 8 0.86 (t, J = 6.6 Hz, 3H), 0.89 (t, J = 6.6 Hz, 3H), 1.15-1.54 (m,<br>
16H), 1.54-1.88 (m, 4H), 2.74 (t, J = 7.0 Hz, 2H), 4.38 (t, J = 6.6 Hz, 2H), 6.94 (t, J =<br>
1.2 Hz, 1H); 13C NMR (CDCI3, 75 MHz): 8 12.2, 12.3, 20.8, 20.9, 23.6, 26.6, 27.2,<br>
27.4, 27.5, 28.6, 29.2, 29.6, 30.1, 68.8, 101.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS<br>
(SIR): 366.55 (M+1).<br>
2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one (100): 322 mg (91%). 1H<br>
NMR (CDCI3, 200 MHz): 8 0.87 (t, J = 6.2 Hz, 6H), 1.04-1.52 (m, 28H), 1.52-1.90<br>
(m, 4H), 2.75 (t, J = 7.0 Hz, 2H), 4.38 (t, J = 6.5 Hz, 2H), 6.94 (s, 1H); 13C NMR<br>
(CDCI3) 75 MHz): 8 12.3, 12.4, 20.9, 21.0, 23.9, 26.6, 27.2, 27.4, 27.5, 27.6, 27.7,<br>
27.8, 27.9, 28.6, 29.2, 30.1, 30.2, 68.8, 11.9, 116.5, 139.4, 152.7, 155.2, 164.0; MS<br>
(SIR): 450.71 (M+1).<br>
6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridin-4-onc (101): 322 mg (86%). 1H NMR<br>
(CDCI3, 200 MHz): 8 0.87 (t, J = 6.6 Hz, 3H), 1.15-1.45 (m, 14H), 1.55-1.75 (m, 2H),<br>
2.75 (t, J = 7.0 Hz, 2H), 7.0 (t, J = 1 Hz, 1H), 7.22-7.51 (m, 5H); 13C NMR (CDCl3, 75<br>
MHz): 8 12.4, 21.0, 27.2, 27.5, 27.6, 27.6, 27.8, 28.6, 29.2, 30.2, 97.7, 97.7, 102.5,<br>
116.5, 119.4, 124.9, 128.0, 140.7, 149.5, 152.3, 154.5, 163.1; MS (SIR): 358.48<br>
(M+1).<br>
2-Decyloxy-6-octyl-5H-th!eno[2,3-b]pyridin-4-one (110): 313 mg (69%). 1H NMR<br>
(CDCIa, 200 MHz): 8 0.85 (t, J = 6.4 Hz, 6H), 1.16-1.50 (m, 24H), 1.50-1.88 (m, 4H),<br>
2.74 (t, J = 6.8 Hz, 2H), 4.38 (t, J = 6.6 Hz, 2H), 6,93 (s, 1H); 13C NMR (CDCI3, 75<br>
MHz): 8 12.3, 20.9, 20.9, 23.9, 26.6, 27.2, 27.4, 27.5, 27.6, 27.7, 27.8, 28.6, 29.2,<br>
30.1, 30.1, 68.8, 111.9,116.5, 139.3, 152.6,155.2,164.0.<br>
6-Benzyl-2-octyloxythieno[2,3-dl[1,3]oxazin-4-one (77)<br>
Light yellow oil in 53% yield.<br>
'H NMR (CDCI3, 200MHz): 5 7.20-7.40 (m, 5H), 6.98 (t, iH, J= 1.0Hz), 4.38 (t, 2H, J<br>
=. 6.6Hz), 4.09 (s, 2H), 1.76(q, 2H, J= 7.2Hz), 1.10-1.50 (m, 10H), 0.88 (t, 3H, J =<br>
7.0Hz). MS (ES) [M*+l] 372.51.<br>
6-Hexyl-2-octyloxythieno[2,3-cQ[1,3]oxazin-4-one (84)<br>
Light yellow oil in 30% yield.<br>
'H NMR (CDCI3, 200MHz): S 6.94 (s, 1H), 4.39 (t, 2H, J = 6.6Hz), 2.76 (t, 2H, J =<br>
7.2Hz), 1.76(q, 2H, J = 7.4Hz), 1.64 (q, 2H, J = 7.6Hz), 1.08-1.50 (m, 14H), 0.80-<br>
0.95 (m, 6H). MS (ES) [M++l] 366.55.<br>
O<br>
6-Decyl-2-octyloxythieno[2,3-c/][1,3]oxazin-4-one (86)<br>
Light yellow oil in 50% yield.<br>
'H NMR (CDCI3) 200MHz): 5 6.94 (s, 1H), 4.39 (t, 2H, J = 6.6Hz), 2.76 (t, 2H, J =<br>
7.2HZ), 1.76(q, 2H, J = 7.4Hz), 1.64 (q, 2H, J = 7.6Hz), 1.08-1.50 (m, 20H), 0.80-<br>
0.95 (m, 6H). MS (ES) [M++l] 422.56<br>
6-Decyl-2-(1-methylheptyloxy)thieno[2,3-d][1,3]oxazin-4-one(90)<br>
Light yellow oil in 22% yield.<br>
!H NMR (CDCI3, 200MHz): 5 6.96 (s, 1H), 5.13 (tq, 1H, J= 5.8, 6.2Hz), 2.76 (t, 2H, J<br>
= 7.6Hz), 1.58-1.83(m, 4H), 1.08-1.50 (m, 26H), 0.80-1.00 (m, 6H). MS (ES) [M++l]<br>
380.57.<br>
6-Heptyl-2-(1-methylheptyloxy)thieno[2,3-cq[1,3]oxazin-4-one(91)<br>
Light yellow oil in 28% yield.<br>
'H NMR (CDCI3, 200MHz): 6 6.96 (s, 1H), 5.13 (tq, 1H, J= 6.2, 6.6Hz), 2.76 (t, 2H, J<br>
= 7.6Hz), 1.58-1.83(171, 4H), 1.08-1.50 (m, 20H), 0.80-1.00 (m, 6H). MS (ES) [M++l]<br>
422.65<br>
6-Decyl-2-(4-phenylpropoxy)thieno[2,3-d][1,3]oxazin-4-one (99)<br>
Light yellow oil in 28% yield.<br>
'H NMR (CDCL, 200MHz): 5 7.17-7.38 (m, 5H), 6.96 (s, 1H), 4.42 (t, 2H, J= 6.6Hz),<br>
2.72-2.85 (m, 4H), 2.05-2.20(m, 2H), 1.50-1.75(m, 2H), 1.20-1.40 (m, 16H), 0.88(t,<br>
3H, J= 6.6Hz). MS (ES) [M++l] 428.62.<br>
6-Decyl-2-(4-phenylbutoxy)thieno[2,3-d][1,3]oxazin-4-one (98)<br>
Light yellow oil in 25% yield.<br>
1H NMR (CDCI3, 200MHz): 8 7.10-7.38 (m, 5H), 6.96 (s, 1H), 4.42 (t, 2H, J= 6.4Hz),<br>
2.60-2.80 (m, 4H), 1.75-1.83(m, 4H), 1.50-1.70(m, 2H), 1.18-1.40 (m, 16H), 0.88(t,<br>
3H, J = 6.4Hz).<br>
Example 23; Pancreatic lipase assay<br>
The use of a pancreatic lipase assay has been described in the literature (Hadvary,<br>
P. et al. Biochem. J. (1988) 256: 357-361; Hadvary, P. et al. Biochem. J. (1991)<br>
266:2021-2027). Pancreatic lipase activity was measured using a 718 Stat Titrino<br>
(Brinkmann) programmed to maintain a pH of 8.0 using 0.1 N NaOH. The substrate<br>
mixture (pH 8) contained 1 mM taurochenodeoxycholate (Sigma), 9 mM<br>
taurodeoxycholate (Sigma), 0.1 mM cholesterol (Sigma), 1 mM phosphatidylcholine<br>
(Sigma), 1.5% BSA, 2 mM Tris base, 100 mM NaCI, 10 mM CaCI2, and 3% triolein<br>
(Sigma). The mixture (5 mL) was emulsified via sonication at room temperature, and<br>
added to the titration vessel with rapid stirring. The Stat Titrino was turned on and<br>
lipase (7.0 nM type VI-S porcine pancreatic lipase (Sigma) dissolved in PBS) was<br>
added to the vessel. After 10 min, inhibitor (700 nM dissolved in 100% DMSO) was<br>
added and the reaction continued for an additional 12.5 min. The k values were<br>
determined for the 12.5 min after the addition of the inhibitor using a one phase<br>
exponential association equation, Y=Ymax*(1-exp(-k*X)), k values for lipase alone<br>
were 0.0004 ± 0.0001 sec. The k values for compounds disclosed herein are<br>
&gt;0.0004 ± 0.0001 sec.<br>
Equivalents<br>
Those skilled in the art will recognize, or be able to ascertain, using no more than<br>
routine experimentation, many equivalents to specific embodiments of the invention<br>
described specifically herein. Such equivalents are intended to be encompassed in<br>
the scope of the following claims.<br><br><br><br>
WE CLAIM: <br>
1.        A compound having the structure:<br>
(Formula Removed)<br>
wherein,<br>
X is O, S, or CH2; Y is O or S;<br>
R1  is H, substituted CI-C15 alkyl, unsubstituted C2-C15 alkyl, C1-C8 alkylaryl,       -C(0)OR4,       -C(0)NR,R,,       -CR„R„ OR,,,       -CR6R6 OC(0)R4, CR6R6OC(0)NHR7, -QCONR8R9, NR8R9, -N(R5)C(0)NHR5, or CH9R4;<br>
R2  is a substituted or unsubstituted, straight chainC1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyi, hclcroarylalkyi or cycloalkyl; and R3 is H, -CH3, -CI I2OCI l3 or C,-CK, cycloalkyl, wherein<br>
R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CII2-aryl, aryl -C|-C«&gt; alkyl, heteroaryl-C1-C30alkyl or C3-C10 cycloalkyl;<br>
R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30 alkyl, heteroarylalkyl or cycloalkyl;<br>
R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group;<br>
R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; and<br>
Rg and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a<br><br>
substituted piperazine or piperidine ring or a dihydro-lH-isoquinoline ring system, or a specific enantiomer thereof, or a specific tautomer, or a pharmaceutically acceptable salt thereof.<br>
2.The compound as claimed in claim 1, having the structure:<br>
(Structure Removed)<br>
wherein, XisOorS;<br>
R1 is H, -C(0)OR4, -C'(0)NR„Rs, -( R„R()OR,, -C R„R(,-OC(0)R4, -CR6R6-OC(0)NHR7, or CH2R4;<br>
R2 is a substituted or unsubstiluled, straight chain or branched C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl; and<br>
R3 is H, -CH3, -CH2OH3, or C3-C10 cycloalkyl, wherein,<br>
R4 is H or a substituted or unsubstiluled, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl;<br>
R5 is H or a substituted or unsubstiluled, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyl or cycloalkyl;<br>
R6 and R6' are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; and<br>
R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyl.<br>
3.The compound as claimed in claim 2, wherein X is O;<br>
R1 is -C(0)0-(C6-C30) alkyl, -C(0)NH-(C6-C30) alkyl or -C(0)OCH2(C6H5); R2 is C6-C30 alkyl; and<br><br>
 (Structure Removed)<br>
The compound as claimed in claim 2, wherein R3 is H or -CH3.<br>
5.        The compound as claimed in claims 3 or 4, wherein X is O.<br>
6.The compound as claimed in claims 3 to 5, wherein R3 is methyl.<br><br>
7.	The compound as claimed in claim 1, having the structure:<br><br>
(Structure Removed)<br>
wherein,<br>
Y is O or S;<br>
R, is 1-1, -(CH2)rCH3, -CH(CH3)2, -CH(CH3)CH2C(CH3),, -CH(CH3)(CH2)3C(=CH2)CI I3, -CH(CH)(CH2)3C(CH3)20C(0)CH3, -CH(CH3)[CH2]3C(CH3)2OCH3, -CHS(C6H5), -C(0)OH, -C(0)NH(CH2)tCH3,-C(0)0(CH2)uCH3, -C(0)OCH[(CH2)3CH3]2,-C(0)NH(CH2)vCH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6Hn), -C(0)(NC4HgN)CH2(C6H5),-C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5))-C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(0)NHCH2C(0)OCH2(C6H5), -e(0)N(CH3)CH2(C5H3N[CH3]),-C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(0)(NC4H8N)[CH2]2(NC5H10),-C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,-C(0)(NC9H8)[OCH3]2,<br><br>
-C(0)NHCH2(C6H3[OCH3]2), -C(0)NHCH2(C7H502), -C(0)NH(CH2)20(C6H5),-C(0)NH(CH2)20CH3) -C(0)NH(CH2)3OCH3, -C(0)NH(CH2)4(C6H5), or -C(0)NH(CH2)3(CH5);<br>
r is an integer from 1 to 15;<br>
s is an integer from 0 to 6;<br>
t is an integer from 0 to 6;<br>
u is an integer from 3 to 8;<br>
v is an integer from 5 to 15; XR2 is -(CH2)nCH3 -O(CH2)mCH3, -OCH(CH3)2 -OCH(CH3)(CH2)5CH3 -OCH2;CH(CH3)2, -O(CH2) 2 OCH3.. -0(CH2)20CH2(C6H5), -0(C'I l2)n(C6H5), -OC'H3(C6H4](CH2)3CH3), -0(CH4|(CH2)3CH3]), -0(CH2)2(6H4](CH3])), -0(CH2)3OCH2(C6H5) or -0(CH2)4OCH2(C6H5);<br>
n is an integer from 6 to 15;<br>
m is an integer from 1 to 15;<br>
p is an integer from 0 to 6;<br>
and R3 is H, -CH3 or -CH2OCH3.<br><br>
8.        The compound as claimed in claim 7, having the structure:<br>
(Structure Removed)<br>
wherein,<br>
Y is O or S;<br>
R, is H, -(CH2)3CH3, -(CH,)SCH3, -(CH2)6CH3, -(CH2)7CH3, -(CH2)9CH3, -(CH2),,CH3, -CH(CH3)2, -CH(CH3)CH2C(CH3)3, -CH(CH3)(CH2)3C(=CH2)CH3, -CH(CH3)(CH2)3C(CH3)20C(0)CH3,<br>
-CH(CH3)[CH2l3C(CH3)20CH3, -CH2(C6H5), -(CH2)2(C6H5), -(CH2)3(C6H5), -(CH2)4(C6H5), -(CH2)5(C6H5), -C(0)OH, -C(0)NHCH3, -C(0)NHCH2CH3, -C(0)NH(CH2)3CH3, -C(0)OCH2(C6H5), -C(0)0(CH2)5CH3, -C(0)0(CH2)6CH3) -C(0)0(CH2)7CH3, -C(0)OCH[(CH2)3CH3]2, -C(0)NH(CH2)5CH3,   -C(0)NH(CH2)7CH3, -C(0)NH(CH2)9CH3,   -C(0)NH(CH2)i 1CH3, -C(0)NH(CH2)|5CH3, -C(0)N(CH3)2, -C(0)NHCH2(C6H5), -C(0)NHCH2(C5H4N),-C(0)N[(CH2)3CH3]2, -C(0)N[(CH2)5CH3]2, -C(0)N[(CH2)7CH3]2, -C(0)NH(C6H„), -C(0)(NC4H8N)CH2(C6H5),-C(0)(NC5H9)CH2(C6H5), -C(0)NH(CH2)30(C6H5),-C(0)NHCH[(CH2)3CH3]2, -C(0)NH(CH2)3N(CH3)2,-C(0)NHCH2C(0)OCH2(C6H5), -C(0)N(CH3)CH2(C5H3N[CH3]),-C(0)NH(CH2)2(C5H4N), -C(0)N(CH2CH3)(CH2)2(C5H4N),-C(0)NHCH2(C4H30), -C(0)(NC4H8N)[CH2]2(NC5H,o), -C(0)NHCH2CH(CH3)2, -C(0)NHCH2(C5H4N),-C(0)NHCH2C(CH3)3, -C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,-C(0)(NC9H8)[OCH3]2, -C(0)NHCH2(C6H3[OCH3]2),-C(0)NHCH2(C7H502),<br><br>
2-Octyloxy-6-(3-phenyl-propyl)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-Octyloxy-6-(4-phenyl-butyl)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-Octyioxy-6-(5-phenyl-pentyI)-thieno[2,3-d][l,3]oxazin-4-one; 6-Decyl-2-(2-methoxy-ethoxy)-thieno[2,3-d][ 1,3]oxazin-4-one; 2-(4-Butyl-phenoxy)-6-decyl-thieno[2,3-d|[l,3]oxazin-4-one; 2-(3-Benzyloxy-propoxy)-6-decyl-thieno[2,3-d |[ 1,3 joxazin-4-one; 2-(3-Benzyloxy-butyloxy)-6-decyl-thieno(2,3-d II1,3 |oxazin-4-onc; 6-Isopropyl-2-octyloxy-thieno[2,3-d |[ 1,3 |oxazin-4-onc; 6-Octyl-2-octyloxy-thieno[2,3-d|| 1,3 |oxa/.in-4-one; 6-Dodecyl-2-octyloxy-thieno[2,3-d || 1,3 |oxazin-4-one; 2-Benzyloxy-6-Decyl-thieno[2,3-d || 1,3 |oxazin-4-one; 2-(4-Butylbenzyloxy)-6-Decyl-lhicno[2,3-d|l 1,3|oxazin-4-one; 6-Decyl-2-(2-p-tolyl-ethoxy)-thienol2,3-d|[I,3]oxazin-4-one; 6-Decy 1-2-phenethy loxy-th ieno( 2,3 -d | [ 1,3 joxazin-4-one; 3-Methyl-6-octyl-2-octyloxy-5U-thieno[2,3-b]pyridin-4-one; 2-Butoxy-6-octyl-5H-thieno[2,3-b|pyridin-4-one; 2-Hexyloxy-6-octyl-5H-thieno[2,3-b|pyridin-4-one; 2-Dodecyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Decyl-2-phenoxy-5H-thieno[2,3-b]pyridin-4-one; 2-Decyloxy-6-octyl-5H-thieno[2,3-b]pyridin-4-one; 6-Benzyl-2-octyloxythieno[2,3-t/][l,3]oxazin-4-one; 6-Decyl-2-octyloxythieno[2,3-d][l,3]oxazin-4-one; 6-Decyl-2-(l-methylheptyloxy)thieno[2,3-d][l,3]oxazin-4-one; 6-Heptyl-2-( 1 -methylheptyloxy)thieno[2,3-d][l ,3]oxazin-4-one; 6-Decyl-2-(4-phenylpropoxy)thieno[2,3-t/][l,3]oxazin-4-one; and 6-Decyl-2-(4-phenylbutoxy)thieno[2,3-c/][l,3]oxazin-4-one.<br><br>
10.      A compound having the structure:<br>
(Structure Removed)<br>
wherein,<br>
Y is O; XR2is -N([CH2]7CH,)C(0)NI I(CH2)7CH3, -N([CH2J6CH3)C(0)NH(CH3)()CH3, -NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15;<br>
Ri is H, substituted C1-C15 alkyl, or unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4,        -C(0)NR4R5,        -CR6R6OR4,        -CR6R60C(0)R4, CR6R60C(0)NHR7, -C(0)NRgR9NR8R9, -N(R5)C(0)NHR5, or CH2R4; R3 is H, -CH3, -CH2OCH3 or C3-C10 cycloalkyl, wherein<br>
R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, aryl -C1-C30 alkyl, heteroaryl-C1-C30alkyl or C3-C10 cycloalkyl; R6 and R6- are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered cycloalkyl or aryl group; R7 is H or substituted or unsubstituted C1-C12 alkyl or C3-C10 cycloalkyl; and<br><br>
R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-1 H-isoquinoline ring system,<br>
or a specific enantiomer thereof, or a specific tautomer, or a pharmaceuticaliy<br>
acceptable salt thereof.<br>
11.      The compound as claimed in claim 10 having the structure:<br>
(Structure Removed)<br>
wherein,<br>
R1 is H,<br>
-(CH2)rCH3,<br>
-CH(CH3)2,<br>
-CH(CH3)CH2C(CH,)3,<br>
-CH(CH3)(CH2)3C(=CH2)CH3,<br>
-CH(CH3)(CH2)3C(CH3)2OC(0)CH3,<br>
-CH(CH3)[CH2J3C(CH3)2OCH3,<br>
-CHs(C6H5),<br>
-C(0)OH,<br>
-C(0)NH(CH2)tCH3,<br>
-C(0)0(CH2)uCH3,<br>
-C(0)OCH[(CH2)3CH3]2,<br>
-C(0)NH(CH2)vCH3,<br>
-C(0)N(CH3)2,<br>
-C(0)NHCH2(C6H5),<br>
-C(0)NHCH2(C5H4N),<br>
-C(0)N[(CH2)3CH3]2,<br>
-C(0)N[(CH2)5CH3]2,<br>
-C(0)N[(CH2)7CH3]2,<br><br>
-C(0)NH(C6Hn),<br>
-C(0)(NC4H8N)CH2(C6H5),<br>
-C(0)(NC5H9)CH2(C6H5),<br>
-C(0)NH(CH2)30(C6H5),<br>
-C(0)NHCH[(CH2)3CH3]2,<br>
-C(0)NH(CH2)3N(CH3)2,<br>
-C(0)NHCH2C(0)OCH2(C6H5),<br>
-C(0)N(CH3)CH2(C5H3N[CH3]),<br>
-C(0)NH(CH2)2(C5H4N),<br>
-C(0)N(CH2CH3)(CH2)2(C5H4N),<br>
-C(0)NHCH2(C4H30)7<br>
-C(O)(NC4H8N)[CH2]2(NC5H10),<br>
-C(0)NHCH2CH(CH3)2,<br>
-C(0)NHCH2(C5H4N),<br>
-C(0)NHCH2C(CH3)3,<br>
-C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,<br>
-C(0)(NC9Hg)[OCH,]2,<br>
-C(0)NHCH2(C6H3[OCI I3I2),<br>
-C(0)NHCH2(C7Hs02),<br>
-C(0)NH(CH2)20(C6H5),<br>
-C(0)NH(CH2)2OCH3,<br>
-C(0)NH(CH2)3OCH3,<br>
-C(0)NH(CH2)4(C6H5), or<br>
-C(0)NH(CH2)3(C6H5);<br>
r is an integer from 1 to 15;<br>
s is an integer from 0 to 6;<br>
t is an integer from 0 to 6;<br>
u is an integer from 3 to 8;<br>
v is an integer from 5 to 15; XR2is<br>
-N([CH2]7CH3)C(0)NH(CH2)7CH3, -N([CH2]6CH3)C(0)NH(CH2)6CH3, -NH(CH2)qCH3,<br><br>
-NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2;<br>
q is an integer from 6 to 15; and R3 is H, -CH3, -CH2OCH3 or C3-C10 cycloalkyl.<br>
12.       The compound as claimed  in claim 11, having the structure:<br>
(Structure Removed)<br><br><br><br>
wherein,<br>
R, is H,<br><br>
-(CH2)3CH3, -(CH2)sCH3,<br>
-(CH2)6CH3,<br>
-(CH2)7CH3)<br>
-(CH2)9CH3,<br>
-(CH2),,CH3,<br>
-CH(CH3)2,<br>
-CH(CH3)CH2C(CH3)3,<br>
-CH(CH3)(CH2)3C(=C H2)C H3,<br>
-CH(CH3)(CH2)3C(CH3)20C(0)CH3,<br>
-CH(CH3)[CH2]3C(CH3)20CH3,<br>
-CH2(C6H5),<br>
-(CH2)2(C6H5),<br>
-(CH2)3(C6H5),<br>
-(CH2)4(C6H5),<br><br>
-(CH2)5(C6H5),<br>
-C(0)OH,<br>
-C(0)NHCH3,<br>
-C(0)NHCH2CH3,<br>
-C(0)NH(CH2)3CH3,<br>
-C(0)OCH2(C6H5),<br>
-C(0)0(CH2)5CH3,<br>
-C(0)0(CH2)6CH3,<br>
-C(0)0(CH2)7CH31,<br>
-C(0)OCH[(CH2)3CH3|2,<br>
-C(0)NH(CM2)sCH3t,<br>
-C(0)NM(CH2)7Cllt,<br>
-C(0)NH(CII2)yCH3,<br>
-C(0)NH(CH2)2CH3,,<br>
-C(0)NH(CH2)isCH3,<br>
-C(0)N(CH3)2,<br>
-C(0)NHCH2(C6H5).<br>
-C(0)NHCH2(C5H4N),<br>
-C(0)N|(CH2)3CH32,<br>
-C(0)N[(CH2)5CH3]2,<br>
-C(0)N[(CH2)7CH,|2,<br>
-C(0)NH(C6H,,),<br>
-C(0)(NC4H8N)CH2(C6H5),<br>
-C(0)(NCSH9)CH2(C6H5),<br>
-C(0)NH(CH2)30(C6H5),<br>
-C(0)NHCH[(CH2)3CH3]2,<br>
-C(0)NH(CH2)3N(CH3)2,<br>
-C(0)NHCH2C(0)OCH2(C6H5),<br>
-C(0)N(CH3)CH2(C5H3N[CH3]),<br>
-C(0)NH(CH2)2(C5H4N),<br>
-C(0)N(CH2CH3)(CH2)2(C5H4N),<br>
-C(0)NHCH2(C4H30),<br>
-C(O)(NC4H8N)[CH2]2(NC5HI0),<br><br>
-C(0)NHCH2CH(CH3)2,<br>
-C(0)NHCH2(C5H4N),<br>
-C(0)NHCH2C(CH3)3,<br>
-C(0)(NC4H8N)CH2C(0)NHCH(CH3)2,<br>
-C(0)(NC9H8)[OCH3]2,<br>
-C(0)NHCH2(C6H3[OCH3]2),<br>
-C(0)NHCH2(C7H502),<br>
-C(0)NH(CH2)20(C6H5),<br>
-C(0)NH(CH2)2OCH3,<br>
-C(0)NH(CH2)3OCH3,<br>
-C(0)NH(CH2)4(Cl,Hs), or<br>
-C(0)NH(CH2),(C()Hs); XR2 is -N([CH2j7CH3)C(0)NII(CH2)7CH3<br>
-N([CH2]6CH3)C(())NH(CH!)(,CHl,<br>
-NH(CH2)()CCH3,<br>
-NH(CH2)7CH3,<br>
-NH(CH2)CH3,<br>
-NH(CH2),13CH,,<br>
-NH(CH2),sCH,,<br>
-NH(C6H4)0(C6H5),<br>
-N(CHj)(CII2)5CH3,<br>
-NHCH[(CII2)3CH,]2,<br>
-NHCI l(CI l3)[CH2|5CH3, or<br>
-N([CH2]7CH3)2; and R3 is H, -CH3 or -CH2OCH3.<br>
13. The compound as claimed in any one of claims 1 to 12, wherein any heterocyclic or heteroaryl ring, if present, is a piperazine, piperidine, (l,4)diazepan, pyrazine, pyridine, pyrrolidine, pyrazole, pyrimidine, thiophene, imidazole, azetidine, pyrrole, benzothiazole, benzodioxolane, dithiolane, oxathiine, imidazolidine, quinoline, isoquinoline, dihydroisoquinoline, indole, isoindole, triazaspiro[4.5]decane, morpholine, furan or an isothiazole ring.<br><br>
14.	The compound as claimed in any one of claims 1 to 12, wherein any substituent, if<br>
present, is halogen, hydroxyl, straight chain (C1-C30)alkyl, branched chain (C3-<br>
C30)alkyl, (C3-C10)cycloalkyl, straight chain(C1-C30)alkylcarbonyloxy, branched chain<br>
(C3-C30)alkylcarbonyloxy, arylcarbonyloxy, straight chain(C1-C30)alkoxycarbonyloxy,<br>
branched chain(C3-C3o)alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, straight<br>
chain(C1-C30)alkylcarbonyl, branched chain (C3-C30)alkylcarbonyl, straight chain (C1-<br>
C3o)alkoxycarbonyl, branched chain (C1-C30)alkoxycarbonyl, aminocarbonyl, straight<br>
chain (C1-C30)alkylthiocarbonyl, branched chain (CVC\to)alkylthiocarbonyl, straight<br>
chain (C1-C30)alkoxyl, branched chain (C1-C30)alkoxyl, phosphate, phosphonato,<br>
cyano, amino, straight chain (C1-C30)alkylamino, branched chain ((.VC'm)alkylamino,<br>
straight chain (Cj-C3o)dialkylamino, branched chain (C3-C30)dialkylamino, arylamino,<br>
diarylamino, straight chain (C1-C30)alkylarylarhino, branched chain (C3-<br>
C3o)alkylarylamino, acylamino, straight chain (C1-C30)alkylearbonylamino, branched<br>
chain (C3-C30)alkylcarbonylamino, arylcarbonylamino, carbamoyl, urcido, amidino,<br>
imino, sulfhydryl, straight chain (C1-C30))alkylthio, branched chain (C1-C30)alkylthio,<br>
arylthio, thiocarboxylate, sulfates, sulfonato, sullamoyl, sullbnamido, nitro,<br>
trifluoromethyl, azido, 4-10 membered hetcrocyclyl, straight chain (C1-C30)alkylaryl,<br>
branched chain (C3-C30)alkylaryl, benzo( l,3)dioxole, or an aromatic or 5-6 membered<br>
heteroaromatic moiety,<br>
which substituent may be further substituted by any of the above.<br>
15.	An in vitro method of inhibiting the hydrolytic activity of pancreatic lipase enzymes in<br>
a cell, comprising contacting the cell with an amount of the compound of any one of<br>
claims I, 2, 7, 8, 10, 11 or 12 which is effective in inhibiting the hydrolytic activity of<br>
pancreatic lipase enzymes.<br><br>
16.A process of manufacturing a compound having the structure:<br>
(Structure Removed)<br>
wherein,<br>
X is O, S or CH2;<br>
R1   is H, substituted C1-C15 alkyl, unsubstituted C2-C15 alkyl, C1-C8 alkylaryl, -C(0)OR4, -C(0)NR4R5, -CR6R6 OR,, -CR6R6, OC(0)R4, -CR6R6 OC(0)NHR7, -C(0)NR8R9, -C(0)NR8R9NR8R9, -N(R5)C(0)NHR5, or CH2R4;<br>
R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyi or cycloalkyi; R3 is H, -CH3, -CH2OCH3 or cycloalkyi;<br>
R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, -CH2-aryl, arylalkyl, heteroarylalkyi or cycloalkyi;<br>
R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, arylalkyl, heteroarylalkyi or cycloalkyi;<br>
R6 and R6 are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or cycloalkyi or together form a 3-7 membered cycloalkyi or aryl group;<br>
R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyi;<br>
R8 and R9 are each independently H, substituted or unsubstituted<br>
C1-C6 alkyl, C1-C6 alkoxy, C|-C6 alkylaryl, or NR8R9 together form a<br>
substituted piperazine or piperidine ring or a dihydro-lH-isoquinoIine<br>
ring system,<br><br>
or<br><br>
XR2is<br><br>
-N([CH2]7CH3)C(0)NH(CH2)7CH3, -N([CH2]6CH3)C(0)NH(CH2)6CH3,<br><br>
-NH(CH2)qCH3, -NH(C6H4)0(C6H5), -N(CH3)(CH2)5CH3, -NHCH[(CH2)3CH3]2, -NHCH(CH3)[CH2]5CH3, or -N([CH2]7CH3)2; q is an integer from 6 to 15;<br>
R1 is H, substituted or unsubstituted C1-C15 alkyl, or unsubstituted C2-C15 alkyl, C1-<br>
C8   alkylaryl,   -C(0)OR4,   -C(0)NR4R5,   -CR6R6OR4,   -CR6R6 OC(0)R4,   -<br>
CR6R6 OC(0)NHR7, -C(0)NR8R9, -C(0)NR8R9NR8R9, -N(R5)C(0)NHR5, or<br>
CH2R4;<br>
R2 is a substituted or unsubstituted, straight chain C1-C30 alkyl or branched C3-C30<br>
alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R3 is H or substituted or unsubstituted C|-C6 alkyl-CH3, -CH2OCH3 or cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30alkyl,<br>
aryl, -CH2-aryl, arylalkyl, heteroarylalkyl or cycloalkyl; R5 is H or a substituted or unsubstituted,  straight chain or branched, C6-C30 alkyl,<br>
aryl C1-C30 alkyl, heteroarylalkyl or cycloalkyl; R6 and R6- are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyi or cycloalkyl or together form a 3-7 membered cycloalkyl or aryl groupring system; R7 is H or substituted or unsubstituted C1-C12 alkyl or cycloalkyl; R8 and R9 are each independently H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkylaryl, or NR8R9 together form a substituted piperazine or piperidine ring or a dihydro-lH-isoquinoline ring system, comprising<br>
(a) reacting<br><br>
(Structure Removed)<br>
in the presence of sulfur, a base and solvent to produce:<br>
(Structure Removed)<br>
 (b) reacting the product of step (a) with<br>
(Structure Removed)<br>
in the presence of a base to produce:<br><br>
(Structure Removed)<br><br>
(c) reacting the product of step (b) with trifluoroacetic acid (TFA) in the presence of solvent to produce:<br>
(Structure Removed)<br><br>
 (d) reacting the product of step (c) with SOCI2 in the presence of solvent to produce the compound.<br>
17.      The process as claimed in claim 16, wherein the intermediates having the structure:<br><br>
(Structure Removed)<br><br>
wherein, R10 is H or substituted or unsubstituted C1-C15 alkyl, C1-C15 alkylaryl, or -C(0)R14,<br>
wherein R11  is hydroxyl, or a substituted or unsubstituted    C1-C30 alkyl,<br>
alkylamino,   dialkylamino,   alkoxy,   benzyloxy,   cycloalkyl,   alkylheteroaryl,<br>
alkylaryl, or a heterocyclic, heteroaryl or aryl ring; R11 is hydrogen or methyl; R12 is hydrogen or tert/-butyl; and R11 is hydrogen or -C(0)ZR15,<br>
wherein Z is CH2, O or N and R15 is substituted or unsubstituted C1-C15 alkyl or<br>
aryl.<br>
18.	The process as claimed in claim 16, wherein the base in step (a) is triethyl amine and the solvent is dimethylformamide (DMF).<br>
19.	The process as claimed in claim 16 or 18, wherein the solvent in step (c) is dichloromethane.<br>
20.       The process as claimed in claim 16 or 19, wherein the solvent in step (d) is pyridine:CH2Cl2.<br><br><br></c></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUNsYWltcy0oMDItMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Claims-(02-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUNsYWltcy0oMTgtMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Claims-(18-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDItMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Correspondence-Others-(02-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMTgtMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Correspondence-Others-(18-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWRlc2NyaXB0aW9uIChjb21wbGV0ZSktMDItMDktMjAwOC5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-description (complete)-02-09-2008.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUZvcm0tMS0oMTgtMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Form-1-(18-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWZvcm0tMTMucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-form-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUZvcm0tMi0oMDItMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Form-2-(02-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUZvcm0tMjYtKDAyLTA5LTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Form-26-(02-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWZvcm0tMjYucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-form-26.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LUZvcm0tMy0oMDItMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Form-3-(02-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LXBjdC0xMDEucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-pct-101.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LXBjdC00MDEucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-pct-401.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LXBjdC00MDgucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-pct-408.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LXBjdC00MDkucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-pct-409.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LXBjdC00MTYucGRm" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-pct-416.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1ERUxOUC0yMDA0LVBldGl0aW9uLTEzNy0oMDItMDktMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">1808-DELNP-2004-Petition-137-(02-09-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTgwOC1kZWxucC0yMDA0LXBldGl0aW9uLTEzOC5wZGY=" target="_blank" style="word-wrap:break-word;">1808-delnp-2004-petition-138.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QuanBn" target="_blank" style="word-wrap:break-word;">abstract.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="226040-guide-blade-of-axial-flow-fan-shroud.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="226042-a-container-for-interior-cooling-by-reception-of-microwave-radiation.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>226041</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1808/DELNP/2004</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>01/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>02-Jan-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>05-Dec-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>24-Jun-2004</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>OSI PHARMACEUTICALS, INC</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>58, SOUTH SERVICE ROAD, MELVILLE, NEW YORK 11747, U.S.A.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>WITTER, DAVID</td>
											<td>12 ARBUTUS ROAD, PUTNAM VALLEY NEW YORK 10579, U.S.A.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>CASTELHANO, ARLINDO L.</td>
											<td>3 EAGLE COURT, NEW CITY NEW YORK 10956 U.S.A.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07D 265/12</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US02/41272</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2002-12-20</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/357,015</td>
									<td>2002-02-13</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>60/342,617</td>
									<td>2001-12-20</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/226041-lipase-inhibitor-compounds by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 02:31:29 GMT -->
</html>
